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aBBReViatiOnS
A activated
AG antigen
ADAMTS13 a disintegrin and metalloproteinase with a thrombospondin type 1 
domain 13 
ANDV Andes virus
APTT activated partial thromboplastin time
AT antithrombin
C complement component
CRP C-reactive protein
DIC disseminated intravascular coagulopathy
DOBV Dobrava virus
EIA enzyme immunoassay
ELISA enzyme-linked immunosorbent assay
F (human coagulation) factor
FVIII:C factor VIII activity
FDP fibrin degradation product
F1+2 prothrombin fragments
GP glycoprotein
HCPS hantavirus cardiopulmonary syndrome
HFRS hemorrhagic fever with renal syndrome
HIV human immunodeficiency virus
HLA human leukocyte antigen
HPA  human platelet (allo)antigen
HTNV Hantaan virus
IG immunoglobulin
IL interleukin
ISTH the International Society of Thrombosis and Haemostasis
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MAC membrane attack complex
MP  microparticle
NE nephropathia epidemica
NET neutrophil extracellular trap
NP nucleocapsid protein
NYV New York virus
PC protein C
PHV Prospect Hill virus
PS protein S free antigen
PT prothrombin time
PUUV Puumala hantavirus
RCO ristocetin cofactor
RNA ribonucleic acid
SAAV  Saaremaa virus
SANGV Sangassou virus
SEOV  Seoul virus
SNV  Sin Nombre virus
TCC terminal complement complex
TNF tumor necrosis factor
TOPV Topografov virus
TSP thrombospondin
TT thrombin time
TTP thrombotic thrombocytopenic purpura
TULV Tula virus
VWF von Willebrand factor
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aBStRaCt
Puumala hantavirus (PUUV) infection, also known as nephropathia epidemica (NE), 
is the most common cause of hemorrhagic fever with renal syndrome (HFRS) in 
Europe. The clinical illness is characterized by fever, headache, gastrointestinal symp-
toms and impaired renal function. Thrombocytopenia is encountered almost invari-
ably, but bleeding manifestations usually remain mild. The clinical severity of acute 
PUUV infection varies from mostly mild to the rarely reported fatal cases.
To investigate markers of platelet and endothelial cell activation together with 
those of blood coagulation and fibrinolysis, 19 hospital-treated patients with serologi-
cally confirmed acute PUUV infection were included. Laboratory abnormalities were 
evaluated by the disseminated intravascular coagulation (DIC) scoring advocated by 
the International Society of Thrombosis and Haemostasis (ISTH). The major platelet 
ligands were all acutely altered, plasma fibrinogen and von Willebrand factor (VWF) 
being increased and plasma fibronectin decreased. ADAMTS13 activity was dimin-
ished. Prothrombin fragments F1+2 and D-dimer were elevated and all the natural 
anticoagulants antithrombin, protein C and protein S were decreased along with low 
platelet counts. Five patients (26%) fulfilled the ISTH criteria for DIC. 
The activation of complement was studied by measuring the plasma levels of ter-
minal complement complexes SC5b-9 and complement components C3 and C4 in 61 
patients with acute PUUV infection. SC5b-9 and C3 levels were associated with several 
variables depicting the clinical severity of the disease. Patients with abnormal chest 
X-ray findings had higher levels of plasma SC5b-9 than those having normal images. 
Several genetic polymorphisms related to platelet aggregation and activation, 
together with those of VWF and plasminogen activator inhibitor (PAI-1), were deter-
mined in 172 patients with acute PUUV infection. The A>G polymorphism of PAI-1 
(rs2227631) was found to be associated with impairment of renal function. Patients car-
rying the functional T>C polymorphism of platelet glycoprotein (GP) VI (rs1613662) 
and the A>G polymorphism of VWF (rs1063856) had lower serum creatinine levels 
compared with non-carriers. The minor C-allele of GP Ia (human platelet alloantigen 
(HPA) -5) was associated with lower platelet count.
In conclusion, the findings imply several rearranged interactions between platelets 
and their ligands during acute PUUV infection. Enhanced thrombin formation and 
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fibrinolysis were observed, and thrombocytopenia was associated with decreased natu-
ral anticoagulants. In this series, these findings did not predict the clininical course of 
the disease. Complement activation via the alternative pathway was associated with 
the severe disease. Polymorphism of PAI-1, the major regulator of fibrinolysis, had an 
adverse impact on the outcome of kidney function in PUUV-induced HFRS. 
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tiiViSteLMÄ
Myyräkuumeen aiheuttaa hantavirusten ryhmään kuuluva Puumala-virus, joka on 
Euroopan yleisin munuaisoireisten verenvuotokuumeiden aiheuttaja. Taudinkuvalle 
tyypillisiä piirteitä ovat kuume, päänsärky, mahasuolikanavan oireet ja munuaisten 
toiminnan heikentyminen. Verihiutaleiden niukkuus todetaan lähes aina, mutta vuoto-
oireet ovat yleensä lieviä. Puumala-viruksen aiheuttaman infektion vaikeus vaihtelee: 
infektio on yleensä lievä, mutta kuolemantapauksiakin esiintyy.
Tässä väitöskirjatyössä tutkittiin verihiutaleiden ja verisuonen seinämän aktivoitu-
miseen sekä veren hyytymiseen ja fibrinolyysiin liittyviä merkkiaineita 19:llä sairaa-
lassa hoidetulla myyräkuumepotilaalla. Poikkeavat laboratoriotulokset pisteytettiin 
kansainvälisellä luokittelulla, jota käytetään konsumptiokoagulopatian (disseminoitu-
nut intravaskulaarinen koagulopatia, DIK) diagnostiikassa. Muutoksia todettiin kaik-
kien tutkittujen verihiutaleisiin sitoutuvien molekyylien pitoisuuksissa. Fibrinogeenin 
plasmapitoisuus oli koholla, fibronektiinin alentunut ja plasman von Willebrand teki-
jän (VWF) aktiivisuus oli koholla. ADAMTS13-aktiivisuus todettiin alentuneeksi. 
Protrombiinifragmentit F1+2 ja D-dimeeri olivat kohonneet. Luonnollisten antiko-
agulanttien antitrombiinin ja proteiini C:n aktiivisuudet ja proteiini S:n vapaa anti-
geeni olivat alentuneet, ja alentumisella todettiin yhteys matalaan verihiutaletasoon. 
Konsumptiokoagulopatian kriteerit täyttyivät 5 potilaalla (26%).
Komplementtijärjestelmän aktivaatiota tutkittiin mittaamalla sen lopputuotteen 
SC5b-9:n ja osatekijöiden C3 ja C4 plasmapitoisuuksia 61 myyräkuumepotilaalla. 
Useiden kliinistä taudinkuvaa mittaavien muuttujien sekä SC5b-9- ja C3-tasojen 
välillä todettiin yhteys. Potilailla, joilla oli korkeat SC5b-9-tasot, oli myös enemmän 
poikkeavia keuhkokuvalöydöksiä.
Verihiutaleiden aggregaatioon ja aktivaatioon liittyviä geneettisiä polymorfioita 
samoin kuin VWF:n ja plasminogeenin aktivaattorin inhibiittori 1:n (PAI-1) poly-
morfioita tutkittiin 172 myyräkuumepotilaalla. PAI-1:n A>G (rs 2227631) polymor-
fiaan liittyi munuaisten toiminnan heikentyminen sairauden akuuttivaiheessa. Glyko-
proteiini (GP) VI:n toiminnallisen T>C (rs1613662) polymorfian ja VWF:n A>G 
(rs1063856) polymorfian kantajilla todettiin lievempi seerumin kreatiniinitason nousu 
myyräkuumeen akuuttivaiheessa kuin näitä polymorfioita kantamattomilla potilailla. 
GP Ia:n (human platelet alloantigen -5) harvinaiseen C-alleeliin liittyi sairauden 
akuutti vaiheessa matala verihiutaleiden taso. 
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Tulokset viittaavat verihiutaleiden ja niihin sitoutuvien molekyylien vuorovaiku-
tukseen myyräkuumeen aikana. Trombiinin muodostus ja fibrinolyysi ovat lisääntyneet, 
ja verihiutaleiden niukkuus liittyy luonnollisten antikoagulanttien kulumiseen. Näillä 
merkkiaineilla ei voitu ennakoida taudin vaikeusastetta. Sen sijaan komplementti-
järjestelmän aktivoituminen oikotien kautta liittyi vaikeaan taudinkuvaan. Fibrinolyy-
sin säätelijän, PAI-1:n, polymorfialla oli epäsuotuisa vaikutus munuaisten toimintaan 
akuutissa myyräkuumeessa.  
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1 intRODuCtiOn
Hantaviruses are the most widely distributed zoonotic viruses on the earth. In humans 
they cause two forms of severe disease, hemorrhagic fever with renal syndrome 
(HFRS) and hantavirus cardiopulmonary syndrome (HCPS) (Bi et al. 2008). Annually, 
HFRS affects approximately 200 000 people predominantly in Asia, with mortali ty rate 
between 6 to 15% in those with more severe form of  disease (Muranyi et al. 2005). 
HCPS occurs much less frequently but with a considerably higher mortality rate. 
Hantaviruses are recognized by the World Health Organization as a significant public 
health problem (WHO 1983), and hantaviral diseases are included in the group of 
emerging infections (Schmaljohn et al. 1997). 
As the disease burden caused to humans by hantaviruses is considerable, much 
effort has been invested in vaccine development, so far with limited success. There is 
still no specific therapy available for hantavirus infection, the treatment being symp-
tomatic even in the most severe cases. The difficulties in developing a therapy against 
hantavirus diseases probably reflect the fact that the hantavirus pathogenesis is a com-
plex multifactorial process which is not currently well understood. It is not known 
whether the therapeutics should target virus replication or the immune system and its 
virally induced reactions (Klingström et al. 2011). 
Puumala hantavirus (PUUV) is the most common cause of HFRS in Europe, and 
70% of reports come from Finland (Heyman et al. 2008). There is an increasing trend 
in incidence, and rates vary widely by season and region (Makary et al. 2010). The acute 
illness is characterized by high fever, headache, back and abdominal pains, visual dis-
turbances, hemorrhages and acute impairment of renal function. Thrombocytopenia 
is almost invariably encountered in PUUV infection, but bleeding manifestations usu-
ally remain mild. The outcome of the disease is usually favorable in terms of long-term 
prognosis and case fatality (Vapalahti et al. 2003). However, 13 deaths due to PUUV 
infection were recorded in Finland during the period 1995-2008 (Makary et al. 2010). 
To improve our understanding of the pathogenesis of hantavirus infection, a series 
of studies was undertaken in the acute phase of PUUV infection and at full recovery. 
The markers of platelet and endothelial cell activation as well as factors related to blood 
coagulation and fibrinolysis were determined. Several genetic polymorphisms related 
to platelet aggregation and activation as well as blood coagulation and fibrinolysis were 
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also investigated. The role of complement activation was further elucidated. As preven-
tion and specific therapy of PUUV infection are yet to be discovered, predictive mark-
ers of disease severity are especially needed to identify the patients who need the most 
intensive symptomatic care as early as possible.
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2 ReVieW OF tHe LiteRatuRe
2.1 Puumala virus and other hantaviruses
2.1.1 Virology
Hantaviruses are enveloped negative-stranded ribonucleic acid (RNA) viruses with a 
diameter of 120 nm belonging to the genus Hantavirus within the family of Bunya-
viridiae. The 12 kb-long RNA genome consists of three segments, the L (large), the M 
(medium), and the S (small) segments. The 6550 nucleotide-long L segment encodes 
an RNA-dependent RNA polymerase. The M segment is about 3680 long, and encodes 
a glycoprotein (GP) precursor cleaved into the G1 and the G2 surface glycoproteins. 
The S segment, about 1830 nucleotides long, encodes a nucleocapsid protein (NP) 
which encapsidates the genomic RNA (Plyusnin 2002). Hantaviruses replicate in the 
host cytoplasm and can infect many types of human cells, e.g. endothelial cells, mac-
rophages and kidney glomerular cells in vitro. Pathogenic hantaviruses do not appear 
to cause cytopathogenic effects in infected cells. The virus is sensitive to heat (30 min 
60°C), 70% ethanol and detergents (Vapalahti et al. 2003, Terajima et al. 2004).
The natural hosts for hantaviruses are persistently infected rodents, and each han-
tavirus species is associated with one (or a few closely related) specific rodent spe-
cies. Hantavirus infection in the natural carrier is asymptomatic and long-lasting, and 
infected rodents continue to secrete the virus in urine, saliva and feces for months. 
Humans catch the virus by inhalation of aerosolized excreta and humans are believed 
to be dead-end hosts (Vapalahti et al. 2003, Klingström et al. 2011). However, the 
Andes virus (ANDV) has been reported to spread between humans (Martinez et al. 
2005), and there is one report of transmission of PUUV via platelet transfusion (Sini-
salo et al. 2010). 
The earliest descriptions of hantavirus-caused disease in humans (HFRS) date 
back to Chinese writings as far back as 900 years ago. The Korean war in 1951–1953 
introduced the illness to thousands of soldiers in the United Nations troops and HFRS 
became better known to the Western medicine. The disease caused by PUUV was first 
described by Swedish authors in 1934 (Myhrman 1934, Zetterholm 1934) and named 
nephropathia epidemica (NE). In Finland, the condition was extensively studied by 
Lähdevirta (1971), and the virus was first detected in samples collected near the vil-
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lage of Puumala in 1977 (Brummer-Korvenkontio et al. 1980). Today, with over 40 
hantavirus species known to exist (Heyman et al. 2009), hantaviruses are classified as 
emerging viruses and considered the most widely distributed zoonotic viruses on earth 
(Johnson 2001).
2.1.2 Geographic distribution
Hantaviruses comprise a genetically and antigenically diverse group of viruses pre-
sent worldwide. They appear to have co-evolved with their hosts for millions of years 
and human infections are geographically restricted by the range of their primary 
hosts (Vapalahti et al. 2003). To demonstrate the worldwide presence of hantaviruses, 
selected species together with their rodent hosts, clinical disease and geographic distri-
bution are presented in Table 1.
PUUV, along with its host, the bank vole, is found throughout Europe with the 
exception of Mediterranean coastal regions and most of the Iberian Peninsula and 
Greece. The large continuous forest areas in northern Europe probably contribute to 
the effective spread and general abundance of PUUV and NE. In temperate Europe for-
ests are more fragmented which possibly explains the local patchy occurence of PUUV. 
The distributions of the Dobrava virus (DOBV) isolated from the yellow-necked mouse 
in Slovenia (Avsic-Zupanc et al. 1992, Avsic-Zupanc et al. 1995) and the Saaremaa 
virus (SAAV) from the striped field mouse in Estonia (Plyusnin et al. 1997b, Nemi-
rov et al. 1999) overlap across most of Europe. An association of human disease with 
the Tula virus (TULV) or the Topografov virus (TOPV) has not been unequivocally 
shown. Amur virus has been identified in severe HFRS cases in the far eastern region 
of the Russia Federation (Yashina et al. 2001, Lokugamage et al. 2004). The Seoul virus 
(SEOV) has been distributed worldwide in rats travelling in ships (Lee et al. 1982). 
The research prompted by HFRS during the Korean conflict (also known as Korean 
hemorrhagic fever) resulted in the identification of the Hantaan virus (HTNV) (Lee et 
al. 1978), the prototype member of the genus Hantavirus. HTNV is widely distributed 
in Asia, causing HFRS, the majority of cases being detected in China (Bi et al. 2008, 
Schönrich et al. 2008). 
There is a large number of hantaviruses causing HCPS (formerly hantavirus pul-
monary syndrome, HPS) throughout the Americas. First, the Sin Nombre virus (SNV) 
was detected in deer mice (Peromyscus manipulatus) in the southwestern United States 
(Nichol et al. 1993) and subsequently, the NY-1 virus (NYV) on an island off the coast 
of New York (Song et al. 1994) and ANDV in Argentina (Lopez et al. 1996). The Pros-
pect Hill virus (PHV) is not known to associate with any human disease (Mackow et 
al. 2009). 
There is a report of specific neutralizing antibodies against Sangassou hantavirus 
(SANGV) in serum samples of Guinean patients, and serosurveys suggest that hanta-
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viruses cause human diseases at least in that part of Africa (Klempa et al. 2010). Han-
tavirus antibody-positive rodents have also been found across Australia. To date, there 
are no reports of human hantavirus disease on that continent (Bi et al. 2005).
table 1. Selected hantavirus species together with their rodent hosts, associated clinical 
diseases, and geographical distribution.
Virus (abbreviation) Rodent host Disease Distribution Reference
Puumala (PUUV) Bank vole HFRS Europe Brummer- Korven-
 (Myodes glareolus)    kontio et al. 1980
Dobrava (DOBV) Yellow necked field mouse  HFRS Europe Avsic-Zupanc et al. 
 (Apodemus flavicollis)    1992
Saaremaa (SAAV) Striped field mouse  HFRS Europe Nemirov et al. 1999
 (Apodemus agrarius)
   
TULA (TULV) European common vole  none Europe Plyusnin et al. 1994
 (Microtus arvalis)
   
Topografov (TOPV) Siberian lemming  none Asia (Siberia),  Plyusnin et al. 1996
 (Lemmus sibericus)  Northern Europe
Amur Korean field mouse  HFRS Far East Russia Yashina et al. 2001
 (Apodemus peninsulae)   
Seoul (SEOV) Rat  HFRS worldwide Lee et al. 1978
 (Rattus rattus, rattus norvegicus)   
Hantaan (HNTV) Striped field mouse  HFRS China, Korea,  Lee et al. 1978
 (Apodemus agrarius)  Russia 
Sin Nombre (SNV) Deer mouse  HCPS Western and Central Nichol et al. 1993, 
 (Peromyscus maniculatus)  United States, Mexico Elliott et al. 1994
New York (NYV) White-footed mouse  HCPS Eastern United States Song et al. 1994
 (Peromyscus leucopus)   
Andes (ANDV) Long-tailed pygmy rice rat  HCPS Argentina, Chile Lopez et al. 1996
 (Oligoryzomys longicaudatus)   
Prospect Hill (PHV) Meadow vole  none North America Rowe et al. 1995
 (Microtus pennsylvanicus)   
Sangassou (SANGV)  Allen’s wood mouse  HFRS Guinea, Africa Klempa et al. 2006
 (Hylomyscus alleni)   
HFRS=hemorrhagic fever with renal syndrome, HCPS=hantavirus cardiopulmonary syndrome.
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2.1.3 Disease burden of hantavirus infections
Hantaviruses cause a wide range of human illnesses and present a significant public 
health threat. Globally 150  000–200  000 patients with HFRS are hospitalized every 
year. In the most endemic country, China, where the majority of HFRS cases are caused 
by HTNV, 40 000–60 000 cases have been reported annually in recent years. Over the 
period 1950 to 2001, the number of clinical cases reported in China was 1 400 000 
and 45 000 deaths occurred (Bi et al. 2008). In more severe forms of HFRS, caused 
by DOBV and HTNV, the mortality rate is up to 10%. In HFRS with milder clinical 
course, as caused by PUUV and SEOV, the mortality rate is estimated to be between 
0.1–1%. The incidence figure for HCPS, with approximately 200 cases reported annu-
ally in the Americas, is much smaller. However, a mortality rate of up to 40% and 
the record of human-to-human transmission of ANDV make it a considerable health 
problem (Vapalahti et al. 2003, Klingström et al. 2011). 
PUUV is the most common cause of HFRS in Europe. The annual number of veri-
fied cases is about 2000 in Finland (incidence rate 31/100 000 population), 100–300 
in Sweden and 100 in Norway (Bi et al. 2008). A recent Finnish study from the period 
1995–2008 reported an increasing trend in incidence, and a wide variation in rates 
by season and region was noted (Makary et al. 2010). Of all the reported 22 681 cases 
in 1995–2008, 52% were hospitalized and 62% were males. Only 3% of all cases were 
registered as occupational disease, the majority of them related to farming and forestry 
(Makary et al. 2010).
2.2 Clinical hantaviral disease
2.2.1 Clinical course of PUUV infection
The incubation period of PUUV is 2–4 weeks. The course of the disease may be divided 
into febrile, hypotensive, oliguric, diuretic and convalescent phases, but these phases 
overlap and may not be easy to recognize. The severity of the disease varies from sub-
clinical to fatal, and the infection is thought to leave lifelong immunity (Vapalahti et 
al. 2003). Clinical PUUV infection in children seems rare, less than 5% of all reported 
patients with NE being under 15 years old. This may reflect the lesser severity of the 
disease in children (Settergren 1991, Mustonen et al. 1994b, Huttunen et al. 2011). 
Clinical PUUV infection has a sudden onset with fever, headache and, after the 
second day, gastrointestinal symptoms such as nausea, vomiting and abdominal or 
back pain (Figure 1) (Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a, 
Braun et al. 2010). Somnolence as well as ocular symptoms due to myopia are com-
mon (70%) in the early phase of the infection (Hautala et al. 2010). In the few severe 
cases hypotension and shock may develop rapidly. Renal symptoms begin around the 
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3rd or 4th day of the illness, typically manifested by transient proteinuria, microscopic 
hematuria and acute renal failure with oliguria followed by polyuria and spontaneous 
recovery. About 5% of all hospital-treated patients need transient hemodialysis treat-
ment (Mustonen et al. 1994a, Braun et al. 2010). 
Figure 1.  Schematic representation of typical clinical course of nephropathia epidemica. 
(Reprinted from Vapalahti et al. 2003. Copyright 2012, with permission from 
Elsevier.)
As rare neurological manifestations, encephalitis, Guillain-Barre syndrome and acute 
disseminated encephalomyelitis have been reported (Mustonen et al. 1994a). Signs of 
inflammation (class IgM PUUV-specific antibodies, elevated protein level or leukocyte 
count) in the cerebrospinal fluid can, however, be detected in half of the hospitalized 
patients with acute PUUV infection (Hautala et al. 2010). 
Almost all patients with acute PUUV infection recover with mortality of 0.08% 
(Makary et al. 2010). The long-term consequences of NE include most often mildly 
impaired renal function and elevated blood pressure (Mäkelä et al. 2000, Miettinen et 
al. 2006, Miettinen et al. 2009). Also chronic hormonal deficiencies and need of hor-
monal replacement therapy have been observed (Mäkelä et al. 2010). No association 
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between the severity of acute PUUV infection and the long-term outcome of patients 
has been noted (Miettinen et al. 2010). 
2.2.2 Laboratory and radiological findings during PUUV infection
An immunoglobulin (Ig) M enzyme immunoassay (EIA) test based on recombinant 
full-length hantavirus NP is currently applied to confirm the diagnosis of acute hanta-
virus infection in humans (Vaheri et al. 2008). Immunographic IgM tests are also avail-
able for rapid diagnosis of several hantavirus infections (Hujakka et al. 2001, Hujakka 
et al. 2003). Previous hantavirus infection can be detected with IgG EIA (Kallio-Kokko 
et al. 1998). Though not in routine clinical use, polymerase chain reaction method can 
detect hantaviral RNA in blood (Plyusnin et al. 1977a), urine (Plyusnin et al. 1977a), 
saliva (Pettersson et al. 2008) and cerebrospinal fluid (Mähönen et al. 2007).
Thrombocytopenia is encountered in a majority of NE patients. The platelet count 
nadir usually occurs 4–5 days after the onset of fever, and normalizes most often within 
7 days from the onset of initial symptoms (Lähdevirta 1971, Rasche et al. 2004, Braun 
et al. 2010). Table 2 presents data on platelet counts in Finnish (Lähdevirta 1971, 
Mustonen et al. 1994a), Swedish (Settergren et al. 1989, Sundberg et al. 2011) and Ger-
man patients (Braun et al. 2010). 
table 2. Platelet counts in patients with acute Puumala hantavirus infection. 
Study Percentage of patients additional data on platelet count (x 109/l)
 with thrombocytopenia 
Lähdevirta 1971 (n=34) 57% 20% with nadir < 100, 7 patients with nadir < 5
Mustonen et al. 1994a (n=126) 75% mean 117, minimum 10, maximum 489
Settergren et al. 1989 (n=74) 52% median 96, range 22–457, 15% with nadir < 50, 
  5% with nadir < 10
Braun et al. 2010 (n=75) 69% mean 137±11, the lowest value observed 16
Sundberg et al. 2011 (n=106) not available median 95, range 17–404
A mildly elevated leukocyte count is frequently (36–57%) detected during the acute 
phase of NE (Lähdevirta 1971, Mustonen et al. 1994a, Braun et al. 2010). Anemia is 
observed in 50% of patients (Mustonen et al. 1994a), but also signs of hemoconcentra-
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tion may be observed.  Increased levels of plasma C-reactive protein (CRP) and serum 
creatinine concentration are found in almost all patients (96–100% and 96%, respec-
tively) (Settergren et al. 1989, Braun et al. 2010). 
Recent studies have discovered laboratory markers not yet in routine clinical use 
but predictive for the course of acute PUUV infection. A high plasma interleukin-6 
(IL-6) concentration has been found to be associated with several variables reflecting 
severe disease (Outinen et al. 2010). High serum indoleamine 2,3-dioxygenase activity 
is linked to renal impairment (Outinen et al. 2011a), and a high plasma pentraxin-3 
level predicts a low platelet count (Outinen et al. 2011b).
Abnormal cardiac signs may be detected by electrocardiogram or echocardiogra-
phy in more than half of patients during acute PUUV infection  (Mäkelä et al. 2009). 
The most common abnormal findings in the electrocardiogram are transient T-wave 
inversions, and in echocardiography impaired contractility of the left ventricle (Mäkelä 
et al. 2009). 
Abnormal findings in chest radiography or computed tomography have been 
described in 16–53% of patients during the acute phase of NE (Lähdevirta 1971, 
Mustonen et al. 1994a, Linderholm et al. 1992, Kanerva et al. 1996, Paakkala et al. 
2004). Pleural effusion, atelectasis and interstitial infiltrates are the most frequent 
observations (Paakkala et al. 2008). The changes are most often mild or moderate, 
being severe in only 2% of cases (Paakkala et al. 2008).
2.2.3 Hemorrhagic manifestations in hantavirus infections
In PUUV infection, bleeding manifestations usually remain mild. In a Finnish study 
petechiae (12%), epistaxis (11%), conjunctival bleeding (6%) and macroscopic hema-
turia (3%) were reported (Lähdevirta 1971). In a subsequent Swedish study 37% of 
patients had some hemorrhagic manifestation, most commonly epistaxis (21%), but 
conjunctival bleeding, metrorrhagia, macroscopic hematuria, melena, hematemesis 
and petechiae were also reported (Settergren et al. 1989). Mild gastrointestinal bleed-
ing has been demonstrated by gastroscopy in nearly all NE patients (Nuutinen et al. 
1992). 
Hemorrhage of the pituitary gland has been demonstrated by MRI (Hautala et al. 
2002, Hautala et al. 2010) and in autopsy (Valtonen et al. 1995, Hautala et al. 2002). 
Additionally, hemorrhage has been documented in the kidneys and other organs in 
fatal cases of NE (heart, liver, lungs and peritoneal cavity) (Valtonen et al. 1995). 
Hemorrhagic manifestations of DOBV infection are more prominent than those 
of PUUV infection: thrombocytopenia is more severe and hemorrhagic complications 
are reported in 26–59% of patients (Avsic-Zupanc et al. 1999).  SAAV infection is con-
sidered less severe than DOBV, but no comprehensive clinical comparisons are avail-
able (Vapalahti et al. 2003). 
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The worldwide-distributed SEOV causes an infection with milder thrombocyto-
penia and hemorrhagic symptoms and less severe clinical disease than HTNV (Kim 
et al. 1995, Zhang et al. 2011). Macroscopic bleeding symptoms are reported in 53% 
of patients, and typically severe bleeding symptoms are missing. Gingival hemorrhage 
(20%), melena (20%), macroscopic hematuria (16%) and epistaxis (16%) are common 
(Zhang et al. 2011).
HTNV causes an infection with a far more distinctive bleeding tendency than that 
typically found in other forms of HFRS. Macroscopic bleeding symptoms are found 
in nearly all patients (94%), and in particular severe hemorrhagic symptoms such as 
hematochezia (6%) and hematemesis or hemoptysis (5%) are present in this group of 
hantavirus infections (Zhang et al. 2011). In fatal cases the hemorrhagic triad of renal 
medulla, right atrial wall and anterior lobe of the pituitary gland has been observed 
(Lukes 1954). 
2.3 Hantaviruses and host genetic factors
Increased endothelial permeability and thrombocytopenia are the clinical hallmarks 
of hantavirus infection, but the pathogenetic mechanisms leading to them are not yet 
completely understood. The suggested pathophysiological processes include hyperacti-
vation of PUUV-specific T-cells, overproduction of tumor necrosis factor (TNF) α and 
other cytokines, and platelet dysfunction (Mackow et al. 2009). With recognition of the 
genetic basis for individual variation in infectious diseases the role of certain genetic 
markers related to potentially important pathogenetic mechanisms has become the 
subject of intense studies in hantavirus as well as in other infections.
2.3.1 Human leukocyte antigen (HLA)-B8-DR3 haplotype
HLA are major cell surface antigens which present the antigen peptides to T cell. 
Increased amounts of CD8+ T cells have been detected in patients with acute hantavi-
rus infection (Terajima et al. 2004). CD8+ T cells dominate in lymphocyte infiltrates of 
kidney biopsies taken in the acute phase of PUUV infection (Temonen et al. 1996) and 
their presence has been shown also in endobronchial biopsies and bronchoalveolar 
lavage fluid taken in the acute phase (Rasmuson et al. 2011). These findings may reflect 
the hyperactivation of PUUV-specific T-cells which could contribute to the endothelial 
damage by attacking the endothelial cells presenting PUUV epitopes (Terajima et al. 
2004, Figure 2). 
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Mustonen and coworkers (1996) studied the role of HLA B8 DR3 haplotype known to 
be associated with increased or altered immune response in the clinical course of acute 
PUUV infection. Individuals with the HLA B8, C4A*Q0 (C4 null allele), DRB1*0301, 
DQA1*0501 and DQB1*0201 alleles suffered from the most severe forms of the dis-
ease, which might be explained by impaired clearance of immune complexes due to the 
deletion of the C4A gene (Mustonen et al. 1996, Terajima et al. 2004). PCR positivity 
of blood or urine sediment specimens taken in the acute phase of PUUV infection has 
been found to be associated with the extended HLA B8 DR3 haplotype (Plyusnin et 
al. 1997a). This would imply that the levels of viremia are higher or the clearance of 
the virus is delayed in patients carrying the HLA B8 DR3 haplotype (Plyusnin et al. 
1997a). The extended haplotype containing the HLA B8, DR3 and TNF 2 alleles is also 
accompanied by abnormal findings on chest radiography, especially pleural effusion 
(Paakkala et al. 2008), a finding reflecting capillary damage.
In regard to further associations between HLA haplotype and acute PUUV infec-
tion, the HLA B27 allele is known to be associated with a benign clinical course of 
the disease, reflected especially in a short treatment time in hospital (Mustonen et al. 
1998a).
Figure 2. Hypothesis of immunopathogenesis in PUUV-HFRS (modified from Terajima et al. 
2004).
HLA=human leukocyte antigen, TNF=tumor necrosis factor, PUUV=Puumala hantavirus.
 
HLA B8DR3+ patient 
C4A null allele Higher/prolonged viremia TNF2 allele 
Impaired clearance of 
immune complexes 
Hyperactivation of 
PUUV-specific T-cells 
Overproduction of TNFα 
Capillary damage 
26 Hemostasis and complement activation in puumala Hantavirus infection
2.3.2 Cytokine gene polymorphisms
TNFα is known to induce vascular permeability and increase the expression of 
endothelial adhesion molecules, and intravenous injection of TNFα induces a number 
of signs and symptoms similar to those seen in acute hantavirus infection (Tracey and 
Cerami 1994). However, the association of elevated plasma TNFα levels with the clini-
cal course of the hantavirus disease remains unclear (Mackow et al. 2009). There are 
also reports on elevated plasma levels of IL-1, IL-6 and IL-10 in HTNV (Krakauer et 
al. 1995) and PUUV (Linderholm et al. 1996) infections. However, only a very limited 
number of studies address the polymorphisms of the genes determining the amount of 
cytokine produced in patients with acute hantavirus infection. 
Probably the most widely studied of the several polymorphisms of the promoter 
region of the TNFα gene on chromosome 6 is a polymorphic site at position -308, 
involving the substitution of a guanine (-308G) by an adenosine (-308A), the latter 
being associated with increased TNFα production (Wilson et al. 1997, Hajeer et al. 
2001). The rarer TNF2 allele, associated with a high TNFα-producer phenotype, is more 
frequently found in patients with acute PUUV infection than in controls (Kaner va et 
al. 1998b). TNF2 allele carriers also suffer from more severe diasease compared with 
non-carriers as measured by several clinical and laboratory parameters (Mäkelä et al. 
2001). However, these findings could be due to the strong linkage disequilibrium with 
the HLA B8 DR3 haplotype known to be associated with a more severe outcome of the 
disease (Mäkelä et al. 2002). In a Brazilian study TNF2 allele has also been suggested to 
represent a risk factor for developing HCPS (Borges et al. 2010).
The IL-1 gene family on chromosome 2, which codes for IL-1α, IL-1β and IL-1 
receptor antagonist proteins, has been addressed in a study involving 87 patients with 
acute PUUV infection. None of the differences in the allele frequencies and genotypes 
of the genes in the IL-1 complex reached statistical significance (Mäkelä et al. 2001).  
2.3.3 Platelet genetic properties
Decreased platelet counts and an increased bleeding tendency are almost inavariably 
present in acute hantavirus infection. Platelet genetic properties as well as polymor-
phisms of genes encoding factors involved in blood coagulation and fibrinolysis have 
an impact on the functional outcome of the hemostatic system. Platelet genetic proper-
ties, such as GP polymorphism, have been studied in a number of disease conditions, 
including diabetes mellitus, atherosclerosis and hepatitis C. Human platelet (allo)anti-
gen (HPA) 1 and 2 polymorphisms have been found to be associated with the severity 
of dengue virus infection (Soundravally and Hoti 2007, Stephens 2010). Studies on the 
association of platelet genetic properties with the clinical disease in HFRS are, how-
ever, few. 
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β3 integrin, an abundant surface receptor of both endothelial cells and platelets, 
is the cellular receptor for HTNV (Gavrilovskaya et al. 1999). β3 integrins have a 
major role in platelet function and in maintaining capillary integrity, both known to 
be altered in acute hantavirus infection. Liu and coworkers (2008) addressed the role 
of β3 integrin in regard to thrombocytopenia and disease severity in HTNV-induced 
HFRS. They measured the percentage of CD61 (β3 integrin) -positive platelets and the 
intensity level of platelet CD61 by flow cytometry in 104 patients. The CD61 intensity 
in the oliguric phase correlated inversely with platelet count and positively with serum 
creatinine level and several other laboratory variables. According to the investigators, 
the intensity of platelet β3 integrin may be indicative of disease severity in patients with 
HFRS (Liu et al. 2008).
Altered platelet activation and platelet-dependent hemorrhagic disorder are 
involved in the pathogenesis of hantavirus infection (Liu et al. 2008, Wu et al. 1992), 
and platelet activation and adhesion are mediated by platelet membrane GPs.  Poly-
morphisms in the genes encoding for the most abundant platelet receptor, platelet GP 
IIb/IIIa or integrin αIIbβ3 (HPA-1 and HPA-3), have been linked to increased plate-
let adhesiveness and aggregation in some studies (Bray 1999, Reiner et al. 2000). The 
functions of β3 integrin in platelet adhesion and activation, maintenance of capillary 
integrity and cellular entry of pathogenic hantaviruses prompted a study by Liu and 
coworkers (2009a) focusing on the association of HPA-1 and HPA-3 polymorphisms 
of GP IIbIIIa in patients with HTNV-HFRS. The study cohort comprised 104 patients, 
and 100 healthy unrelated blood donors served as controls. The investigators found 
no association between HPA-1 polymorphism, which is present on GP IIIa (β3), and 
the disease or its severity. On the other hand, there were significant differences in the 
HPA-3 polymorphism both between HFRS patients and controls and between HFRS 
patients of different clinical types. Based on these findings, the investigators considered 
HPA-3 polymorphism to constitute one possible inherited risk factor associated with 
susceptibility to hantavirus infection and disease severity in HFRS (Liu et al. 2009a). 
2.4 Role of complement activation in hantavirus infection
2.4.1 Molecular mechanisms between the complement and coagulation systems
The complement system is a proteolytic cascade composed of serine proteases with 
three major pathways of activation, the classical, the alternative and the lectin-depend-
ent. These differently activated pathways all converge on complement component C3, 
which has a key function in the complement system (Walport 2001). When the com-
plexes are formed in the absence of a target membrane in the fluid phase, C5b-9 binds 
to S-protein (vitronectin), forming a non-lytic soluble SC5b-9 terminal complement 
complex (TCC). The cytolytic membrane attack complex (MAC) is the final product 
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of the complement cascade (Podack et al. 1979). The complement and coagulation sys-
tems are commonly described as separate cascades, even though both belong to a com-
plex inflammatory network (Rittirsch et al. 2008) and exhibit some similar characteris-
tics in respect of the specialized functions of their activators and inhibitors (Figure 3).
Figure 3. Simplified model of the serine protease system depicting the complex interplay 
between the coagulation/fibrinolysis cascade and the complement system. 
The serine proteases of the complement, coagulation and fibrinolysis systems 
are highlighted in yellow. The black dotted arrow bars show previously known 
interactions between these systems. The red arrows identify the new paths of  
complement activation by the coagulation/fibrinolysis factors, resulting in the 
generation of C3a, and C5a. aPC=activated protein C, MAC=membrane attack 
complex, MBL=mannan-binding lectin, PK=prekallikrein. (Amara U et al. 2010. 
Copyright 2010. The American Association of Immunologists, Inc.)
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Multiple links have been found between the complement and coagulation cascades. 
Activated (a) human coagulation factor (F) XII is known to be able to activate comple-
ment factor C1r and thereby initiate activation of the classical pathway, and the C1r 
esterase inhibitor suppresses both complement activation and intrinsic coagulation 
cascade (FXIIa, kallikrein; Ghebrehiwet et al. 1981). Thrombin is capable of generat-
ing the complement activation product C5a in the absence of C3 (Huber-Lang et al. 
2006) and possibly even in the absence of C4 (Clark et al. 2008). C5a is able to induce 
tissue factor (TF) activity and may thus be involved in the activation of the extrinsic 
coagulation pathway (Ikeda et al. 1997). Importantly, the terminal complement com-
plex (TCC; SC5b-9) is able to catalyze prothrombin cleavage to thrombin and thus 
increase platelet prothrombinase activity (Wiedemer et al. 1986). On the other hand, 
C5a is also known to have fibrinolytic activity (Wojta et al. 2002). The lectin pathway of 
the complement system and coagulation cascade are linked by mannan-binding lectin 
–associated serine protease 2, which has been found to promote fibrinogen turnover by 
cleaving prothrombin into thrombin (Krarup et al. 2007).
Amara and coworkers (2010) described several molecular mechanisms linking the 
coagulation and fibrinolysis cascades with the central complement components C3 
and C5 (Figure 3). Thrombin, FXIa, FXa, FIXa and plasmin were all found to cleave C3 
and C5 into products displaying molecular weights identical to the native anaphylatox-
ins C3a and C5a. Cleavage products exhibited chemoattraction of human mast cells 
and neutrophils. FXa-induced cleavage of C3 was suppressed by fondaparinux and 
enoxaparin, the selective FXa inhibitors. The investigators also reported a very early 
appearance and correlation of coagulation (thrombin-antithrombin complexes) and 
the complement activation product C5a in plasma samples from 12 patients with mul-
tiple injuries (Amara et al. 2010). This study further stresses the extensive cross-talk 
between molecular mechanisms active in blood coagulation and fibrinolysis with the 
complement system. 
2.4.2 Complement activation and clinical hantaviral disease
Studies addressing the possible association between complement activation and clini-
cal outcome of hantavirus disease are few. Wang and coworkers (1986) observed the 
peak of complement activation in HTNV-HFRS to appear during the hypotensive 
phase and gradually disappear in the convalescent phase. A study by Lee reported the 
appearance of circulating immune complexes along with decreased C3 and normal C4 
levels in the serum of patients with HFRS induced presumably by HTNV. A significant 
decrease of serum C3 was most evident in patients with disseminated intravascular 
coagulation (DIC; by Colman’s criteria) (Lee 1987).
The complement system is also known to be activated in PUUV-HFRS. A study by 
Paakkala and coworkers (2000) included 25 hospital-treated patients with serologically 
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confirmed acute PUUV infection. The complement system was activated in 23 of them, 
an activation through the alternative route being a more frequent finding. However, 
classical pathway activation was associated with more severe clinical course of the dis-
ease (Paakkala et al. 2000). 
2.5 Hemostatic system and hantavirus infection
2.5.1 Platelets, their functions and mechanisms of thrombocytopenia
Platelets are small anucleate cells which are derived from megacaryocytes in the bone 
marrow. There are approximately one trillion platelets circulating in the blood of an 
adult human (platelet count reference range 150–360 x 109/l), and their average daily 
consumption ranges between 7–10 x 109/l. If not consumed earlier, they are destroyed 
in the spleen after 8–10 days. 
The primary physiological role of the platelets is to initiate blood clotting to block 
circulatory leakage in the damaged vessel endothelium (Italiano and Hartwig 2007, 
Semple et al. 2011). As a functional response to vessel wall injury platelets manifest 
adhesion, activation-secretion and aggregation. The adhesion of platelets is mediated 
by specific membrane receptors, platelet GPs, known to be polymorphic (Rozman 
2002). 
Platelets also influence the innate and adaptive immune responses. They can syn-
thesize and store molecules in the alpha and dense granules and lysosomes (Semple et 
al. 2011). Following activation with thrombin, platelets are capable of secreting over 
300 different proteins, and some of them are clearly involved in processes other than 
blood clotting (Coppinger 2007, Semple et al. 2011). Platelet-derived CD154 supports 
B cell differentiation and immunoglobulin class-switching, thus promoting adaptive 
immune responses (von Hundelshausen and Weber 2007). Platelet-expressed CD154 
also enhances leukocyte recruitment to inflammatory sites by inducing upregulation of 
intercellular and vascular adhesion molecules (Andre et al. 2002), and also augments 
CD8+ T cell responses (Elzey et al. 2008). Other examples of the ways platelets pro-
mote innate immunity include expression of toll-like receptors (Shiraki et al. 2004) and 
ligands for triggering receptors expressed on myeloid cells 1 (Haselmayer et al. 2007). 
Platelets have been shown to have roles in the initiation of inflammation, angiogenesis, 
atherosclerosis, lymphatic development and tumor growth (Smyth et al. 2009).
The most common mechanism of thrombocytopenia is accelerated platelet destruc-
tion caused by immunologic or nonimmunologic processes. Thrombocytopenia may 
also result from deficient platelet production as a consequence of hypoplastic mega-
caryocytes, ineffective thrombopoiesis, disorders in thrombopoietic control or heredi-
tary thrombocytopenia. Abnormal pooling of the platelet mass may produce throm-
bocytopenia, as seen in the various disorders associated with splenomegaly (Rodgers 
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2009). In viral infections, the development of thrombocytopenia often involves multiple 
mechanisms. In dengue virus infection, bone marrow suppression, enhanced immune 
response and activation of endothelial cells all contribute to a decrease in platelet count 
(Srichaikul and Nimmannitya 2000, Sosothikul et al. 2007). The mechanisms of throm-
bocytopenia in chronic hepatitis C infection include bone marrow suppression and 
platelet antibody formation (Olariu et al. 2010). In human immunodeficiency virus 
(HIV) infection, thrombocytopenia is generally associated with decreased platelet sur-
vival (Savona et al. 1985). In addition, defective megacaryopoiesis and splenomegaly 
may contribute to thrombocytopenia particularly in patients with advanced disease 
(Savona et al. 1985, Zauli et al. 1992, Kunzi et al. 1993). 
2.5.2 Platelets in hantavirus infection
HTNV-induced HFRS is known for severe hemorrhagic problems. Potential causes of 
thrombocytopenia during HFRS as cited in the literature involve immune mechanisms, 
vascular injury and DIC (Cosgriff 1991, Cosgriff and Lewis 1991). Immune complexes 
on platelet surfaces in HFRS patients are thought to induce platelet aggregation, as 
well as lysis of platelets by complement and phagocytosis of platelets by mononuclear 
phagocytes. Vascular injury contributes to decreased platelet counts through platelet 
adherence and aggregation to subendothelial connective tissue. Platelet dysfunction 
(Cosgriff et al. 1991) and the “exhausted platelet syndrome” (the continued circulation 
of platelets which have already been activated) have some role in bleeding tendency, as 
well as uremia and inhibition of platelet aggregation by fibrinogen degradation prod-
ucts (Cosgriff and Lewis 1991).  
In a study of coagulation, fibrinolysis, kinine and immune systems in HTNV-
induced HFRS, Lee (1987) showed that the most frequently observed abnormality in 
the coagulation profile was a decrease in the platelet count. The life-span of platelets 
was significantly shortened, and the peripheral blood smear revealed giant platelets. In 
vitro aggregations to ADP, epinephrine and collagen were decreased (Lee 1987). The 
finding of decreased platelet aggregation and release in HTNV-HFRS were later veri-
fied by Xiang and coworkers (1990). In the bone marrow an increase in the number 
and size of megakaryocytes and active formation of platelets from the megakaryocytes 
was noted in an electron microscopic study (Lee 1987). Bone marrow aspiration has 
also been performed in five cases of PUUV-HFRS by Lähdevirta (1971), and plasma 
cell reaction together with increased megakaryocyte formation and number of imma-
ture megakaryocytes were noted.
Decreased platelet counts and bleeding of variable severity occur in all hantavi-
rus infections. However, it is not yet clarified why certain hantavirus species cause 
deeper thrombocytopenia and more severe hemorrhagic problems than others. The 
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divergence of hantavirus surface GPs (G1 and G2) is likely to contribute to  pathogenic 
reponses to individual viruses (Mackow and Gavrilovskaya 2001).
2.5.2.1 β
3  
integrin
Gavrilovskaya and coworkers (1999) published findings demonstrating that the cellu-
lar entry of pathogenic hantaviruses (HTNV, SEOV and PUUV) but not the nonpatho-
genic PHV is mediated by β3 integrins, which are abundantly present on the surfaces 
of platelets, endothelial cells and macrophages. The pathogenic hantaviruses bind the 
plexin-semaphorin-integrin domains present at the apex of inactive, bent αvβ3 integrins 
(Raymond et al. 2005). The entry of pathogenic hantaviruses to endothelial cells could 
be inhibited by antibodies to αvβ3 integrins and the integrin ligand vitronectin. The cel-
lular entry of the nonpathogenic PHV was blocked by α5β1-specific sera and the inte-
grin ligand fibronectin. Interestingly, a mouse–human hybrid β3 integrin-specific Fab 
fragment c7E3 (ReoPro) inhibited the infectivity of HTNV, SEOV, PUUV, as well as 
SNV and NY-1 associated with HPS (Gavrilovskaya et al. 1999). As β3 integrins regu-
late platelet function and vascular permeability, the pathogenic hantavirus regulation 
of β3 integrin possibly impacts platelet functions and contributes to the thrombocyto-
penia and loss of vascular integrity seen in hantavirus infection (Mackow et al. 2009). 
	  
Figure 4.  Model depicting cell-associated hantavirus directing the adherence of quiescent 
platelets to surface of infected endothelial cells. (Mackow et al. 2009. Copyright 
permission no 302/11/2011 by Schattauer GmbH.)
EC=endothelial cell.
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The interaction between pathogenic hantaviruses, platelets and endothelial cells was 
further discussed by Gavrilovskaya and coworkers (2010) based on observations of 
pathogenic hantaviruses binding quiescent platelets and platelets binding to endothe-
lial cells infected with pathogenic hantaviruses. They concluded that a platelet layer 
covers the surface of infected endothelial cells (Figure 4) which changes the appear-
ance of these cells. This may alter cellular immune responses, platelet activation 
and endothelial cell functions and result in a loss of vascular integrity. These could 
be mechanisms by which hantaviruses cause thrombocytopenia and induce hypoxia 
(Gavrilovskaya et al. 2010).
2.5.2.2 Platelet ligands and serum thrombospondin-1
Vitronectin, a ligand of platelet αIIbβ3 integrin, is produced mainly by the liver and 
stored in platelet alpha-granules. Vitronectin plays a role in platelet adhesion, aggre-
gation and fibrinolysis (Seiffert et al. 1996, Reheman et al. 2005). Vitronectin is also 
involved in complement activation (Podack et al. 1979). Vitronectin gene expression 
is up-regulated in inflammation and has been identified as an acute-phase reactant 
(Korc-Grodzicki et al. 1988). Liu and coworkers (2009b), however, found decreased 
serum vitronectin levels in 112 patients with HTNV-HFRS from China, and the low-
est levels of vitronectin were measured during the hypotensive and oliguric phases. 
There was no association between serum vitronectin levels and the  clinical severity of 
the disease. The authors consider the decreased alteration of vitronectin as a possible 
consequence of inflammation, abnormal coagulation and liver damage in HFRS (Liu 
et al. 2009b).
Another ligand of β3 integrin, fibronectin, is derived mainly from vascular 
endothelial, fibroblast and liver cells. Fibronectin is firmly bound to fibrinogen and 
fibrin at low temperatures (0–4°C) in vitro and subsequently released as the tempera-
ture rises (Ruoslahti and Vaheri 1975). Fibronectin participates in plug formation by 
gluing platelets to each other especially under arterial share rates (Ni et al. 2003), and 
it is thought to play a role in the infectious disease process due to its participation in 
adhesion and signal transduction pathways (Orem et al. 2002, Ruiz Martin et al. 2004). 
Serum fibronectin concentrations have been found to be increased and associated with 
disease severity in 112 patients with HTNV-HFRS (Han et al. 2010). However, the tem-
perature at which the ELISA analyses were carried out was not provided. 
Thrombospondin (TSP)-1 is a matricellular GP released mainly from the alpha-
granules of activated platelets. TSP-1 plays a role in several cell-matrix or cell-cell inter-
actions, which influence platelet function, angiogenesis, tumor biology, wound healing 
and vascular disease (Taraboletti et al. 1990, DiPietro et al. 1996, Frangiogannis et al. 
2005). The plasma level of TSP-1 is usually low in the healthy vascular system and over-
expressed during inflammation or injury (Esemuede et al. 2004, McMaken et al. 2011). 
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The serum TSP-1 levels of the above mentioned 112 Chinese HTNV-HFRS patients 
were found to be significantly decreased in the febrile and hypotensive phases com-
pared with the controls (30 healthy volunteers without a history of HFRS-like disease) 
(Liu et al. 2008b). The reduction in TSP-1 level was more profound in patients with 
severe clinical disease. The investigators assumed that the interaction of hantavirus 
and αIIbβ3 integrin may lead to the activation of platelets and release of the contents of 
alpha-granules. In the course of the HFRS platelets become more seriously affected and 
in the severe cases thrombocytopenia emerges, resulting in decreased production and 
release as well as increased consumption of TSP-1 (Liu et al. 2008b).
2.5.3 Activation of coagulation and fibrinolysis
Vascular injury is thought to play a major role in the activation of the coagulation 
system in HFRS. Exposure of subendothelial tissue leads to activation of FXII, which 
results in the generation of thrombin via the intrinsic pathway. Exposure of tissue fac-
tor on the surface of endothelial cells and platelets, again, can activate extrinsic coagu-
lation pathway (Cosgriff and Lewis 1991). Tissue factor may also be produced as a 
response to IL-1 and TNF-α (Bevilacqua et al. 1986). Tissue factor might possibly be 
elaborated by monocytes during the course of HFRS (Edwards and Rickles 1984), but 
so far there are no published data on this mechanism in hantavirus infection. 
In a study of coagulopathy in patients with HTNV-HFRS Lee (1987) noted a 
marked prolongation of the bleeding time along with a decrease in platelet counts. 
Prothrombin time (PT) and partial thromboplastin time were prolonged in 30–80% of 
patients and normalized within 2 weeks from the beginning of the disease. The activi-
ties of coagulation factors II, V, VIII, IX and X were decreased, but factor VIII -related 
antigen was increased and Von Willebrand factor ristocetin cofactor (VWF:RCo) 
activity remained normal. The blood fibrinogen concentration was decreased in 20% 
of patients and the fibrinogen half-life was markedly shortened. Thrombin time (TT) 
was prolonged and increased levels of fibrin degradation products (FDP) were noted. 
Lowered plasma levels and activities of plasminogen, alpha 2 -plasmin inhibitor and 
antithrombin (AT) were observed. Thromboelastogram confirmed the presence of 
procoagulant activity (Lee 1987). 
The findings of Xiang and coworkers (1990) in 134 patients with HTNV-HFRS are 
consistent with those of Lee in 1987. Both TT and PT were prolonged. The concentra-
tions of plasma fibrinogen and plasminogen and the activity of AT were all decreased 
(Xiang et al. 1990).
Settergren and coworkers (1989) observed prolongation of activated partial throm-
boplastin time (APTT) and/or PT in 41% of patients with PUUV infection. Elevated 
blood levels of FDP were also noted in some cases (Settergren et al. 1989). Previously, 
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Lähdevirta (1971) had observed consistent abnormalities in coagulation tests in a 
small number of patients included in his larger study of PUUV-HFRS. 
2.5.4 Disseminated intravascular coagulopathy
In the literature DIC is considered to be common in HFRS induced by HTNV (Cos-
griff and Lewis 1991). There are also published data supporting a relationship between 
laboratory findings of DIC, risk of hemorrhage and overall disease severity in patients 
with HFRS (Luo et al. 1979). However, the diagnostic criteria for DIC vary and the 
scoring system recommended by the International Society of Thrombosis and Haemo-
stasis (ISTH) (Taylor et al. 2001) is not applied. 
In a study including patients admitted to Seoul National University Hospital and 
the Army General Hospital during the period 1979–1986, Lee (1987) observed DIC 
by Colman’s criteria in 100% of patients on the 4th day of clinical illness. Decreased 
platelet count, prolonged bleeding time together with PT and PTT, decreased levels of 
coagulation factors, activation of the fibrinolytic system, presence of plasma procoagu-
lant activity and fibrin thrombi in autopsy cases were also demonstrated (Lee 1987). 
Settergren and coworkers (1983) described a patient with NE and DIC from Swe-
den. The symptoms and laboratory findings included macroscopic hematuria, increased 
levels of FDP, decreased prothrombin complex and prolonged APTT. In 1995 four fatal 
cases of NE and presumed DIC from Finland were presented. All patients had macro-
scopic hematuria and signs of bleeding in autopsy, but except for low platelet counts no 
data on markers of coagulation and fibrinolysis were presented (Valtonen et al. 1995). 
In a study of 74 patients with NE Settergren and coworkers (1989) found that 5% of 
them developed DIC, which was defined as clinically evident bleeding, positive ethanol 
gelation test, increased serum FDP levels and platelet count below 100 x 109/l. 
A large outbreak of PUUV-induced HFRS occurred in northern Sweden in 2006–
2008, with several patients falling critically ill with thromboembolic complications and 
life-threatening bleeding. Sundberg and coworkers (2011) included 106 patients in 
their study designed to establish the variability of DIC in consecutive patients and to 
evaluate different DIC scores as prognostic markers for severe illness. The investigators 
based their diagnosis of DIC on the scoring system recommended by the ISTH (Taylor 
et al. 2001) (Table 3), which they modified by including correction for the fibrinogen/
CRP ratio. They found that 28% of the patients met the criteria for overt DIC, and the 
diagnosis of DIC correlated with more severe disease. ISTH score with fibrinogen/CRP 
ratio was predictive for moderate or severe illness and bleeding of moderate or major 
importance (Sundberg et al. 2011). 
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table 3. The ISTH score for overt DIC. A score of 5 points or more is indicative of DIC 
(modified from Taylor et al. 2001).
test Result Points
Platelet count (x109/l) <100 1
 <50 2
D-dimer (mg/l) >0.5 2
 >4.0 3
Thromboplastin time (%) <70 1
 <40 2
Fibronogen (g/l) <1.0 1
ISTH=the International Society of Thrombosis and Haemostasis, DIC=disseminated intravascular coagulopathy.
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3 aiMS OF tHe StuDY
The aims of the present study were to assess
1. the activation of coagulation and fibrinolysis in acute PUUV infection and relate 
the findings to the clinical course of the disease
2. whether disseminated intravascular coagulopathy could be diagnosed with the 
ISTH score during acute PUUV infection
3. the adhesive platelet ligands related to endothelial function and acute phase reac-
tions in PUUV infection and relate the findings to the clinical course of the disease
4. the complement activation along with the clinical disease in PUUV infection
5. the possible associations between genetic polymorphisms involved in platelet func-
tion, blood coagulation and fibrinolysis and the clinical course of PUUV infection
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4 PatientS anD MetHODS
4.1 Patients
All patients came from the Pirkanmaa region of Finland and were hospitalized in Tam-
pere University Hospital with serologically confirmed acute PUUV infection.  Studies 
I–III were carried out in Tampere University Hospital, the University of Tampere 
School of Medicine, the University of Helsinki Haartman Institute and the Laboratory 
of Helsinki University Central Hospital. Study IV was carried out in Tampere Univer-
sity Hospital and the University of Tampere School of Medicine. As depicted in Figure 
5, all patients in studies I–II (n=19) were included in study III (n=61) and study IV 
(n=172). Studies III and IV had 48 patients in common.
Figure 5.   Distribution of patients participating in studies I–IV. 
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Studies I–II involved 19 patients (17 men, median age 38 years, ranging from 30–64 
years) selected from those who participated in a larger prospective study during the 
period from September 2000 to December 2002. Selection was based on the availability 
of laboratory samples. 
Regarding the medical history of the patients in studies I–II, there were two 
patients with a neurological disease (multiple sclerosis and epilepsy) and two patients 
with dyslipidemia. One patient had coronary heart disease, one arterial hypertension 
and one paroxysmal atrial fibrillation. One patient with chronic inflammatory bowel 
disease was treated with mesalazine medication. Two patients used anti-platelet ther-
apy (aspirin). No patient was receiving anticoagulation or immunosuppression. 
Study III was prospective involving 61 patients (44 men, median age 46 years, rang-
ing from 22–77 years) and conducted between September 2000 and January 2004. The 
study group included patients with multiple sclerosis, epilepsy, Sjögren’s syndrome, 
fibromyalgia, hypothyroidism, paroxysmal atrial fibrillation, Crohn’s disease and sar-
coidosis, one each. Two patients had dyslipidemia, coronary heart disease, asthma or 
prostatic hyperplasia. There were eight patients with arterial hypertension.
Study IV, involving 172 prospectively collected patients (118 men, median age 40 
years, ranging from 15 to 74 years) was conducted during the period from Septem-
ber 1997 to February 2009. Patients’ medical histories included arterial hypertension 
(12 patients), dyslipidemia (7 patients), asthma (6 patients), coronary heart disease (5 
patients), paroxysmal atrial fibrillation and rheumatoid disease (3 patients each). Two 
patients had celiac disease, inflammatory bowel disease, valvular heart disease or a 
neurological disease.  
4.2 Study protocols
In studies I–II, three blood samples per patient were collected during the acute phase 
of the disease. The first sample was obtained as early as possible on admission, 2–9 
(median 6) days after the onset of fever. The second sample was obtained 3–10 (median 
7) days and the third 6–13 (median 10) days after the onset of fever. The fourth sam-
ple for the study was drawn at full recovery (ranging 32–54 days after the onset of 
fever, median 43 days). Citrate-anticoagulated (109 mM sodium citrate) samples were 
 centrifuged at 1500 g for 20 min and the separated plasma samples were frozen at 
-70°C. Prior to analyses the defrozen samples were recentrifuged at 2500 g for 15 min.
In study III, the median number of plasma samples taken from the patients during 
the hospital stay was 4 (range 1–6). Again, the first sample was obtained on admission, 
2–16 (median 5) days after the onset of fever, and the second 4–16 (median 6) days 
after the onset of fever. The third sample was taken 6–17 (median 8) days after the onset 
of fever and the fourth 6–14 (median 9) days after the onset of fever. The fifth sample 
was drawn 7–11 (median 10) and the sixth 13–18 (median 16) days after the onset of 
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fever. The last study sample was taken at full recovery, 18–55 (median 38) days after the 
onset of fever. The set of samples for SC5b-9 analyses were stored at -70°C and the set 
for C3/C4 analyses at -20°C.
In study IV, the DNA needed for genotyping was extracted from whole blood using 
a commercially available kit (Quiagen Inc., Hilden, Germany).
Basic laboratory parameters determined at the Laboratory Centre of Pirkanmaa 
Hospital District together with clinical data were retrieved from patient charts for all 
four studies. Plasma IL-6 measurements were made on three consecutive mornings 
starting from the first morning of the hospital stay. For the patients in studies I–II 
treatment with plasma transfusions or platelets to correct possible coagulopathy as well 
as treatment with heparin were noted. In study III, all chest radiographs were studied 
retrospectively by an experienced radiologist.
4.3 Controls
In studies I–III, the samples taken in the recovery phase served as controls. In the case 
of study IV, data on the allele frequencies of the platelet antigens, VWF and plasmi-
nogen activator inhibitor (PAI-1) in the general population in the Pirkanmaa region 
are missing. This should not, however, be interpreted as a major shortcoming of study 
IV, since the focus of the study was on the severity of the disease in hospital-treated 
patients, not on the prevalence of the disease.
4.4 Methods
4.4.1 Serological diagnosis of PUUV infection
The specific serological diagnosis of acute PUUV infection was based on an IgM- 
capture EIA and PUUV Sotkamo strain full-length NP expressed by using the bacu-
lovirus system in Sf9 insect cells (Vapalahti et al. 1996). In comparison with various 
other protocols, the assay showed optimal sensitivity and specificity (Sjölander KB et 
al. 1997). The blood sample for the assay was taken in the beginning of the hospital 
stay, and the analyses were carried out at the Department of Virology in the University 
of Helsinki. 
4.4.2 Basic laboratory tests and assessment of clinical disease
During the hospital stay, basic laboratory tests such as complete blood count (CBC), 
plasma C-reactive protein (CRP) and serum potassium and creatinine concentrations 
were carried out according to the clinical needs of the patients. Determinations were 
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made at the Laboratory Centre of Pirkanmaa Hospital District using standard meth-
ods.
Unfortunately there is not available any clinical score or grading system to assess 
the severity of hantavirus infection. Probably the most objective tool to measure the 
severity of hantavirus disease is the length of hospital stay. Widely accepted indicators 
of severe hantavirus disease include impaired renal function as measured by elevated 
serum creatinine concentration and need of transient hemodialysis treatment, hemor-
rhagic problems, clinical shock and death. 
4.4.3 Biomarkers of coagulation and fibrinolysis (study I)
Laboratory analysis included PT expressed as % (PT%, Nycotest PT®, Axis-Shield PoC 
As), APTT (Actin FSL®, Siemens Healthcare Diagnostics) and TT (Siemens Health-
care Diagnostics). Fibrinogen was measured with a modification of the Clauss method 
(Multifibren® U, Siemens Healthcare Diagnostics) and D-dimer with an immunotur-
bidimetric assay (Tina-quant D-Dimer®, Roche Diagnostics).  Prothrombin fragments 
(F1+2) were measured by an enzyme immunoassay (Enzygnost® F1+2, monoclonal, 
Siemens Healthcare Diagnostics). The reference values for PT% were 70–130%, APTT 
23–33 s, TT 17–25 s, fibrinogen 1.7–4.0 g/l, D-dimer ≤ 0.5 mg/l and F1+2 69–229 
pmol/l. The protein S free antigen (PS) level was determined by an automated latex 
ligand immunoassay (Instrumentation Laboratory), reference values being 66–158% 
for males and 50–177% for females. AT and protein C (PC) activities were both deter-
mined by chromogenic assays (Berichrom®Antithrombin III and Berichrom®Protein 
C, Siemens Healthcare Diagnostics), reference values being 84–108% and 74–141%, 
respectively. All laboratory analyses were performed in the Laboratory of Helsinki 
University Central Hospital. 
4.4.3.1 Scoring for disseminated intravascular coagulopathy
The DIC scoring system by ISTH was used to evaluate individual patients (Taylor et al. 
2001, Table 3). The most abnormal value for each variable was chosen for scoring based 
on the three acute assessments. 
4.4.4 Platelet ligands and acute phase reactants (study II)
The activity of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospon-
din type 1 domain 13) was determined by immunochemical detection of its proteo-
lytic target, i.e. VWF (Technozym Elisa, Technoclone). Factor VIII activity (FVIII:C) 
was determined by one-stage clotting assay (Pathromtin SL and Coagulation Factor 
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VIII Deficient Plasma, Siemens Healthcare Diagnostics). VWF antigen (VWF:Ag) 
and VWF:RCo were measured using the BCS XP analyser with BC VWF Reagent and 
VWFAg Latex Reagent (Siemens Healthcare Diagnostics). Fibrinogen was measured 
with a modification of the Clauss method (Multifibren® U, Siemens Healthcare Diag-
nostics). Analyses of ADAMTS13, FVIII:C, VWF:Ag, VWF:RCo and fibrinogen were 
made in the Laboratory of Helsinki University Central Hospital. Fibronectin concen-
tration was determined at room temperature by enzyme-linked immunosorbent assay 
(human Fibronectin ELISA, Bender MedSystems) at the Haartman Institute. Plasma 
IL-6 concentrations were determined using a commercially available ELISA (PeliKine 
Compact ™ human IL-6 kit, Central Laboratory of the Netherlands, Red Cross Blood 
Transfusion Service) with a detection limit of 0.4 pg/ml.
4.4.5 Complement system (study III)
Complement analyses were carried out at the Haartman Institute and in the Labo-
ratory of Helsinki University Central Hospital. Plasma complement component C3 
and C4 levels were measured by nephelometry (Dade Behring) and SC5b-9 using an 
ELISA kit (Quidel). Some patient samples did not meet the quality-control criteria for 
measurements of C3, C4 and SC5b-9 levels defined by the manufacturer. These sam-
ples were thus excluded from the respective analyses.
4.4.6 Genotyping (study IV)
The gene polymorphisms of GP IIIa (HPA-1) T>C (rs5918) and GP Ib (HPA-2) C>T 
(rs6065) were genotyped with Assay-By-Design from Applied Biosystems under 
standard conditions using the ABI Prism 7900HT Sequence Detection System 
(Taqman, Applied Biosystems). The GP Ia (HPA-5) T>C (rs1126643) and the VWF 
A>G (rs1063856) were genotyped as previously described (Kekomäki et al. 1995 and 
Kunkel et al. 1990, respectively). Genotyping of the GPVI T>C (rs1613662) was per-
formed with minor modifications (Lepäntalo et al. 2006). For PAI-1 A>G (rs2227631) 
a commercial kit from Applied Biosystems was used. The distributions of all SNPs did 
not deviate from the Hardy–Weinberg equation. 
4.4.7 Statistical methods
In studies I–III, the most abnormal value of each continuous variable measured during 
the acute phase of NE was designated the minimum or maxium value. In study I, the 
highest values of APTT, F1+2 and D-dimer and the lowest values of platelet count, PT, 
TT, fibrinogen, AT, PC and PS were used. In study II, the lowest of three ADAMTS13 
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and fibronectin values and platelet counts and the highest values of FVIII:C, VWF:Ag, 
VWF:RCo and fibrinogen were taken. In study III, the highest value of SC5b-9 was 
chosen to respresent the peak of complement activation, and the lowest values of C3 
and C4 were chosen to represent the consumption during the acute phase of NE. 
In studies I–III, the change between the maximum or the minimum and the con-
trol value (the fourth sample) was calculated. Means (± standard deviations) and medi-
ans (ranges) were provided. To evaluate changes for each variable between the acute 
and the control phase, paired samples t-test or Wilcoxon’s test was used. Relationships 
between continuous variables were examined using Pearson’s or the Spearman rank 
correlation coefficient. Comparisons between the groups were based on the Mann-
Whitney U test for numerical and χ2 test for categorical data.
In study IV, allele frequencies were counted and patients were divided into  groups 
of carriers and non-carriers of the rarer (minor) allele. Comparisons between the 
groups were based on Mann-Whitney U or Kruskal-Wallis test for numerical and χ2 or 
Fisher’s exact test for categorical data.
In all four studies, the limit of significance was set at 0.05 (2-tailed). Computation 
was carried out using SPSS for Windows statistical software (version 7.5 in studies I–II, 
version 18 in study III and version 14 in study IV). 
4.5 Ethical considerations
Written informed consent was obtained from all patients. The study design was 
approved by the Ethics Committee of Tampere University Hospital. 
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5 ReSuLtS
5.1 The clinical features (studies I–IV)
In all four studies, all patients were suffering from clinically typical acute PUUV infec-
tion. All 185 patients recovered. 
In studies I–II, the most prominent symptoms on admission were: fever 100% 
(n=19), nausea and/or vomiting 63% (n=12), headache 47% (n=9), blurred vision 32% 
(n=6) and abdominal or back pain 16% (n=3). During the hospital stay only minor 
bleeding events occurred: two patients suffered from epistaxis and one from minor con-
junctival bleed. One of the three patients who needed transient hemodialysis treatment 
showed oozing at the base of the central venous catheter for several days and received a 
platelet transfusion of two units. The patients with minor bleeding symptoms had IL-6 
levels, leukocyte counts and CRP values higher than those without (p=0.007, p=0.019, 
for the last two, respectively). Five patients were treated with low-molecular-weight 
heparin for a few days either for thromboprophylaxis or maintenance of hemodialysis.
Four out of 61 (7%) patients participating in study III needed transient hemodi-
alysis. In study IV, three out of 172 patients (2%) were in clinical shock at the time of 
admission. Seven patients (4%) needed transient hemodialysis treatment.
Basic clinical and laboratory findings in patients included in studies I–IV are pre-
sented in Table 4.
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table 4. Basic clinical and laboratory findings in patients participating in studies I–IV.
Variable Studies I–II Study III Study IV
   
Length of hospital stay (days) 7 (3–15) 6 (2–15) 6 (2–15)
Diur 
min
 (ml) 880 (40–4770) 1620 (50–5800) 1450 (50–7000)
Change in weight (kg)* 3.2 (0.2–12.0) 2.7 (0–12.0) 2.1 (0–12)
Hematocrit 
min
 0.36 (0.28–0.45) 0.36 (0.25–0.43) 0.36 (0.25–0.46)
Leukocyte count max (x10
9/l) 11.8 (7.3–23.2) 9.9 (3.9–31.2) 10.0 (3.9–31.2)
Platelet count 
min
 (x109/l) 75 (13–238) 67 (0–238) 62 (3–238)
S-Creatinine max (µmol/l) 321 (74–1285) 175 (65–1285) 185 (51–1499)
P-CRP max (mg/ml) 61 (6–198) 69 (17–269) 75 (11–269)
P-Interleukin 6 max (pg/ml) 16.7 (3.6–96.6)
1 11.7 (1.3–96.6)2 14.5 (1.3–107)3
Diur=daily urinary output, min=minimum, max=maximum, S=serum, P=plasma, CRP=C reactive protein. *Change in weight reflects the 
amount of fluid accumulated in the body during the oliguric phase of the disease. 1 n=19, 2 n=48, 3 n=118. The values represent median 
(range). Reference values: hematocrit 0.35–0.50 for males and 0.35–0.46 for females, leukocyte count 3.4–8.2 x 109/l, platelet count 
150–360 x109 /l, S-creatinine <105 µmol/l for males and <95 µmol/l for females, P-CRP <10 mg/l.
5.2 Platelet ligands, coagulation and fibrinolysis (studies I–II)
Laboratory markers of endothelial cell activation, coagulation and fibrinolysis during 
the acute phase of PUUV infection and at recovery are presented in Table 5.
In study I, a markedly increased D-dimer during the acute phase of the disease was 
a prominent finding. The D-dimer level was 24-fold higher acutely compared with 
the control (Figure 1a in original publication I). F1+2 also increased 3.4-fold in the 
acute phase compared with recovery (Figure 1b in original publication I). D-dimer and 
F1+2 correlated positively (Figure 6a). Both remained within normal limits in only one 
patient. 
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table 5. Laboratory markers of coagulation, fibrinolysis and endothelial cell activation during 
the acute phase and at recovery in 19 patients with Puumala hantavirus infection 
(studies I–II).
Variable  Reference values Acute phase Recovery phase p
APTT max (s)  23–33  34 (29–47)  29 (26–34)  <0.001
Prothrombin time min (%)  70–130  84 ± 23  119 ± 31  <0.001
Thrombin time min (s)  17–25  16 ± 1.6  19 ± 1.9  <0.001
Fibrinogen min (g/l)  1.7–4.0  3.6 ± 1.2  3.2 ± 0.8  0.14
F1+2 max (pmol/l)  69–229  726 (160–1461)  213 (95–351)  <0.001
D-dimer max (mg/l)  ≤0.5  4.8 (0.3–19.5)  0.2 (0.1–1.4)  <0.001
Antithrombin activity min (%)  84–108  72 (52–113)  95 (64–119)  <0.001
Protein C activity min (%)  74–141  61 (32–121)  106 (64–185)  <0.001
Protein S free antigen min (%)  66–158  60 (19–90)  92 (68–121)  <0.001
VWF:Ag max (%)  51–169  252 (113–459)  88 (39–192)  <0.001
VWF:RCo max (%)  44–183  267±112  98±39  <0.001
FVIII:C max (%)  52–148  118 (56–173)  88 (39–192)  0.002
Fibrinogen max (g/l)  1.7–4.0  5.0±1.3  3.2±0.9  <0.001
ADAMTS13 max (%)  40–130  56 (34–90)  63 (45–85)  0.003
Fibronectin (µg/ml)  117–338  221 (114–350)  330 (138–928)  0.001
Max=maximum, min=minimum, APTT=activated partial thromboplastin time, F1+2=prothrombin fragments, 
VWF:Ag=von Willebrand factor antigen, VWF:RCo=VWF ristocetin cofactor activity, FVIII:C=factor VIII activity, 
ADAMTS13=a disintegrin and metalloproteinase with a thrombospondin type 1 domain 13 activity. The values 
represent median (range) or mean ± SD. 
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Figure 6. Correlations between (a) D-dimer and prothrombin fragments (F1+2), and platelet 
count and (b) antithrombin (AT), (c) protein C (PC) and (d) protein S free antigen 
(PS) in 19 patients with Puumala hantavirus infection.
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Acutely, the levels of natural anticoagulants PC and AT (Figures 1c and 1d in original 
publication I) as well as PS were low and TT was shortened (p<0.001 for all) compared 
with the recovery phase. APTT was prolonged and PT% decreased (p<0.001 for both) 
compared with recovery. Among the most distinct of the number of correlations found 
in study I were the negative correlation between CRP and PC (r=-0.58, p=0.009) and 
the positive correlation between PC and AT (r=0.73, p<0.001). 
In study II, the major platelet ligands VWF, fibrinogen and fibronectin were all 
affected in the acute phase of the infection (Figures 1a, 1b and 1d in original publica-
tion II). VWF:Ag and VWF:RCo levels were nearly threefold higher during the acute 
compared with the recovery phase, correlating well with each other (r=0.94, p<0.001). 
Only a slight increase in FVIII:C was noted acutely, and VWF levels did not corre-
late with FVIII:C. FVIII:C correlated with the maximum fibrinogen level (r=0.589, 
p=0.008), and this level was 1.6-fold higher during the acute compared with the recov-
ery phase. ADAMTS13 activity as well as fibronectin concentration were lower in the 
acute phase compared with recovery (p=0.003 and p=0.001, respectively; Figures 1c 
and 1d in original publication II). 
The reduced blood platelet count seen during the acute phase correlated with sev-
eral variables. Especially strong correlations were observed between platelet count and 
AT and PC activities and PS (Figures 6b, 6c and 6d, respectively). Platelet counts cor-
related positively with minimum fibrinogen concentrations (r=0.72, p<0.001, study I) 
and negatively with maximum fibrinogen concentrations (r=-0.468, p=0.043, study II).
Renal function impairment, as assessed by maximum serum creatinine concen-
tration or minimum daily urinary output, did not correlate with the platelet ligands, 
endothelial markers or coagulation variables, except for the shortening of thrombin 
time (r=-0.59, p=0.007 and r= 0.53, p= 0.02, respectively).
A number of correlations between the platelet ligands and ADAMTS13 (study II) 
and the variables measuring blood coagulation and fibrinolysis (study I) were noted. 
The plasma fibronectin level correlated negatively with D-dimer and F1+2 levels 
(r=-0.49, p=0.03 and r=-0.71, p=0.001, respectively) and positively with the PC level 
(r=0.50, p=0.028). Plasma fibrinogen maximum correlated inversely with thrombin 
time (r=-0.64, p=0.003). Positive correlations were found between plasma ADAMTS13 
level and the natural anticoagulants AT and PC (r=0.54, p=0.018 and r=0.52 and 
p=0.024, respectively), negative correlations between ADAMTS13 and APTT and 
D-dimer (r=-0.53, p=0.019 and r=-0.63, p=0.004, respectively). 
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5.2.1 Disseminated intravascular coagulopathy
Five of the 19 patients (26%) reached at least 5 points in the ISTH score (Taylor et 
al. 2001, Table 3), indicating a diagnosis of DIC. In addition to the typical low plate-
let count and high D-dimer, all five had prolonged APTT and elevated F1+2 (Table 
6). These five included the one who needed transient hemodialysis and experienced 
oozing at the site of the central venous catheter. However, there was no statistically 
significant difference between a positive DIC score and the length of hospitalization, 
maximum creatinine concentration, need for transient hemodialysis, or bleeding ten-
dency (data not shown).
table 6. Data on five patients compatible with DIC according to the ISTH score (5 or over) 
(original article I, copyright Elsevier). 
Pt Gender Age Dialysis Platelet PT APTT D-dimer Fibrinogen F1+2 DIC
 (F / M) (years)  count min min max max min max score
    (x109/l) (%) (s) (mg/l) (g/l) (pmol/l) 
1  M  34  no  31  70  35  5.6  3.5  438  5
2  F  49  no  34  83  41  12.1  1.50  1125  5
3  M  30  no  39  40  38  19.5  1.8  726  6
4  M  36  no  36  76  46  6.0  2.4  1461  5
5  M  36  yes  13  60  40  3.2  2.5  789  5
DIC=disseminated intravascular coagulopathy, ISTH=the International Society of Thrombosis and Haemostasis, min=minimum, 
max=maximum, PT=prothrombin time, APTT=activated partial thromboplastin time, F1+2=prothrombin fragments. Reference values: 
platelet count 150–360 x 109/l, PT% 70–130%, APTT 23–33 s, D-dimer ≤ 0.5 mg/l, fibrinogen 1.7–4.0 g/l and F1+2 69–229 pmol/l. 
Table 7 presents a comparison of coagulation results between DIC-negative and DIC-
positive patients according to the ISTH score. 
5.3 Markers of complement activation (study III) 
The highest and lowest concentrations of SC5b-9 and C3, respectively, were found in 
the first or second sample in 50 out of 61 patients (82%) and in the third or fourth sam-
ple in the others. The lowest concentration of C4 was found in the first or second sam-
ple in 40 patients. Plasma SC5b-9 concentration in the acute phase was significantly 
higher than at recovery (Table 8). The acute-phase C3 level was decreased compared 
to that measured at recovery. The acute-phase C4 level was not significantly different 
from that measured at recovery.
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table 7. Acute phase coagulation results of DIC-negative and DIC-positive patients 
according to the ISTH score (n=19).
 Reference DIC negative DIC positive p
 values
Platelet count min (x 109/l) 150–360  88 (50–238)  34 (13–39)  0.001
APTT max (s) 23–33  33 (29–47)  40 (35–46)  0.009
Prothrombin time min (%) 70–130  86 (64–140)  70 (40–83)  0.02
Fibrinogen min (g/l) 1.7–4.0  4.0 (2.7–6.7)  2.4 (1.5–3.5)  0.005
Antithrombin activity min (%) 84–108  78 (53–113)  55 (52–68)  0.01
Protein C activity min (%) 74–141  65 (32–121)  40 (38–54)  0.03
Protein S free antigen min (%) 66–158  70 (48–90)  36 (19–44)  0.001
DIC=disseminated intravascular coagulopathy, ISTH=the International Society of Thrombosis and Haemostasis, 
APTT=activated partial thromboplastin time, min=minimum, max=maximum. The values represent median (range). 
table 8. The highest concentration of plasma SC5b-9 and lowest concentrations of plasma 
C3 and C4 in the acute phase and at recovery in 61 patients with PUUV infection. 
Variable Acute-phase value Recovery-phase value  p
SC5b-9 max (ng/ml) 493 (103–1034) 197 (100–522) <0.001
C3 
min 
(g/l) 1.26 (0.65–2.24) 1.47 (0.84–2.44) <0.001
C4 
min 
(g/l) 0.26 (0.08–0.52) 0.27 (0.09–1.1)   0.48
SC5b-9=the terminal complement complex SC5b-9, C3= complement component C3, C4=complement component C4, 
PUUV=Puumala hantavirus, max=maximum, min=minimum. The values represent median (range). Reference values: 
C3 0.71–1.41 g/l, C4 0.12–0.34 g/l.
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Fourteen of those 50 patients (28%) who had chest X-ray taken had abnormal find-
ings, including accumulation of pleural fluid (n=6) and atelectasis (n=12). The patients 
with chest X-ray abnormalities during the acute phase had significantly higher lev-
els of SC5b-9 than those having normal images (median 637 vs 464 ng/ml, p=0.028), 
while these levels were no longer different at the time of recovery. The patients with 
pathological findings in chest X-ray had lower minimum C3 levels than those with 
normal X-ray, but the difference did not reach statistical significance. No differences 
were observed in C4 levels (data not shown).
5.3.1 Correlation with the clinical course of the disease
Acute-phase levels of SC5b-9 and C3 correlated significantly with a number of vari-
ables reflecting the clinical severity of PUUV infection. As to the highest SC5b-9, the 
strongest correlations were found with the length of hospital stay, the highest blood 
leukocyte count, and change in weight during hospital stay (r=0.46, r=0.43 and r=0.42, 
respectively, p<0.001 for all). The variables which showed the strongest correlation 
with the lowest C3 were the highest plasma IL-6, the lowest blood hematocrit, and 
the lowest serum sodium (r=-0.62, r=0.52 and r=0.44, respectively, p<0.001 for all). 
The leukocyte counts correlated inversely with C3 levels (r=-0.30, p=0.02), as well as 
with the length of hospital stay (r=-0.30, p=0.025). Acute-phase levels of C4 showed no 
significant correlation with any of the clinical or laboratory findings (data not shown).
5.3.2 Associations between the markers of complement activation (study III)  
and the findings in studies I–II
The level of C3 in the acute phase was associated with several of the laboratory vari-
ables in studies I–II measuring coagulation activity (n=19). An inverse correlation 
was noted between C3 and APTT (r=-0.70, p=0.003), and a positive correlation pre-
vailed between C3 and all natural anticoagulants AT, PC and PS (r=0.76, p<0.001; 
r=0.53, p=0.025; r=0.64, p=0.004; respectively). No associations were found between 
SC5b-9 and C4 and the variables measuring the platelet ligands, blood coagulation and 
fibrinolysis.
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table 9. The genotype distributions and allele frequencies of platelet GP IIIa, GP Ib, GP Ia, 
GP VI, VWF and PAI-1 in 172 patients with acute PUUV infection (original article IV, 
copyright Elsevier).
 Genotype % Allele %
Polymorphism homozygote heterozygote homozygote common rare
 common  rare
GP IIIa (HPA-1) 66 (TT) 32 (TC) 2 (CC) 82 (T) 18 (C)
GP Ib (HPA-2) 78 (CC) 21 (CT) 1 (TT) 88 (C) 12 (T)
GP Ia (HPA-5) 93 (TT) 7 (TC) 0 (CC) 96 (T) 4 (C)
GP VI T>C (rs1613662) 79 (TT) 19 (TC) 2 (CC) 89 (T) 11 (C)
VWF A>G (rs1063856) 68 (AA) 25 (AG) 7 (GG) 81 (A) 19 (G)
PAI-1 A>G (rs227631) 32 (AA) 53 (AG) 15 (GG) 59 (A) 41 (G)
GP=glycoprotein, VWF=von Willebrand factor, PAI-1=plasminogen activator inhibitor 1, PUUV=Puumala hantavirus, 
HPA=human platelet antigen.
5.4 Genetic polymorphisms of platelet antigens, VWF and  
 PAI-1 (study IV)
Table 9 presents the genotype distributions and allele frequencies of GP IIIa (HPA-1), 
GP Ib (HPA-2), GP Ia (HPA-5), GP VI, VWF and PAI-1. Genotyping was successful 
in 162 out of 172 patients (94%) for HPA-1, in 169 patients (98%) for HPA-2, in all 172 
patients for HPA-5, in 171 patients (99%) for GPVI, in 162 patients (94 %) for VWF 
and in 169 patients (98%) for PAI-1.
5.4.1 Associations of polymorphisms with the clinical disease
Renal function impairment in the acute phase of the disease was associated with the 
rare G-allele of the PAI-1 gene. The carriers of the PAI-1 gene G-allele had a 1.7 times 
higher maximum level of creatinine than non-carriers (213 µmol/l vs. 122 µmol/l, 
p=0.01; Figure 1a in original publication IV). Also, the level of creatinine exceeded 300 
µmol/l 1.7 times more often in G-carriers compared with non-carriers (38% vs. 22%, 
p=0.04). Of all PAI-1 G-carrier genotypes, GG-homozygotes had the highest maxi-
mum level of creatinine, followed by AG-heterozygotes and AA-homozygotes (249 
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µmol/l, 204 µmol/l and 122 µmol/l, respectively, p= 0.03). Six out of seven hemodialysis 
patients were G-allele carriers, and one of them was a GG-homozygote. 
The rare G-allele of VWF A>G was associated with a lower level of maximum 
creatinine (131 µmol/l vs. 241 µmol/l, p=0.02). Accordingly, the level of creatinine 
exceeded 300 µmol/l less often in carriers of the VWF G-allele than in non-carriers 
(21% vs. 38%, p=0.03). The carriers of the rare GP VI gene C-allele had likewise maxi-
mum creatinine levels > 300 µmol/l less often than non-carriers (17% vs. 36%, p=0.03).
Analyses of genotype combinations revealed that patients (n=18, 11% of all 
patients) carrying the favorable VWF G-allele and not carrying the unfavorable PAI-1 
G-allele had lower levels of creatinine compared with those not carrying the VWF 
G-allele and carrying the PAI-1 G-allele (n=73, 46% of all patients; 99 µmol/l vs. 250 
µmol/l, respectively, p=0.002).
The platelet count nadir was lower in carriers of the rare GP Ia (HPA-5) gene 
C-allele compared to non-carriers (44 x 109/l vs. 64 x 109/l, p=0.02). The minor G-allele 
carriers of the PAI-1 gene proved to have a higher platelet count nadir compared with 
non-carriers (65 x 109/l vs. 54 x 109/l, p=0.04; Figure 1b in original publication IV). 
The maximum level of plasma IL-6 was lower in carriers of the rare GP IIIa (HPA-
1) C-allele than in non-carriers (13.4 pg/ml vs. 16.5 pg/ml, p=0.05). There were no 
significant associations with GP IIIa (HPA-1) genotype and CRP or leukocyte count 
(data not shown).
There were no statistically significant differences in the length of hospital stay, low-
est blood pressure, maximum weight change, need for transient hemodialysis treat-
ment or occurrence of shock compatible with polymorphisms studied here (data not 
shown). 
The numbers of patients participating in studies I–II (n=19) and both studies 
III and IV (n=48) were quite small and the frequency of the minor GP Ia (HPA-5) 
C-allelle was low (4%). Thus the possible associations between the most interesting 
genetic polymorphisms, namely those of PAI-1,VWF and GP Ia and the findings con-
cerning platelet ligands, blood coagulation, fibrinolysis (studies I–II) and complement 
activation (study III) could not be reliably assessed (data not shown).  
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6 DiSCuSSiOn
6.1 Platelet ligands, thrombin formation and fibrinolysis (studies I–II)
The most prominent finding in study I was the 24-fold increase in D-dimer during the 
acute phase of the disease. This could indicate markedly upregulated fibrin degradation 
or turnover or reduced elimination of fibrin fragments, or both. Thrombin generation 
was not proportionate to fibrinolysis, as the increase in F1+2 level was 3-fold in the 
acute phase compared with recovery. Interestingly, increased thrombin formation as 
indicated by elevated F1+2 appeared to correlate with the length of hospital stay, which 
is an objective assessment of disease severity. Despite the laboratory abnormalities, a 
beneficial clinical balance between prothrombotic and fibrinolytic activities prevailed, 
as indicated by the lack of overt clinical coagulation problems. 
Endothelial activation is thought to play a role in the pathogenesis of hantavirus 
infection (Cosgriff 1991, Cosgriff and Lewis 1991), and endothelial injury could con-
tribute to the increase of thrombin formation and fibrinolysis in the acute phase of NE 
(Lippi et al. 2008). Platelet ligands VWF, fibrinogen and fibronectin carried by platelets, 
mediate platelet-platelet interactions and are implicated in the acute phase reactions 
and endothelial activation. Interestingly, all of these molecules are ligands of αIIbβ3, 
which contains the β3 integrin receptor for the pathogenic hantaviruses (Gavrilovskaya 
et al. 1999). In the context of endothelial activation and increased thrombin formation 
and fibrinolysis in acute NE, the determinations of platelet ligands WFW, fibrinogen 
and fibronectin (study II) were thus of interest. 
The levels of VWF:Ag and VWF:RCo were increased almost three-fold acutely 
compared with the recovery phase. As VWF is produced by the endothelium and mega-
karyocytes and carried in the α-granules of circulating platelets, an increase in VWF 
level could imply endothelial cell injury and platelet activation with granule release. 
These mechanisms of enhanced platelet adhesion and activation could result in platelet 
consumption and thrombocytopenia, as has been described in dengue virus infection 
(Basuki 2003, Sosothikul et al. 2007). In study II, the increase in FVIII did not quite 
follow VWF levels and the ratios between VWF:Ag and FVIII in the acute phase and at 
recovery differed markedly. This could be explained by increased thrombin formation 
in the acute phase of the disease, as FVIII degrades rapidly after release from its carrier 
molecule VWF by the action of thrombin (Sadler 1998). Other possible mechanisms 
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include binding of FVIII to platelet-derived microparticles stimulated by thrombin or 
the complement proteins C5b-9 (Wiedemer et al. 1986, Gilbert et al. 1991). The obser-
vation of only a modest increase in FVIII during the acute phase of PUUV infection 
is compatible with findings in a study on dengue virus, in which reduced levels of 
coagulation factors were associated with low platelet count and the clinical severity of 
the disease (Srichaikul et al. 2000).
The maximum plasma concentration of fibrinogen was 1.6-fold higher acutely 
compared with the recovery phase. This could be a consequence of platelet activation 
and granule release, an assumption supported by the negative correlation between 
plasma fibrinogen and platelet count. Elevated fibrinogen could also reflect an acute 
phase reaction strong enough to outweigh the consumption due to the ongoing coag-
ulation activity, as observed during the acute phase of PUUV-HFRS in study I and 
HTNV-HFRS in earlier East-Asian studies (Lee 1987, Xiang et al. 1990).
The plasma fibronectin level decreased significantly during the acute phase of the 
disease compared with recovery, an observation consistent with a previous report of 
diminished plasma fibronectin levels in sepsis (Ruiz Martin et al. 2004). These find-
ings differ from a previously published study reporting increased plasma fibronectin 
levels in HTNV-HFRS (Han et al. 2010). As fibronectin binds to fibrinogen and fibrin 
at low temperatures and the temperature in which the tests were carried out was not 
provided, the discrepancy of the findings in these studies could well be explained by 
methodological aspects. Thrombin enhances the binding of fibronectin to platelets 
(Ginsberg et al. 1983), and diminished plasma fibronectin levels could reflect the bind-
ing of fibronectin to thrombin-activated platelets and consumption during coagulation 
activity shown to be ongoing in study I. This concept is supported by the inverse cor-
relation between plasma fibronectin level and the indicators of thrombin formation 
(F1+2) and fibrinolysis (D-dimer) as well as the positive correlation between fibronec-
tin and the natural anticoagulant PC. 
While the increase in plasma fibrinolytic activity as reflected by the 24-fold D-dimer 
in the acute compared with the recovery phase was substantial, the bleeding problems 
were few and minor. A number of procoagulant changes which probably helped to 
retain a beneficial clinical balance could be noted. The diminished activities of the 
natural anticoagulants AT, PC and PS were marked, but also rapidly reversed after the 
acute phase of the disease. VWF enhances early platelet adhesion and aggregation dur-
ing both physiological and pathological thrombosis (Sadler 1998), and an increase in 
plasma VWF level shifts the balance in the procoagulant direction. Fibrinogen contri-
butes to thrombus stability by anchoring the thrombi to the vessel wall and individual 
platelets to the thrombus (Denis et al. 2007), and an increase in plasma fibrinogen level 
ensures the sufficient availability of fibrinogen needed to maintain hemostasis during 
the ongoing fibrinolytic activity. All these procoagulant changes are likely to contribute 
to the maintenance of hemostasis in spite of the decreasing platelet count and markedly 
increased fibrinolytic activity. 
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ADAMTS13 is an enzyme specifically involved in the cleavage of high-molecular-
weight VWF. It is known to play a role in the pathogenesis of thrombotic thrombocy-
topenic purpura (TTP), a thrombotic microangiopathy characterized by thrombocyto-
penia, hemolytic anemia and ischemic organ failure caused by thrombotic occlusions 
in the arterioles. Since thrombocytopenia and capillary injury are clinical hallmarks of 
acute NE and variable neurological symptoms are also encountered, the determination 
of ADAMTS13 activity in the acute phase of the disease was of interest. The finding of 
modestly reduced ADAMTS13 activity during the acute phase of NE is in accord with 
the reports implying that  ADAMTS13 activity is diminished in dengue virus infection 
(Sosothikul et al. 2007) as well as in several other conditions (Kavakli et al. 2002). The 
positive correlations between ADAMTS13 and the natural anticoagulants AT and PC 
as well as the negative correlation between ADAMTS13 and APTT and D-dimer fur-
ther point a role for endothelial injury in the pathogenesis of the enhanced coagulation 
and fibrinolysis encountered in the acute phase of NE. 
The patients participating in studies I–II were clinically quite ill. Coagulation 
problems were minor, but three out of 19 (16%) needed transient hemodialysis. This 
figure is clearly higher than the 5% presented in the literature (Vapalahti et al. 2003). 
No association was found between the depth of thrombocytopenia and the degree of 
renal impairment. Neither the indicators of thrombin formation and fibrinlysis nor the 
increased consumption of coagulation inhibitors provided tools to predict the sever-
ity of kidney injury in this study. The only association to be found was that between 
creatinine concentration and thrombin time. Thrombocytopenia and short thrombin 
time could imply microvesiculation, i.e. membrane shedding with enhanced coagu-
lation activity. This mechanism has been described in several conditions, including 
severe inflammation, complement activation and immune-mediated thrombocyto-
penia induced by heparin or hepatitis (Warkentin et al. 1999, Peerschke et al. 2008, 
Burnier et al. 2009). The strong positive correlations between the platelet count and the 
natural anticoagulants AT, PC and PS suggest temporal interactions between the plate-
lets, their activation and impaired coagulation inhibitors, compatible with endothelial 
injury or activation. The interaction of platelets with the endothelium, their activa-
tion and P-selectin expression could thus provide a mechanism of thrombocytopenia 
during PUUV infection, as has been described in other forms of viral inflammation 
(Wagner et al. 2003, Dole et al. 2005, Zahn et al. 2006, Iannacone et al. 2007). On the 
other hand, thrombocytopenia in hantavirus infection has also been considered more 
of a result of platelet inactivation (Cosgriff et al. 1991) and binding of hantaviruses 
and hantavirus-infected endothelial cells to quiescent platelets via β3 integrin receptor 
(Gavrilovskaya et al. 2010).
The number of patients participating in studies I–II was small, but the findings 
were consistent. As is frequently the case in clinical studies, the timing of the  samples 
overlapped slightly, since the patients sought medical assistance at different time inter-
vals from the beginning of the disease. However, the findings of altered platelet ligands 
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and endothelial markers together with ongoing coagulation and fibrinolysis in the 
acute phase of NE were clear.  
6.1.1 Findings suggestive of disseminated intravascular coagulopathy
To date there is still no specific treatment available for HFRS. Since even the most 
severely ill patients are treated symptomatically, a useful predictive tool for selecting 
those in need of early and intensive treatment would be particularly valuable. As earlier 
reports have suggested the presence of DIC in some patients with PUUV-HFRS, the 
ISTH score for overt DIC (Taylor et al. 2010, Table 3) was applied to grade the labora-
tory findings and determine the possible associations between the score and the clini-
cal course of the disease. 
In this study five of the 19 patients (26%) reached the score of at least five points 
indicative of DIC. Such an incidence is comparable to that (28%) observed in a recent 
Swedish study of 106 patients (Sundberg et al. 2011). Interestingly, only one of the 19 
patients had minor problems with hemostasis and there were only two patients with 
abnormal PT. No association could be found between the positive score and the two 
most prominent findings in study I, namely elevated D-dimer and F1+2. The score was 
not associated with clinical variables, and it failed to predict the clinical course of the 
disease in this small group of PUUV patients. However, as the Swedish study showed, 
the ISTH score for overt DIC, including the fibrinogen/CRP–ratio, might provide a 
clinical tool with high negative predictive value (Sundberg et al. 2011).
6.2 Complement activation and association with disease severity  
 (study III)
Study III showed that the complement system is activated through the alternative path-
way during the acute phase of PUUV infection. The terminal complement complex 
SC5b-9 was elevated acutely compared with recovery, and the level was significantly 
higher in patients with chest X-ray abnormalities. As a sign of increased consumption, 
the level of complement component C3 was decreased acutely. The level was lower, 
though not significantly, in patients with X-ray abnormalities compared to those with 
normal X-ray.
Capillary leakage has been suggested to contribute to the lung disease in HCPS 
and HFRS (Kanerva et al. 1998a), and immunological mechanisms may be partially 
responsible for the disturbed endothelial function. SC5b-9 is capable of increasing 
endothelial permeability by ligating β3 integrin, the receptor for the pathogenic han-
taviruses, which may result in elevated hydraulic conductivity (Tsukada et al. 1995). 
SC5b-9 releases bradykinin and platelet-activating factor, thus promoting  endothe-
lial permeability (Bossi et al. 2004). Also, the non-soluble equivalent of SC5b-9, the 
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MAC complex, is known to trigger cellular reactions and production of inflammatory 
cytokines capable of altering endothelial function (Morgan BP 1999). Obviously, the 
findings in study III do not prove a causal relationship between any of these mecha-
nisms and lung disease in NE, since no experimental evidence is provided. 
The markers of complement system activation, elevated SC5b-9 and decreased C3, 
proved to be associated with several variables reflecting the clinical disease. The length 
of hospital treatment, which is an objective means of measuring disease severity, cor-
related with both markers, implying complement activation through the alternative 
pathway. Interestingly, an inverse correlation was found between the plasma levels of 
C3 and IL-6, the latter known to be a useful tool in the evaluation of disease severity 
in acute PUUV infection (Outinen et al. 2010). A previous study (Paakkala et al. 2000) 
on complement activation and NE linked classical pathway activation to more severe 
disease. However, as that study included only six patients with mainly classical route 
activation, the common occurrence of complement activation (23 out of 25 patients) 
could equally be interpreted as the major finding in that study. These findings of com-
plement activation associated with variables reflecting the clinical disease are in line 
with those indicating that complement activation contributes to a more severe clini-
cal outcome in dengue fever and H1N1 pandemic influenza (Nascimento et al. 2009, 
Monsalvo et al. 2011).
The molecular intercommunication between complement system and blood 
co agulation and fibrinolysis is extensive, and the 19 patients participating in all studies 
I–III provided an opportunity to study possible associations between the biomarkers 
active in these cascades. SC5b-9 is able to catalyze prothrombin cleavage to thrombin 
(Wiedemer et al. 1986). Thrombin is capable of generating the complement activation 
products C3a and C5a (Huber-Lang et al. 2006, Amara et al. 2010), and C5a, in turn, 
possesses fibrinolytic activity (Wojta et al. 2002). Increased levels of SC5b-9, F1+2 and 
D-dimer were the major findigs in studies I–III, indicating the activation of both com-
plement and blood coagulation and fibrinolysis. In this series no association between 
these biomarkers could be established, a finding that might be explained by the small 
number of patients. However, the associations between C3 and APTT and natural anti-
coagulants AT, PC and PS all imply ongoing simultaneous activity in the alternative 
pathway of the complement system and blood coagulation in PUUV-HFRS. This is in 
line with the previous reports establishing associations between decreased C3 levels 
and coagulation factors in HTNV-HFRS (Lee 1987) and stating that activation through 
the alternative route is a frequent finding in PUUV-HFRS (Paakkala et al. 2000). 
To conclude, the findings in study III indicate that complement is activated through 
the alternative pathway in acute PUUV infection and the activation is associated with 
disease severity especially in the lungs. The simultaneous loss of natural anticoagu-
lants emphasizes the molecular interaction between the complement system and blood 
coagulation and fibrinolysis. 
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6.3 Polymorphisms of PAI-1 and platelet GP Ia and  
 clinical course of the disease (study IV)
The platelet count as well as the platelet function and blood coagulation and fibrinoly-
sis are clearly altered in hantavirus infection. However, studies on the genetic poly-
morphisms affecting platelet functions and factors involved in blood coagulation and 
fibrinolysis in hantavirus infection are limited to one (Liu et al. 2009a). In study IV 
here, the aim was to establish possible associations between the polymorphisms of the 
main antigens involved in platelet activation and aggregation (GPs IIIa, Ib, Ia and VI) 
and VWF and PAI-1, and the clinical course of Puumala hantavirus disease. 
The most prominent finding in study IV was the association of the PAI-1 gene 
minor G-allele with the major outcome of the disease, namely kidney function. The 
maximum level of creatinine and the proportion of patients having creatinine values > 
300 µmol/l were higher among those carrying the G-allele compared with non-carri-
ers. The finding was further emphasized by observations of GG-homozygotes having 
the highest creatinine levels and the G-allele carriers being over-represented among 
the patients who needed transient hemodialysis. In addition, the minor G-allele of the 
VWF gene (rs1063856) and the minor C-allele of GP VI (rs1613662) offered some pro-
tection of renal function in terms of serum creatinine level. The other clinical hallmark 
of PUUV infection, low platelet count, was associated with the low frequency C-allele 
of GP Ia (HPA-5).  
PAI-1 is secreted by a variety of cells, including platelets and endothelial cells, both 
intimately involved in the pathogenesis of hantavirus infection, and PAI-1 is the pri-
mary physiological regulator of plasminogen activators and fibrinolysis. PAI-1 poly-
peptide is encoded by the SERPINE1 (SERine Proteinase Inhibitor, clade E, member 
1) gene on chromosome 7q21.3-q2 (Koch et al. 2010). Association of the 4G/5G poly-
morphism (rs1799889) with increased PAI-1 levels of 4G/5G carriers has been sug-
gested in several studies, and the SNP rs2227631 investigated in study IV is very close 
to the 4G/5G polymorphism (rs1799889), and has a relatively high correlation with 
4G/5G (Kathiresan et al. 2005). The 4G-allele seems to be associated with atheroscle-
rotic diseases of the coronary arteries (Koch et al. 2010) and reduced kidney graft sur-
vival (Rerolle et al. 2008). Moreover, elevated levels of PAI-1 have been related to poor 
outcome in conditions such as dengue virus infection, pneumonia, sepsis and menin-
gococcal disease (Wills et al. 2002, Hermans et al. 2005, Mairuhu et al. 2005, Madach 
et al. 2010). Unfortunately the plasma levels of PAI-1 were not measured in study IV, 
and there are no published data on the plasma level and role of PAI-1 in hantavirus 
infection. 
High plasma VWF levels during the acute phase of PUUV infection were reported 
in study II, all the same patients being included in study IV. Moreover, the A>G poly-
morphism of the VWF gene (rs1063856) in exon 18 of chromosome 12 investigated 
in study IV, is known to be associated with high VWF levels. It is also close to SNP 
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rs10638857, which is associated with VWF levels in healthy subjects (Lacquemant et 
al. 2000, Klemm et al. 2005, Campos et al. 2011). However, even if the VWF gene is 
highly polymorphic, genetic factors are responsible for only up to 66% of the variation 
in plasma VWF levels (Campos et al. 2011). Since the VWF levels in the minor G-allele 
(rs1063856) carriers and non-carriers were not compared in study IV, it is not possible 
to conclude whether or not the favorable effect of this polymorphism on kidney func-
tion depends on modulation of plasma VWF levels.
Polymorphisms of both collagen receptors GP VI and GP Ia (HPA-5) were associ-
ated with clinical disease, the minor C-allele of GP VI offering some protection of renal 
function and the minor C-allele of GP Ia correlating with low platelet count nadir. Low-
frequency allele homozygotes of GP VI such as the CC genotype of T>C rs1613662 are 
associated with reduced platelet activation and responses to collagen when compared 
with high-frequency allele homozygotes (Joutsi-Korhonen et al. 2003). As the plate-
let functions were not studied here, it can not be concluded whether these effects on 
clinical disease depended on modulation of the polymorphisms on platelet activation, 
procoagulant activity and the formation of hemostatic plug contributed by collagen 
receptors. 
The GP IIbIIIa complex binds platelet ligands VWF, fibrinogen and fibronectin, all 
shown to be altered in study II. The receptor for the pathogenic hantaviruses, subunit 
β3 integrin (IIIa), is carried by GP IIbIIIa. Carriers of the low-frequency C-allele of GP 
IIIa (HPA-1) had slightly lower levels of plasma IL-6, a variable correlating with disease 
severity in acute PUUV infection. This finding is in line with an earlier report stating 
that HPA-1 polymorphism of GP IIIa is not associated with severe disease in HTNV 
infection (Liu et al. 2009a).
Here, for the first time, genetic polymorphisms related to platelet activation, blood 
coagulation and fibrinolysis are reported to have an impact on both kidney function 
and platelet counts in HFRS. The impact of the polymorphism of PAI-1, a major regu-
lator of fibrinolysis, on kidney function is the major finding of the study.
6.4 Future considerations
The number of patients participating in studies I–II was somewhat limited, but the 
findings of activated endothelium, ongoing coagulation activity and fibrinolysis were 
clear. Complement was shown to be activated via the alternative route in study III, 
and moreover, to be associated with the clinical disease. As evidence of molecular 
interaction between the complement system and blood coagulation and fibrinolysis is 
accumulating, it would be of interest to expand studies I–II to include all 61 patients 
who participated in study III. Most important would be to investigate the markers of 
thrombin formation and fibrinolysis (prothrombin fragments F1+2 and D-dimer) in 
all patients in study III. Recent data suggest that coagulation/fibrinolysis proteases may 
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act as natural C3 and C5 convertases, and of particular therapeutic interest is the ability 
of the FXa inhibitors fondaparinux and enoxaparin to suppress the FXa-induced cleav-
age of C3 (Amara et al. 2010). 
As previously discussed, several polymorphisms related to platelet aggregation and 
activation, blood coagulation and fibrinolysis were shown to be associated with the 
clinical disease during the acute phase of PUUV infection. To further clarify the role 
of these polymorphisms in the pathogenesis of PUUV infection, platelet functions and 
plasma levels of factors involved in blood coagulation and fibrinolysis should be mea-
sured in patients carrying and not carrying particular polymorphisms. The role of GPs 
and platelet immunology in PUUV-induced thrombocytopenia could be evaluated by 
detecting possible GP antibodies.
Microparticles (MP) derive from different cell types, including platelets, the main 
source of MPs, but also from monocytes, granulocytes, lymphocytes, erythrocytes and 
endothelial cells. MPs are released from the cells upon activation or apoptosis and 
when circulating in the blood provide an additional procoagulant phospholipid sur-
face enabling the assembly of the clotting enzyme complexes and thrombin formation 
(Burnier et al. 2009). Elevated levels are encountered in several clinical conditions of 
bleeding and thrombotic disorders (for example, heparin-induced thrombocytopenia, 
antiphospholipid syndrome and TTP), cardiovascular diseases and infectious diseases 
(for example, sepsis, HIV infection and prion disease) (Nomura et al. 2008). However, 
challenges remain regarding the methods used in the determination of MPs, and their 
significance in various conditions remains to be further elucidated. The findings of 
thrombocytopenia and short thrombin time in study I could imply MP formation, and 
the association of thrombin time with kidney function provides a further stimulus to 
investigate MP formation. Moreover, the complement activation observed in study III 
suggests a possible role of MP formation in the pathogenesis of PUUV infection, as 
both SC5b-9 and thrombin stimulate MP formation (Peerschke et al. 2008, Burnier et 
al. 2009). MPs might also be a part of an explanation for the only modestly increased 
FVIII observed in study II, since FVIII may be bound to MPs (Gilbert et al. 1991).
Neutrophil extracellular traps (NET) are part of the innate immune response to 
infections. They form a meshwork of deoxyribonucleic acid fibers comprising histones 
and antimicrobial proteins which immobilize and kill microbes. NETs are formed 
inside the vasculature in both infectious and non-infectious diseases, and platelets 
enhance the ability of neutrophils to make NETs. NETs, in turn, promote platelet adhe-
sion, aggregation and activation. They are important in the control of infection, yet in 
excess or at inappropriate locations they contribute to vascular toxicity, organ failure 
and death (Fuchs et al. 2010, Esmon et al. 2011). The literature on NETs in viral infec-
tions is so far very limited, but the decreased platelet count with ongoing coagulation 
activity and microvascular injury are suggestive of NET formation as a possible mecha-
nism in hantavirus infection. Unfortunately, detection of NET formation still remains 
challenging. 
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7 SuMMaRY anD COnCLuSiOnS
The main findings in the present series can be summarized as follows:
I Enhanced thrombin formation and marked fibrinolysis characterize the acute 
phase of PUUV infection. The commonly seen thrombocytopenia is associated 
with decreased natural anticoagulants AT, PC and PS. 
II Five out of 19 patients fulfilled the ISTH criteria for DIC. The scoring could not 
predict the outcome of patients in terms of the most prominent laboratory findings 
(elevated F1+2 and D-dimer) or the clinical variables. 
III Platelet ligands VWF, fibrinogen and fibronectin are all altered during the acute 
phase of PUUV infection. FVIII does not quite follow the increase observed in 
VWF level, and the activity of ADAMTS13 is only modestly reduced.
IV The complement system becomes activated via the alternative pathway during the 
acute phase of PUUV infection. The level of activation is associated with the sever-
ity of the disease. 
V Polymorphism of PAI-1 and platelet GP Ia are associated with renal function and 
thrombocytopenia in PUUV infection. 
The findings of enhanced thrombin formation and especially fibrinolysis were con-
spicuous, and natural anticoagulants were markedly diminished. Nonetheless none of 
these variables was associated with disease severity, and also the ISTH score for DIC 
failed to predict clinical outcome in this small series of patients. The adhesive plate-
let ligands and biomarkers related to endothelial activation and acute-phase reactants 
were altered, but none of them provided a prognostic clinical tool in the assessment of 
disease severity. On the other hand, complement activation via the alternative pathway 
was associated with several clinical and laboratory variables depicting disease severity. 
Especially pulmonary X-ray findings were more frequent in patients with high SC5b-9 
levels and low C3 levels, which could be taken to signify a role of complement activa-
tion in capillary leakage causing pulmonary symptoms in PUUV infection. 
For the first time, associations between several polymorphisms related to platelet 
activation, blood coagulation and fibrinolysis and severity of disease in acute hantavi-
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rus infection were here investigated. The most prominent finding was the association 
between PAI-1, the major regulator of plasma fibrinolytic activity, and kidney func-
tion. This observation emphasizes the impact of the hemostatic system on the outcome 
of PUUV-HFRS, a form of hantavirus infection usually presenting with only modest 
hemostatic impairment.
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Introduction: Nephropathia epidemica (NE) is a viral hemorrhagic fever with renal syndrome associated with
thrombocytopenia and mild bleeding. We assessed activation of coagulation and ﬁbrinolysis during the acute
phase of NE.
Materials and methods: 19 hospital-treated patients were involved. Plasma levels of D-dimer, prothrombin
fragments 1+2 (F1+2), activated partial thromboplastin time (APTT), prothrombin time (PT%), thrombin
time (TT), ﬁbrinogen, antithrombin (AT), protein S free antigen (PS), protein C (PC) and complete blood
count (CBC) were measured three times during the acute phase and once at 32-54 days after the onset of
fever (recovery phase). Laboratory abnormalities were evaluated by the disseminated intravascular
coagulation (DIC) scoring advocated by the International Society of Thrombosis and Haemostasis (ISTH).
Results: APTT was prolonged and D-dimer and F1+2 increased during the acute phase of NE. AT, PC and PS
decreased, and TT was shortened, all implying increased thrombin generation. Acutely F1+2 was 3.4-fold
and D-dimer even 24-fold higher compared with the recovery phase (median 726 vs 213 pmol/l, and median
4.8 vs 0.2 mg/l, respectively, pb0.001 for both). Platelet count correlated with AT, PC, and PS (r=0.73,
r=0.81, and r=0.71, respectively, pb0.001 for all) as well as with ﬁbrinogen (r=0.72, pb0.001). Only ﬁve
patients fulﬁlled the ISTH diagnosis of DIC.
Conclusions: During acute NE thrombocytopenia was associated with decreased natural anticoagulants,
shortened thrombin time and enhanced ﬁbrinolysis. Augmented thrombin formation and ﬁbrinolysis
characterize this hantavirus infection.
© 2010 Elsevier Ltd. All rights reserved.Introduction
Puumala virus (PUUV), a member of the Hantavirus genus in the
Bunyaviridae family, is an enveloped RNA virus transmitted to humans
by inhalation of aerosolized excreta of infected rodents. The natural
host of PUUV is the bank vole, Myodes glareolus, which can be found
throughout Europe with the exception of Mediterranean coastal
regions and most of the Iberian Peninsula and Greece [1].prothrombin fragments; APTT,
time; TT, thrombin time; AT,
BC, complete blood count; DIC,
ational Society of Thrombosis
gic fever with renal syndrome;
ctive protein, and HPA, human
58 50 541 5205; fax: +358 3
l rights reserved.In humans hantaviruses cause a spectrum of illnesses which are
often divided into two clinical diseases, hemorrhagic fever with renal
syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syn-
drome (HCPS) in the Americas. Acute PUUV infection, i.e. nephropathia
epidemica (NE), is a mild form of HFRS. The disease may, however, in
rare cases be fatal. In Finland most infections probably remain
subclinical or undiagnosed, since only about 1000-2000 serological
diagnoses are made annually despite a seroprevalence of 6% [2,3]. The
clinical onset of the disease is characterized by high fever, headache,
nausea and vomiting with abdominal and/or lower back pains [2].
Transient proteinuria, hematuria and rising serum creatinine levels
indicate renal involvement and about 5% of hospital-treated patients
require transient hemodialysis [4]. Pulmonary manifestation is also
common in NE [5]. Although clear thrombocytopenia is encountered in
the majority of NE patients, bleeding manifestations are usually mild.
Petechiae, epistaxis, macroscopic hematuria and conjunctival bleeding
have been reported [6]. Nuutinen and coworkers demonstrated mild
gastrointestinal bleeding by gastroscopy in nearly all NE patients [7]. In
155O. Laine et al. / Thrombosis Research 126 (2010) 154–158fatal cases of NE hemorrhage of the pituitary gland and other organs has
been reported [8–10].
Thrombocytopenia and bleeding tendency in NE are commonly
considered signs of disseminated intravascular coagulopathy (DIC)
[11,12]. However, so far data published on the activity and regulation
of coagulation and ﬁbrinolysis in NE remain sparse.
We aimed to evaluate different laboratory markers of coagulation
and ﬁbrinolysis during the acute phase of NE in association with the
clinical severity of the disease. Further, we sought to grade the
possible DIC during the acute phase of NE with the ISTH score.Materials and methods
The study was carried out in Tampere University Hospital,
University of TampereMedical School, and Helsinki University Central
Hospital, Finland. The patients were selected from those who
participated in a previous larger prospective study basing on the
availability of the laboratory samples. All patients came from the
Pirkanmaa region and were hospitalized in Tampere University
Hospital with serologically conﬁrmed acute PUUV infection during
the period from September 2000 to December 2002. The study group
consisted of 19 patients (17 males), median age 38 years (range
30-64 years). Regarding medical history, two of the patients had a
neurological disease (1 multiple sclerosis, 1 epilepsy) and one a
chronic inﬂammatory bowel disease treated with mesalazine medi-
cation. There were patients with dyslipidemia (n=2), coronary heart
disease (n=1), arterial hypertension (n=1) and paroxysmal atrial
ﬁbrillation (n=1). No patient was under immunosuppression or
anticoagulation. Two patients used anti-platelet therapy (aspirin).
The patient charts were retrospectively reviewed to establish the
length of hospital stay (days), daily urinary output (ml), need of
transient hemodialysis treatment (no/yes) and signs of bleeding
(no/yes). The treatment with platelet or plasma transfusions to correct
the possible coagulopathy as well as the treatment with heparin were
noted.
To assess the activation of coagulation and ﬁbrinolysis, three blood
samples per patient were collected during the acute phase of the
disease. The ﬁrst sample was obtained on admission as early as
possible, 2-9 (median 6) days after the onset of fever. The second
sample was obtained 3-10 (median 7) days, and the third 6-13
(median 10) days after the onset of fever. The last sample of the study,
the fourth sample, was drawn at full recovery (ranging 32-54 days
after the onset of fever, median 43 days), this representing a control
sample. Citrate-anticoagulated (109 mM sodium citrate) samples
were centrifuged at 1500 g for 20 min and separated plasma samples
were frozen at -70 °C. Once defrosted the samples were recentrifuged
at 2500 g for 15 min prior to analysis.
Laboratory analysis included plasma prothrombin time expressed
as % (PT%, Nycotest PT®, Axis-Shield PoC As, Oslo, Norway), activated
partial thromboplastin time (APTT, Actin FSL®, Siemens Healthcare
Diagnostics, Marburg, Germany) and thrombin time (TT, Siemens
Healthcare Diagnostics). Fibrinogen was measured with a modiﬁca-
tion of the Clauss method (Multiﬁbren® U, Siemens Healthcare
Diagnostics) and D-dimer with an immunoturbidimetric assay
(Tina-quant D-Dimer®, Roche Diagnostics, Mannheim, Germany).
Prothrombin fragments (F1+2) were measured by an enzyme
immunoassay (Enzygnost® F1+2, monoclonal, Siemens Healthcare
Diagnostics). The reference values for PT% were 70-130%, APTT
23-33 s, TT 17-25 s, ﬁbrinogen 1.7-4.0 g/l, D-dimer≤0.5 mg/l and
F1+2 69-229 pmol/l. Protein S free antigen (PS) level was deter-
mined by an automated latex ligand immunoassay (Instrumentation
Laboratory, Lexington, MA), reference values being 66-158% for males
and 50-177% for females. Antithrombin (AT) and protein C (PC)
activities were both determined by chromogenic assays (Berichro-
m®Antithrombin III and Berichrom®Protein C, Siemens HealthcareDiagnostics), reference values being 84-108% and 74-141%,
respectively.
During the hospital stay, complete blood count (CBC), plasma C-
reactive protein (CRP) and serumcreatininewere taken according to the
clinical needs of the patients, and determined at the Laboratory Centre
of the Pirkanmaa Hospital District using standard methods. The
reference values for serum creatinine were b105 μmol/l for males and
b95 μmol/l for females and for CRPb10 mg/l. For platelet and leukocyte
counts the reference values were 150-360 and 3.4-8.2×109/l, respec-
tively. The reference values for blood hemoglobin were 134-167 g/l for
males and 117-155 g/l for females.
The DIC scoring system by the International Society of Thrombosis
and Haemostasis (ISTH) was used to evaluate individual patients [13].
The most abnormal value for each variable was chosen for scoring
based on the three acute assessments.
Statistics
To analyse the data, the most abnormal value of each continuous
variable measured during the acute phase of NE was designated the
maximum or the minimum value. The change between the maximum
or the minimum and the control value (the fourth sample) was
calculated. Means (±standard deviations) and medians (ranges)
were provided. To evaluate changes for each variable between the
acute and the control phase, paired samples t-test or Wilcoxon's test
was used. Relationships between continuous variables were exam-
ined using Pearson's or the Spearman rank correlation coefﬁcient.
Comparisons between the groups were based on the Mann-Whitney
U test for the numerical and χ2 test for the categorical data. The limit
of signiﬁcance was set at 0.05 (2-tailed). SPSS 7.5 was used for
computation.
Results
Clinical and laboratory ﬁndings
All 19 patients presented with clinical characteristics typical of NE.
The most prominent symptoms on admission were: fever 100%
(n=19), nausea and/or vomiting 63% (n=12), headache 47% (n=9),
blurred vision 32% (n=6) and abdominal or back pain 16% (n=3).
The median duration of hospitalization was 7 days (range 4-15 days).
During the hospital stay only minor bleeding events occurred: two
patients suffered from epistaxis and one from minor conjunctival
bleed. The median lowest daily urinary output was 880 ml (range
40-3740 ml). Three of the 19 patients needed transient hemodialysis
treatment; one of them showed oozing at the base of the central
venous catheter for several days and received a platelet transfusion of
two units. Five patients were treated with low molecular weight
heparin for a few days either for thromboprophylaxis or maintenance
of hemodialysis. All patients recovered.
During the acute phase of NE the lowest platelet count ranged from
13 to 238×109/l (median 75×109/l), and thrombocytopenia was found
in 15 (79%) patients. However, 17 patients (89%) had their platelet
countwithin normal values by the timeof discharge. Seventeenpatients
had a leukocyte count higher than 10.0×109/l (median maximum
11.8×109/l, range 7.3 - 23.2×109/l), and 15 patients were anemic
(median minimum hemoglobin 126 g/l, range 98 - 157 g/l). CRP was
elevated in 17 patients (medianmaximum61 mg/l, range 6 - 198 mg/l),
and creatinine concentrationwas elevated in 18 (95%) patients (median
maximum 321 μmol/l, range 74 - 1258 μmol/l).
Laboratory markers of coagulation and ﬁbrinolysis
The values for coagulation variables during the acute phase and at
recovery are shown in Table 1.
Table 1
Coagulation variables in the acute phase and at recovery in 19 patients with NE.
Reference
values
Acute phase Recovery
phase
p
APTT max (s) 23-33 34 (29-47) 29 (26-34) b0.001
Prothrombin time min (%) 70-130 84±23 119±31 b0.001
Thrombin time min (s) 17-25 16±1.6 19±1.9 b0.001
Fibrinogen min (g/l) 1.7-4.0 3.6±1.2 3.2±0.8 0.14
F1+2 max (pmol/l) 69-229 726 (160-
1461)
213 (95-
351)
b0.001
D-dimer max (mg/l) ≤0.5 4.8 (0.3-19.5) 0.2 (0.1-1.4) b0.001
Antithrombin activity min (%) 84-108 72 (52-113) 95 (64-119) b0.001
Protein C activity min (%) 74-141 61 (32-121) 106 (64-
185)
b0.001
Protein S free antigen min (%) 66-158 60 (19-90) 92 (68-121) b0.001
Abbreviations: APTT=activated partial thromboplastin time, F1+2=prothrombin
fragments, max=maximum, min=minimum. The values represent mean or median
and standard deviation or range (in brackets).
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increased plasma D-dimer, the median maximum level being 24-fold
higher than that measured at the control visit (Fig. 1a). D-dimer
remained within normal values in only one patient. F1+2 concen-
tration was 3.4-fold higher during the acute phase than at the control
visit (Fig. 1b), and the concentration exceeded normal values in 18 of
the 19 patients. D-dimer and F1+2 levels correlated positively (r=
0.59, p=0.007). During the acute phase, coagulation activity (F1+2)
appeared to correlate with the length of hospitalization (r=0.53,
p=0.02). Neither D-dimer nor F1+2 correlated with creatinine con-
centration or platelet count (data not shown).
Acutely, the levels of natural anticoagulants PC and AT (Fig. 1c and
d), as well as PS were low and TT was shortened (pb0.001 for all)
compared with the recovery phase. APTT was prolonged and PT%
decreased (pb0.001 for both) compared with the recovery values.
The reduced blood platelet count during the acute phase
correlated with several variables. Especially strong correlations wereFig. 1. Concentrations of (a) D-dimer and (b) prothrombin fragments (F1+2) and activities
maximum (a,b) or minimum (c,d). The timing is counted from the beginning of the fever.observed between platelet count and AT and PC activities and PS
(r=0.71, r=0.73, and r=0.81, respectively, pb0.001 for all).
Correlation was also evident between platelet count and ﬁbrinogen
concentration (r=0.72, pb0.001).
A number of associations between CRP, AT, PC, PS, and ﬁbrinogen
were found, among the most distinct of them were the negative
correlation between CRP and PC (r=-0.58, p=0.009) and the
positive correlation between PC and AT (r=0.73, pb0.001).
Renal function impairment, assessed by maximum creatinine
concentration or minimum daily urinary output, did not correlate
with the coagulation variables, except with the shortening of thrombin
time (r=-0.59, p=0.007 and r=0.53, p=0.02, respectively).
Five of the 19 patients (26%) reached at least ﬁve points in the ISTH
score, indicating a diagnosis of DIC (Table 2). In addition to the typical
low platelet count and high D-dimer, all ﬁve had prolonged APTT and
elevated F1+2. One of the patients with DIC needed transient
hemodialysis and experienced oozing at the site of the central venous
catheter. However, there was no statistically signiﬁcant difference
between a positive DIC score and the length of hospitalization, the
maximum creatinine concentration, the need of transient hemodial-
ysis, or the bleeding tendency (data not shown).
Coagulation results of DIC negative and DIC positive patients
according to the ISTH score are presented in Table 3.
Discussion
The ﬁndings of enhanced thrombin generation and ﬁbrinolysis were
conspicuous. An over 3-fold increase in F1+2 during the acute
compared with the recovery phase indicated thrombin formation, and
it applied to 18 of the 19 patients. Disproportionate to the thrombin
generation, the 24-fold increase in D-dimer during the acute phase
indicated markedly upregulated ﬁbrin degradation and turnover or
reduced elimination of the ﬁbrin fragments. It could be attributable to
the endothelial activation often suspected to be involved in the
pathogenesis of acuteNE [14,15]. However, the lack of overt coagulationof (c) protein C (PC) and (d) antithrombin (AT) in 19 patients with NE. Values represent
Table 2
Data of ﬁve patients compatible with DIC according to the ISTH score (5 or over).
Pt Gender
(F / M)
Age
(years)
Dialysis Platelet count min
(x109/l)
PT min
(%)
APTT max
(s)
D-dimer max
(mg/l)
Fibrinogen min
(g/l)
F1+2 max
(pmol/l)
DIC score
1 M 34 no 31 70 35 5.6 3.5 438 5
2 F 49 no 34 83 41 12.1 1.50 1125 5
3 M 30 no 39 40 38 19.5 1.8 726 6
4 M 36 no 36 76 46 6.0 2.4 1461 5
5 M 36 yes 13 60 40 3.2 2.5 789 5
Reference ranges: platelet count 150-360×109/l, PT% 70-130%, APTT 23-33 s, D-dimer≤0.5 mg/l, ﬁbrinogen 1.7-4.0 g/l, and F1+2 69-229 pmol/l. Abbreviations: min=minimum,
max=maximum.
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and ﬁbrinolytic activities, despite the laboratory abnormalities. Inter-
estingly, enhanced thrombin generation associated with the prolonga-
tion of hospital stay, one way of assessing the severity of the disease.
DIC promoted by vascular injury is considered common in HFRS
and is often suggested as a possible cause of thrombocytopenia in NE
[14]. However, the deﬁnition and laboratorymeasurements applied to
diagnose DIC during NE vary greatly in the literature. Settergren et al
reported 5% of 74 patients as having DIC, deﬁned as clinically evident
bleeding, positive ethanol gelation test, elevated levels of ﬁbrin
degradation products and platelets less than 100×109/l [12]. Four
fatal cases of NE with assumed DIC from Finland and some sporadic
cases elsewhere have been reported [8,11,16]. We evaluated our data
with the uniform scoring system for DIC developed by the ISTH [13]. In
addition to platelet count the score is based on PT and concentrations
of D-dimer and ﬁbrinogen. Five of the 19 patients here (26%) reached
at least ﬁve points indicative of DIC. Interestingly, only two of them
showed abnormal prothrombin time, and only one had clinical, albeit
minor, problems with hemostasis. The positive score did not associate
with elevated D-dimer or F1+2, the two most prominent ﬁndings in
the study. Neither did the score associate with the clinical variables,
and it failed to predict outcome in this group of acute NE patients.
Despite the lack of overt coagulation problems, our patients were
clinically quite ill: three of the 19 (16%) needed transient hemodialysis
compared with the 5% presented in the literature [4]. However, no
association was observed between the degree of renal impairment and
the depth of thrombocytopenia, although both are well-known clinical
markers of NE. Neither minimum daily urinary output, maximum
creatinine nor the need of hemodialysis correlated with indicators of
thrombin formation and ﬁbrinolysis or increased consumption of
coagulation inhibitors, with the remarkable exception of thrombin
time. Thrombocytopenia and short thrombin time could imply micro-
vesiculation, i.e. membrane shedding with markedly enhanced coagu-
lation activity, as reported in severe inﬂammation, complement
activation and immune-mediated thrombocytopenia induced by hep-
arin or hepatitis [17–19].Table 3
Coagulation results of DIC negative and DIC positive patients according to the ISTH
score.
Reference
values
DIC negative DIC positive p
Platelet count min (×109/l) 150-360 88 (50-238) 34 (13-39) 0.001
APTT max (s) 23-33 33 (29-47) 40 (35-46) 0.009
Prothrombin time min (%) 70-130 86 (64-140) 70 (40-83) 0.02
Thrombin time min (s) 17-25 16 (13-19) 16 (15-18) 0.9
Fibrinogen min (g/l) 1.7-4.0 4.0 (2.7-6.7) 2.4 (1.5-3.5) 0.005
F1+2 max (pmol/l) 69-229 584 (160-1330) 789 (438-1461) 0.4
D-dimer max (mg/l) ≤0.5 4.7 (0.3-14.2) 5.6 (3.2-19.5) 0.2
Antithrombin
activity min (%)
84-108 78 (53-113) 55 (52-68) 0.01
Protein C activity min (%) 74-141 65 (32-121) 40 (38-54) 0.03
ProteinSfreeantigenmin(%) 66-158 70 (48-90) 36 (19-44) 0.001
Abbreviations: APTT=activated partial thromboplastin time, F1+2=prothrombin
fragments, min=minimum, max=maximum. The values represent median (range).In this study many of the altered coagulation variables reﬂect the
inﬂammation during the acute viral disease. The diminished activities
for the natural anticoagulants AT, PC and PS were marked, but were
also rapidly reversed after the acute phase of the disease. The close
correlation between protein C and antithrombin appears particularly
interesting. It could reﬂect their consumption, the shedding and
downregulation of the regulatory elements of coagulation activity.
Also, the simultaneous loss of natural anticoagulants and platelets
suggests temporal interactions between platelets, their activation and
impaired natural anticoagulants, compatible with endothelial injury
or activation. The interaction of platelets with endothelium, their
activation and P-selectin expression could provide mechanisms of
thrombocytopenia during hantavirus infection, as in several other
forms of viral inﬂammation [20–23].
Capillary leak and increased vascular permeability, as well as
decreased platelet count are cardinal clinical features in both HFRS
andHCPS, but themechanisms leading to them are not fully understood
[24]. Interestingly, pathogenic hantaviruses, which cause either HFRS or
HCPS, use beta 3 integrins for entry to host cells [25]. Beta 3 integrins are
abundant surface receptors on both endothelial cells and platelets, and
regulate both vascular permeability and platelet activation and
adhesion. The use of these receptors by hantaviruses may therefore be
fundamental to hantavirus pathogenesis, and speciﬁcly to hantavirus-
associated thrombocytopenia. Recently, the intensity level of platelet
beta 3 integrin in patients with HFRS was suggested to be associated
with disease severity [26]. Moreover, another newly discovered
mechanism which associates with disease severity of HFRS is human
platelet alloantigen (HPA) -3 polymorphism [27].
The earlier literature indicates hemostasis impairment in NE due
to remaining dysfunctional platelets. This could result from acute
renal failure and increased ﬁbrin degradation, both conﬁrmed in our
study. Furthermore, exhausted circulating platelets could be implied,
referring to their in vivo activation leading to impaired aggregation
and release reactions when tested in vitro [14,28].
We are aware that the timing of the samples during the acute phase
overlaps because the patients sought medical assistance at different
time intervals from the beginning of their disease. Another limitation of
the study is the relatively small number of patients included, which
undermines the value of subgroups of the patients. However, this is the
ﬁrst study on coagulation and ﬁbrinolysis activity during the acute
phase and recovery of Puumala hantavirus infection. Our ﬁndings show
that severe NE inﬂuences the platelets and the coagulation system and
may sometimes result in DIC. In this study the altered coagulation was
not important for the major outcome of the disease, namely, kidney
function.
In conclusion, the conspicuous elevations of prothrombin fragments
and especially D-dimer found in our study indicate increased thrombin
formation andmarked ﬁbrinolytic activity during the acute phase of NE.
Enhancedﬁbrinolysis could compensate for the coagulation activity and
contribute to clinical recovery. In addition to themarkers of endothelial
involvement and the transient organ failure in the kidneys, further
studies could focus on the functions of platelets, including microvesi-
culation, complement activation, and their interactions with coagula-
tion and ﬁbrinolysis [17,29,30].
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C468 Original articlePlatelet ligands and ADAMTS13 during Puumala
hantavirus infection and associated thrombocytopenia
Outi Lainea, Satu Ma¨kela¨a, Jukka Mustonena,b, Mika Helminenc,
Antti Vaherid, Riitta Lassilae and Lotta Joutsi-KorhoneneWe aimed here to elucidate the role of adhesive platelet
ligands and endothelial involvement during the acute phase
of Puumala hantavirus (PUUV) infection. Nineteen hospital-
treated patients with serologically confirmed diagnosis of
acute PUUV infection were included. Patient charts were
reviewed for clinical and basic laboratory data. Plasma
levels of von Willebrand factor antigen (VWF :Ag), ristocetin
cofactor (VWF :RCo), factor VIII (FVIII : C) and a disintegrin
and metalloproteinase with a thrombospondin type 1
domain 13 (ADAMTS13) activities as well as fibrinogen and
fibronectin were measured three times acutely and once
during the recovery phase. VWF :Ag and VWF :RCo were
nearly three-fold higher acutely compared with recovery
(median 252 vs. 88%, and mean 267 vs. 98%, respectively;
P<0.001 for both), whereas FVIII : C was only slightly
elevated (median 118 vs. 88%, PU0.002) and remarkably
failed to show association with VWF in the acute phase.
ADAMTS13 activity and fibronectin concentration were
lower in the acute compared with the recovery phase
(median 56 vs. 63%, PU0.003, and median 221 vs.
330mmol/l, PU0.001, respectively). Fibrinogen raised
acutely (mean 5.0 vs. 3.3 g/l, P<0.001), negatively
correlating with the platelet count (rUS0.468, PU0.043).opyright © Lippincott Williams & Wilkins. Unauth
0957-5235  2011 Wolters Kluwer Health | Lippincott Williams & WilkinsMarkedly upregulated fibrinogen and VWF together with
decreased levels of ADAMTS13 activity and fibronectin were
observed during acute PUUV infection. VWF and FVIII : C did
not associate during the acute phase, whereas
thrombocytopenia correlated negatively with fibrinogen.
These findings imply several rearranged interactions
between platelets and their ligands. Blood Coagul
Fibrinolysis 22:468–472  2011 Wolters Kluwer Health |
Lippincott Williams & Wilkins.
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Puumala hantavirus infection (PUUV), also known as
nephropathia epidemica, is the most common cause of
hemorrhagic fever with renal syndrome (HFRS) in
Europe, some 1000–2000 serological diagnoses being
made annually in Finland [1,2]. The acute illness is
characterized by high fever, headache, back and abdomi-
nal pains, visual disturbances, hemorrhages and acute
impairment of renal function. The clinical severity of
acute PUUV infection varies from mostly mild, even
subclinical disease to rarely reported fatal cases. Throm-
bocytopenia is encountered almost invariably in nephro-
pathia epidemica but bleeding manifestations are usually
mild [3,4].
The cellular entry of hantaviruses which cause HFRS is
mediated by b3 integrins expressed on platelets, endo-
thelial cells and macrophages [5]. Pro-inflammatory cyto-
kines interleukin-6 (IL-6), tumor necrosis factor a, and
interleukin-1 (IL-1) are released and have a modifying
effect on vascular permeability. The increased capillary
permeability manifested by vascular leakage explains
many symptoms and features of nephropathia epidemica[6,7]. Enhanced cytokine activity also increases expres-
sion of intercellular and vascular cell adhesion molecules,
as has been detected in kidney samples obtained during
the acute phase of nephropathia epidemica [8,9]. The
increased expression of adhesion molecules is likely to
associate with procoagulant changes in platelets and
endothelium during the acute phase [7]. Recently, we
reported enhanced thrombin formation and fibrinolysis
during the acute phase of nephropathia epidemica [10].
Here we assessed adhesive platelet ligands related to
endothelial function and acute-phase reactions in the
early phase of nephropathia epidemica and at recovery.
We sought to elucidate the role of these adhesion mol-
ecules in the pathogenesis of nephropathia epidemica
and to establish possible associations between laboratory
findings and the clinical course of the disease.
Methods
The collection of clinical data including the routine
laboratory measurements as well as the collection of
study blood samples and processing to plasma as
described in detail in our recent article [10]. The studyorized reproduction of this article is prohibited.
DOI:10.1097/MBC.0b013e328346a420
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firmed acute PUUV infection (17 men, median age of
patients 38 years, ranging from 30 to 64 years). The
fibronectin samples were collected in EDTA, whereas
other samples were collected in 3.2% sodium citrate.
During the acute phase of the disease three samples
were obtained. The first was collected on admission as
early as possible, 2–9 (median 6) days after the onset of
fever. The second was obtained 3–10 (median 7) days
and the third 6–13 (median 10) days after the onset
of fever. The last sample in the study, that is the
control sample, was collected at full recovery (ranging
32–54 days from fever onset, median 43 days).
The activity of a disintegrin and metalloproteinase with a
thrombospondin type 1 domain 13 (ADAMTS13) was
determined by immunochemical detection of its proteo-
lytic target, that is von Willebrand factor (VWF; Tech-
nozym Elisa, Technoclone, Vienna, Austria). Factor VIII
activity (FVIII : C) was determined by one-stage clotting
assay (Pathromtin SL and Coagulation Factor VIII
Deficient Plasma; Siemens Healthcare Diagnostics, Mar-
burg, Germany). Von Willebrand factor antigen
(VWF : Ag) and ristocetin cofactor activity (VWF : RCo)
were measured with the BCS XP analyzer with BC von
Willebrand Reagent and VWF : Ag Latex Reagent (Sie-
mens Healthcare Diagnostics). Fibrinogen was measured
with a modification of the Clauss method (Multifibren U;
Siemens Healthcare Diagnostics). Fibronectin concen-
tration was determined at room temperature by enzyme-
linked immunosorbent assay (human Fibronectin
ELISA; Bender MedSystems, Vienna, Austria).
Plasma IL-6 was measured on three consecutive morn-
ings starting the first morning of hospital stay. The
concentration was determined using a commercially
available enzyme-linked immunosorbent assay (PeliKine
Compact human IL-6 kit; Central Laboratory of the
Netherlands, Red Cross Blood Transfusion Service,
Amsterdam, the Netherlands). The detection limit for
the assay was 0.4 pg/ml.
The study was carried out in Tampere University
Hospital and Helsinki University Central Hospital,
Finland and was approved by the Ethics Committees
of these hospitals.Copyright © Lippincott Williams & Wilkins. Unaut
Table 1 Laboratory markers of coagulation and endothelial cell activa
nephropathia epidemica
Variable Reference values
VWF : Ag (%) 51–169 25
VWF : RCo (%) 44–183
FVIII : C (%) 52–148 11
Fibrinogen (g/l) 1.7–4.0
ADAMTS13 activity (%) 40–130 5
Fibronectin (mg/ml) 117–338 22
Values represent means (SD) or medians (range). ADAMTS13, a disintegrin and meta
VWF : Ag, von Willebrand factor antigen; VWF : RCo, VWF ristocetin cofactor activityStatistical analysis
The highest value of continuous variables known to
increase during the infection was chosen to represent
the maximum for the variable in the acute phase. The
lowest of three ADAMTS13 and fibronectin values and
platelet counts were taken to represent the minimum
values. Paired samples t-test or Wilcoxon’s test was used
when appropriate. Pearson’s or the Spearman rank cor-
relation coefficient was calculated. Comparisons were
made using the Mann–Whitney U-test. The limit of
significance was set at 0.05 (two-tailed). SPSS 7.5 (SPSS
Inc., Chicago, Illinois, USA) was used for computation.
Results
During the acute disease phase thrombocytopenia was
found in 15 of the 19 patients, but by the time of
discharge, 17 had platelet counts within normal values.
The median lowest daily urinary output was 880 ml, and
three of the 19 patients needed transient hemodialysis
treatment. The acute IL-6 concentration was 16.7 pg/ml
(median, range 3.6–96.6). Four patients with minor
bleeding symptoms had higher IL-6 levels, leukocyte
counts and C-reactive protein values than those without
(P¼ 0.007, P¼ 0.019 for the last two, respectively).
VWF : Ag and VWF : RCo levels were nearly three-fold
higher during the acute compared with the control phase
(Table 1). Eighteen patients evinced elevated VWF : Ag
levels (Fig. 1a), in contrast we noted only a slight increase
in FVIII : C acutely. VWF : Ag and VWF : RCo levels
correlated well with each other (r¼ 0.94, P< 0.001),
but intriguingly not with FVIII : C. The ratio between
VWF : Ag and FVIII : C was nearly three-fold higher
acutely compared with the control phase (median 3.72
vs. 1.25, P< 0.001). FVIII : C correlated with fibrinogen
(r¼ 0.589, P¼ 0.008). Fibrinogen was 1.6-fold higher
during the acute compared with the control phase, and
14 patients had acutely elevated fibrinogen levels
(Fig. 1b). The negative correlation prevailed between
fibrinogen and platelet count (r¼0.468, P¼ 0.043).
ADAMTS13 activity was lower in the acute phase com-
pared with the control phase (Fig. 1c). However, only four
patients had their minimum values below the lower
reference limit.horized reproduction of this article is prohibited.
tion during the acute phase and at recovery in 19 patients with
Acute phase Recovery phase P
2 (113–459) 88 (39–192) <0.001
267112 9839 <0.001
8 (56–173) 88 (39–192) 0.002
5.01.3 3.20.9 <0.001
6 (34–90) 63 (45–85) 0.003
1 (114–350) 330 (138–928) 0.001
lloproteinase with a thrombospondin type 1 domain 13; FVIII : C, factor VIII activity;
.
Copyright © Lippincott Williams & Wilkins. Unauth
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Fig. 1
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Von Willebrand factor antigen (VWF : Ag) (a), fibrinogen (b),
ADAMTS13 activity (c), and fibronectin (d) during the acute phase and
at recovery in 19 patients with Puumala hantavirus infection. The
reference ranges are indicated by broken lines. Days are counted from
the onset of fever.Fibronectin was also low in the acute phase (Fig. 1d), the
mean being 1.6-fold higher in the control phase. Only two
patients had minimum values below the lower reference
limit.
Discussion
We here assessed the role of platelet ligands VWF,
fibrinogen and fibronectin in the acute phase of nephro-
pathia epidemica and related the findings to the clinical
course of the disease. In addition to mediating platelet–
platelet interaction, the adhesion molecules in question
are carried by platelets and implicated in acute-phase
reaction and endothelial activation. We found an almost
three-fold increase in the levels of plasma VWF : Ag and
VWF : RCo and a 1.6-fold increase in fibrinogen in the
acute phase of nephropathia epidemica compared with
the control phase.
VWF is produced by the endothelium and megakaryo-
cytes and carried in the a-granules of circulating platelets.
VWF enhances early platelet adhesion and aggregation to
injured endothelium during both physiological primary
hemostasis and pathological thrombosis [11]. Aside fibri-
nogen and fibronectin it is an important ligand of aIIbb3
which contains the b3 integrin receptor for hantaviruses
capable of causing HFRS [5,12]. An increased VWF level
could imply endothelial cell injury and exposure of the
adhesive matrix to platelets. Also, strong platelet acti-
vation and granule release could increase circulating
VWF levels, which in this study raised three-fold. These
mechanisms of enhanced platelet adhesion and activation
could result in platelet consumption and the thrombo-
cytopenia encountered in the acute phase of nephro-
pathia epidemica, as described in dengue virus infection
[13,14].
Fibrinogen, another major platelet constituent and exter-
nal ligand of aIIbb3, contributes to thrombus stability by
anchoring the thrombi to the vessel wall and individual
platelets to the thrombus [12]. The fibrinogen concen-
tration in plasma increased 1.6-fold acutely compared
with the control phase. This could imply platelet acti-
vation and release of fibrinogen as well as inflammation-
triggered synthesis of fibrinogen by the liver. Elevated
fibrinogen could reflect an acute-phase reaction in the
liver strong enough to outweigh the consumption due to
the coagulation activity ongoing during the acute phase of
nephropathia epidemica, as observed in our previous
study [10]. Such a conception is supported by the nega-
tive correlation between fibrinogen and platelet count, as
a decreasing platelet count may mirror increased platelet
activation and consumption. The finding of increased
VWF and fibrinogen may counterbalance bleeding
tendency, despite the low platelet count encountered
in the acute phase of the disease.
Fibronectin, the third ligand of aIIbb3, is a high-
molecular-weight glycoprotein present in a soluble formorized reproduction of this article is prohibited.
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the extracellular matrix [12,15]. Fibronectin is firmly
bound to fibrinogen and fibrin at low temperatures
in vitro (at 0–48C) and subsequently released as the
temperature rises [16]. Fibronectin participates in
plug formation by gluing platelets to each other, thus
enhancing thrombus formation, especially under
arterial share rates, such as in the microcirculation
[17]. Recently, increased serum fibronectin levels in
patients with HFRS caused by Hantaan virus were
reported to be associated with disease severity [18].
However, the temperature at which the ELISA
analyses were carried out was not provided. Another
group has previously reported diminished fibronectin
levels as a marker of sepsis [19]. We observed a con-
siderable decrease in plasma fibronectin concentrations
in the acute phase of nephropathia epidemica. The
binding of fibronectin to platelets is enhanced by throm-
bin but not by other platelet activators [20]. This may be
compatible with our previous finding of thrombin
activity in early hantavirus infection [11], and a loss of
fibronectin could reflect the binding to thrombin-
activated platelets and consumption during coagulation
activity.
In circulation FVIII is bound to VWF while inactive and
degrades rapidly when released from VWF by the action
of thrombin [11]. Interestingly, in our study the increase
in FVIII : C did not follow VWF levels and the ratios
between VWF : Ag and FVIII in the acute and control
phase markedly differed. This may be in keeping with
our recent observation of enhanced thrombin generation
during the acute phase of nephropathia epidemica and
utilization of FVIII in coagulation and fibrin formation
[10]. FVIII may also be bound to microparticles from
platelets stimulated by thrombin or the complement
proteins C5b-9 [21,22]. The finding of only modest
increase in FVIII : C is also compatible with dengue virus
infection, in which reduced coagulation factors correlated
with the degree of thrombocytopenia and the clinical
severity of the disease [23].
A decrease in the activity of ADAMTS13, an enzyme
specifically involved in the cleavage of high-molecular-
weight VWF, is known to have an important role in the
pathogenesis of thrombotic thrombocytopenic purpura
(TTP). This form of thrombotic microangiopathy is
characterized by thrombocytopenia, hemolytic anemia,
and ischemic organ failure due to thrombotic occlusions
in the arterioles [24]. Thrombocytopenia is frequent in
acute nephropathia epidemica and variable neurological
symptoms (headache, visual disturbances, even acute
disseminated encephalomyelitis and Guillain–Barre´ syn-
drome) are also encountered [25]. In our study,
ADAMTS13 activity was modestly reduced during the
acute phase of nephropathia epidemica, in accordance
with studies implying that decreased ADAMTS13
activity is not restricted to TTP [14,26].Copyright © Lippincott Williams & Wilkins. UnautThe participants here evinced quite severe organ failure
in the kidneys. Three of the 19 patients needed transient
hemodialysis compared with the 5% presented in the
literature [2]. In this small study, the degree of renal
impairment was not associated with any of the platelet
ligands or fibronectin. Low platelet count was predicted
by the high level of fibrinogen.
In conclusion, markedly enhanced VWF with only a
slight increase in FVIII together with decreased levels
of ADAMTS13 activity and plasma fibronectin were
observed during the acute phase of nephropathia epide-
mica. The findings support previous evidence of the role
of activated platelets and the endothelium in the patho-
genesis of nephropathia epidemica. Further studies are
warranted on platelet activation and the formation of
microparticles during the acute phase of nephropathia
epidemica.
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Abstract 24 
Introduction: Hantaviruses are important human pathogens that cause clinical diseases 25 
characterized by renal and cardiopulmonary manifestations. Their pathogenesis is currently 26 
poorly understood. We have studied the role of the complement system in the pathogenesis of 27 
Puumala (PUUV) hantavirus infection. 28 
Material and Methods: We studied the activation of complement by measuring the terminal 29 
complement complex SC5b-9 and complement component C3 and C4 levels in patients with 30 
acute PUUV infection. Several laboratory parameters and clinical findings reflecting the 31 
severity of PUUV-HFRS were evaluated with regard to complement activation. 32 
Results: The levels of SC5b-9 were significantly increased and C3 decreased in the acute 33 
stage as compared to the levels at full recovery (P<0.001). We found that SC5b-9 levels were 34 
higher in patients with chest x-ray abnormalities than in patients with a normal x-ray during 35 
the acute stage (P=0.028). Furthermore, SC5b-9 and C3 levels showed significant correlation 36 
with several clinical and laboratory parameters that reflect the severity of the acute PUUV 37 
infection. 38 
Conclusions: We showed that complement system becomes activated via the alternative 39 
pathway in the acute stage of PUUV infection and the level of activation correlates with 40 
disease severity. The results further suggest that complement activation may contribute to the 41 
pathogenesis of acute PUUV infection. 42 
 43 
Keywords:  C3, C4, complement, hantavirus, HFRS, SC5b-9 44 
 45 
 46 
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 Key messages:   47 
1) Complement activation via the alternative pathway in the acute stage of PUUV hantavirus 48 
infection correlates with disease severity. 49 
2) Complement activation may contribute to the pathogenesis of acute PUUV infection. 50 
 51 
. 52 
 53 
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 60 
 61 
 62 
 63 
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Abbreviations  64 
HFRS- hemorrhagic fever with renal syndrome 65 
HCPS- hantavirus cardiopulmonary syndrome 66 
NE- nephropathia epidemica 67 
MAC-membrane attack complex 68 
PUUV- Puumala virus 69 
 70 
 71 
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 73 
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 75 
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 80 
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Introduction 81 
Puumala virus (PUUV), a member of the Hantavirus genus in the Bunyaviridae family, is a 82 
rodent-borne zoonotic virus with a segmented, negative-stranded RNA genome. PUUV is 83 
carried by the bank vole, Myodes glareolus, which is found in most of Europe [1]. Numerous 84 
hantaviruses are known pathogens to humans and cause two diseases: hemorrhagic fever with 85 
renal syndrome (HFRS) in Eurasia, and hantavirus cardiopulmonary syndrome (HCPS) in the 86 
Americas (1). Acute PUUV infection, known as nephropathia epidemica (NE), is a mild form 87 
of HFRS with approximately 0.1% mortality (2).  88 
PUUV-HFRS has an incubation period of 2-6 weeks and the disease begins with high fever, 89 
headache, nausea and vomiting. Signs of renal insufficiency include proteinuria, hematuria 90 
and increased creatinine levels as well as oliguria followed by polyuria. Transient 91 
hemodialysis treatment is needed in approximately 5% of hospitalized patients (3). General 92 
laboratory findings include leukocytosis, thrombocytopenia, hypoproteinemia and increased 93 
CRP levels. The severity of the disease is associated with HLA B8, DR3 and DQ2 haplotype 94 
(4).  95 
Pulmonary involvement has been described in about one third of PUUV-infected patients (5-96 
8) and over half of the patients have abnormal cardiac findings (9). It is believed that 97 
capillary leakage due to increased capillary permeability plays a role in the pathogenesis of 98 
pulmonary changes in HFRS and HCPS, which is more frequently characterized by severe 99 
pulmonary dysfunction (10,11). 100 
A previous study on complement activation in PUUV infection showed that complement 101 
activation is common and suggested that the classical pathway of complement is associated 102 
with disease severity (12) . However, the role of the complement system in the pathogenesis 103 
of PUUV-HFRS has not been further studied in larger patient populations. The complement 104 
6 
 
system has three major pathways; the classical, alternative and the lectin-dependent pathway.  105 
These pathways are activated differently but they all converge on complement component C3 106 
that has a key function in the complement system (13). The end product of the complement 107 
cascade is the cytolytic membrane attack complex (MAC), formed by sequential assembly of 108 
complement proteins C5b, C6, C7, C8 and C9 to a target cell membrane. When the 109 
complexes are formed in the absence of a target membrane in the fluid phase, C5b-9 binds to 110 
S-protein (vitronectin) or clusterin and a non-lytic soluble SC5b-9 terminal complex is 111 
formed (14).  112 
We measured the levels of SC5b-9, C3 and C4 in 61 hospitalized patients in the acute stage 113 
of PUUV infection and at recovery to study the role of complement in the pathogenesis of 114 
PUUV-HFRS. 115 
 116 
 117 
 118 
 119 
 120 
 121 
 122 
 123 
 124 
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Material and Methods 125 
Ethics statement 126 
Written informed consent was obtained from all patients, and the Ethics Committee of the 127 
Tampere University Hospital approved the study protocol. 128 
Patients and methods 129 
This prospective study included 61 consecutive hospitalized patients with serologically 130 
confirmed acute PUUV infection. The serological diagnosis is based on µ-capture PUUV-131 
IgM enzyme immunoassay (15). All patients, 44 males and 17 females, median age 46 132 
(range; 22-77), were treated at the Tampere University Hospital during the period from 133 
September 2000 to January 2004.  134 
The median number of plasma samples taken from patients during hospital care was 4 (range 135 
1-6). The first sample (n=61) was obtained upon admission to hospital 2-16 (median 5) days 136 
after the onset of fever. The second sample (n= 58) was obtained 4-16 (median 6), the third 137 
sample (n=45) 6-17 (median 8), the fourth sample (n=31) 6-14 (median 9), the fifth sample 138 
(n=10) 7-11 (median 10) and the sixth sample (n=2) 13-18 (median 16) days after the onset 139 
of fever. The last sample (n=53) was taken at full recovery 18-55 days (median 38) after the 140 
onset of fever and represented the control sample in the analyses.  141 
Laboratory parameters, determined at the Laboratory Center of the Tampere University 142 
Hospital, and clinical findings were retrieved from patient charts. All chest radiographs were 143 
studied retrospectively by a radiologist (A.P.). Complement analyses were performed at the 144 
Haartman Institute and at HUSLAB. Plasma C3 and C4 levels were measured by 145 
nephelometry (Dade Behring, Marburg, Germany) and SC5b-9 using an ELISA kit (Quidel, 146 
San Diego, CA). Different sets of samples were used for SC5b-9 and C3/C4 analyses and the 147 
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samples were stored at -70 °C or -20°C, respectively. A number of patient samples did not 148 
meet the quality-control criteria for the measurements of C3, C4 and SC5b-9 levels defined 149 
by the manufacturer. Thus, these samples were excluded from the respective analyses.  150 
Statistical analyses 151 
Statistical analyses were performed using SPSS software version 18 (USA). The highest and 152 
lowest values of continuous variables measured during hospital care were designated as 153 
maximum or minimum values. As for the SC5b-9 the maximum, and for the C3 and C4 154 
levels, the minimum values during the acute stage, respectively, were used. The maximum 155 
level of SC5b-9 reflects the peak of complement activation and minimum level of C3 and C4 156 
the degree of C3 and C4 consumption during the acute stage of PUUV infection.  157 
We used Mann-Whitney U test to compare SC5b-9, C3 and C4 levels between different 158 
patient groups and Wilcoxon’s rank sum test to compare the levels in the same individual at 159 
different time points (acute stage and full recovery). To express a relationship between the 160 
continuous variables, Spearman’s rank correlation coefficients were computed. All P-values 161 
are two tailed and statistical significance was considered at 5% level. 162 
 163 
 164 
 165 
 166 
 167 
 168 
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Results 169 
SC5b-9, C3 and C4 levels. We measured the plasma levels of SC5b-9, C3 and C4 during the 170 
hospital care and at full recovery. The highest and lowest concentrations of SC5b-9 and C3, 171 
respectively, were found in the first or second acute-stage sample in nearly all patients (n=50) 172 
and from the third or fourth sample in the others. The lowest concentration of C4 was found 173 
in the first or second acute-stage sample in 40 patients. 174 
As shown in Figure 1A, the median maximum plasma SC5b-9 concentration in the acute 175 
stage was significantly higher than at full recovery (493 ng/ml, range 103- 1034 ng/ml vs. 176 
197 ng/ml, range 100- 522 ng/ml, p<0.001). The acute-stage median minimum C3 level was 177 
decreased compared to the level measured at full recovery (1.26 g/l, range 0.65-2.24 g/l vs. 178 
1.47 g/l, range 0.84-2.44 g/l, p<0.001, Figure 1B). The acute-stage median minimum C4 level 179 
was not significantly different from  the level measured at full recovery (0.26 g/l, range 0.08-180 
0.52 g/l vs. 0.27 g/l, range 0.09-1.1 g/l, p=0.48, Figure 1C). 181 
Fifty patients had chest x-ray taken upon hospitalization. Fourteen of them (28%) had 182 
abnormal findings including accumulation of pleural fluid (n=6) and atelectasis (n=12). The 183 
patients with chest x-ray abnormalities during the acute stage had significantly higher levels 184 
of SC5b-9 than patients with normal x-ray (P=0.028) but the levels were no longer different 185 
at the time of recovery (Figure 2A). The patients with pathological findings in chest x-ray in 186 
the acute stage tended to have lower minimum C3 levels than patients with normal x-ray but 187 
the difference was not statistically significant (P=0.08) (Figure 2B). No differences were 188 
observed in C4 levels (Figure 2C).  189 
Correlation of SC5b-9, C3 and C4 levels with disease severity. Clinical and laboratory 190 
findings of patients are shown in Table 1. Acute-stage levels of SC5b-9 and C3 correlated 191 
significantly with a number of variables that reflect the clinical severity of PUUV infection 192 
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(Table 2).  As for maximum levels of SC5b-9, the strongest correlations were found with the 193 
treatment time at hospital, the highest blood leukocyte count, and the change in weight during 194 
hospital care (r=0.46, r=0.43 and r=0.42, respectively, P<0.001 for all). The variables that 195 
showed the strongest correlation with minimum C3 levels were the highest levels of IL-6, the 196 
lowest blood hematocrit level, and lowest serum sodium level (r=-0.62, r=0.52 and r=0.44, 197 
respectively,  P<0.001 for all). The highest blood leukocyte count also correlated inversely 198 
with C3 levels (r=-0.3, P=0.020).  Acute-stage levels of C4 did not show significant 199 
correlation with any of the clinical or laboratory findings (Table 2). 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
 211 
 212 
11 
 
Discussion 213 
Our study shows that the alternative pathway of complement system becomes activated in the 214 
acute stage of PUUV infection, observed as elevated levels of SC5b-9 and decreased levels of 215 
C3 (Figure 1). The levels of C4 were not significantly altered between the acute stage and full 216 
recovery. The actual peak of complement activation, however, had possibly occurred before 217 
the patients were hospitalized. Furthermore, we showed that SC5b-9 levels were significantly 218 
higher in patients with chest x-ray abnormalities than in patients with a normal x-ray during 219 
the acute stage of PUUV-HFRS (Figure 2A). We also found that consumption of C3 was 220 
higher among patients with x-ray abnormalities, although this was not statistically significant 221 
(Figure 2B), possibly due to the small sample size.  In general, we consider the level of 222 
SC5b-9 a better measure of complement activation since C3 levels are influenced not only by 223 
consumption but also by increased synthesis related to the acute phase response. This likely 224 
explains why some individuals had higher C3 levels in the acute stage of PUUV-HFRS than 225 
at the recovery (Figure 1B). 226 
Previous studies have suggested that the pathogenesis of lung disease in HCPS and HFRS is 227 
attributable to increased capillary permeability in lungs (11). Puumala and Sin Nombre 228 
hantaviruses can infect endothelial cells in vitro without causing any visible changes in cell 229 
morphology or necrosis in the infected endothelium in vivo (10,16). Therefore, it is believed 230 
that immunological mechanisms contribute to changes disturbing the function of endothelium 231 
and thereby lead to capillary leakage. It has been suggested that cytotoxic CD8+ T cells 232 
would trigger capillary leakage (17) and that cytokines may contribute to the increased 233 
capillary permeability (5,18).  234 
Studies in the rat have shown that the soluble form of C5b-9 (SC5b-9) can increase the 235 
endothelial permeability by ligating αvβ3-integrin of lung endothelium by increasing the 236 
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hydraulic conductivity in a dose-dependent manner (19,20). SC5b-9 can also promote the 237 
permeability in human endothelial cells through the release of bradykinin and platelet 238 
activating factor (21) and SC5b-9 has been shown to promote pulmonary edema in the adult 239 
respiratory distress syndrome (ARDS) (22). Based on our findings, it is possible that 240 
complement activation during the acute stage of PUUV-HFRS may contribute to the 241 
pathogenesis of vascular leakage in the lungs. Although pleural fluid indicating leakage was 242 
not visible in all patients with pathological findings in the chest x-ray, the presence of fluid 243 
cannot be excluded since small amount of fluid accumulation is not detectable in 244 
posteroanterior radiographs (23). Our data cannot, however, prove a direct causal link 245 
between complement activation and vascular leakage since no direct experimental evidence is 246 
provided. Additional immunopathological mechanisms could be involved.  247 
The role of complement system in the pathogenesis of other viral diseases has recently been 248 
studied. Increased permeability of the endothelium without morphological damage to the 249 
cells is a key feature of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) 250 
(24) and recent studies showed that patients with DHF had significantly higher SC5b-9 and 251 
lower C3 levels in plasma than patients with less severe dengue fever during the acute stage 252 
of the disease (25,26). The authors observed highest levels of SC5b-9 in the pleural fluids and 253 
plasma of DSS patients (25). The SC5b-9 levels found in our study were however clearly 254 
lower than in DSS patients, which is in line with the milder course of PUUV infection 255 
compared to DSS. However, our levels were similar to those seen in DHF patients.A recent 256 
study also suggested that complement activation contributes to a more severe clinical 257 
outcome of H1N1 pandemic influenza (27) . 258 
We showed in our study that complement system activation, observed as elevated levels of 259 
SC5b-9 and/or lower levels of C3, in the acute stage of PUUV-HFRS correlated significantly 260 
with several laboratory and clinical findings that reflect the disease severity such as 261 
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leukocytosis and thrombocytopenia (Table 2). One previous study showed that low serum 262 
protein level, a good marker of capillary leakage, was strongly associated with abnormal 263 
chest x-ray findings (7). However, we did not have protein levels available in this study.  The 264 
length of hospital treatment, probably the most objective measure to define severity, showed 265 
significant correlation with both high SC5b-9 and low C3 concentrations.   266 
We observed an inverse correlation between the C3 and IL-6 levels in the acute stage of 267 
PUUV infection (Table 2). Significant increase in plasma IL-6 levels has been reported in 268 
patients with acute PUUV infection (28) and IL-6 secretion has been found to stimulate C3 269 
synthesis (29). In our study, the low C3 levels associated with high IL-6 levels probably 270 
reflect the level of tissue injury and consumption of C3 in the acute stage of the disease. An 271 
increase in C3 levels due to IL-6 secretion was probably not observed at the time samples 272 
were taken because it usually follows a 2-5 days delay. 273 
Our hypothesis is supported by our recent findings concerning two fatal cases of PUUV-274 
HFRS (unpublished data). The first patient with severe pulmonary edema had high SC5b-9 275 
and low C3 levels during the acute stage of PUUV infection as compared to the levels found 276 
in this study and the immunohistochemical staining showed extensive accumulation of C5b-9 277 
and C3 in lung tissue. Heavy deposition of C5b-9 and C3 complexes was also detected in 278 
hypophysis, characterized by hemorrhages, and in the liver. As for the second patient, plasma 279 
levels of complement proteins were not obtained but immuhistochemical staining showed 280 
similar accumulation, although to a slightly lesser extent, of C5b-9 and C3 in lungs and 281 
hypophysis.  282 
We measured the level of SC5b-9 that reflects overall activation of the complement system in 283 
the specimen. SC5b-9 is the soluble equivalent of the membrane-associated MAC complex. 284 
Therefore, the result indirectly suggests that formation of membrane attack complexes, 285 
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known to trigger cellular reactions and production of inflammatory cytokines (30), also 286 
contributes to the pathology of PUUV-HFRS. In addition to the terminal complement 287 
complex, elevated plasma levels of C5a, known to play role in the pathogenesis of ARDS 288 
(31), may also contribute to pulmonary dysfunction in PUUV HFRS as C5a attracts and 289 
aggregates leukocytes that can result in capillary obstruction and leakage (29).  Correlation 290 
between complement activation and blood leukocyte count was observed in our study.  291 
The sample size of this study was relatively small. Thus, it has an impact on the statistical 292 
power and addresses the need for further studies. However, for a prospective panel of 293 
hantavirus patient samples studied comprehensively with similar methodology, the number of 294 
cases is considerable. The time elapsed from the onset of fever to the time point when the 295 
first acute-stage samples were taken varied between individual patients. This time frame was 296 
not, however, significantly different between the patients with chest x-ray abnormalities and 297 
other patients (data not shown). Thus, analyses on SC5b-9 and C3 levels were presumably 298 
not biased. There were no significant differences in the age and sex distribution or in the 299 
frequency of previous illnesses between the patients with chest x-ray abnormalities and other 300 
patients.  301 
The only previous study on complement activation in PUUV infection (12) indicated that 302 
complement activation via the classical pathway is associated with the disease severity. Our 303 
study, with a considerably larger sample size, confirmed that complement becomes activated 304 
in the acute stage of PUUV and further extends the findings by demonstrating that SC5b-9 305 
and C3 levels, indicating the alternative pathway activation, correlated with disease severity. 306 
Although our data showed that C4 levels were not significantly altered between the acute 307 
stage and recovery, it cannot be excluded that classical pathway activation also occur as it is 308 
possible that consumption is compensated by increased synthesis. However, our data 309 
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indicated that the activation of the classical pathway is not as strong or long-standing that it 310 
would be observable in changes in total C4- levels.  311 
Our study did not address the question of what actually triggers the complement activation in 312 
PUUV-HFRS and why do some individuals have stronger responses than others. A previous 313 
study showed that individuals with the HLA B8, DR3 and DQ2 haplotype are likely to have 314 
severe PUUV-HFRS (4), and a more recent study established that the presence and the 315 
severity of abnormal chest radiography findings are apparently associated with this haplotype 316 
(6). This haplotype regularly carries a deletion of the C4A gene that encodes the C4A protein, 317 
one of the two isotypes of complement component C4. C4 is an essential component of the 318 
complement system and deficiencies of C4A are associated with defective clearance of 319 
immune aggregates and persistence of viral infections (32). Abnormal complement activation 320 
may thus be associated with this particular HLA haplotype and mechanistically, it may relate 321 
to the deficiency of C4A. The C4A deficiency may lead to impaired classical pathway 322 
activation and an inability to process immune aggregates, e.g. antigen-antibody complexes, 323 
which in turn would lead to further inflammation and complement activation via the 324 
alternative pathway. However, the total plasma levels of C4 measured in this study does not 325 
indicate the level of C4A proteins specifically. Individuals with elevated complement 326 
activation may also have impaired regulation of the alternative complement pathway. A 327 
recent study showed that alternative complement pathway deregulation correlates with the 328 
severity of DHF and this may be linked to complement factor H dysfunction (26).  329 
Taken together, our data indicate that complement activation via the alternative pathway in 330 
the acute stage of PUUV hantavirus infection correlates with disease severity and may 331 
contribute to the pathology of PUUV-HFRS. The complement system may thus be 332 
considered a potential therapeutic target to suppress severe hantavirus disease.  333 
16 
 
Acknowledgements 334 
The skilful technical assistance of Ms Katriina Yli-Nikkilä, Ms Mirja Ikonen, Ms Marita 335 
Siren and Tytti Manni is greatly appreciated. 336 
The study was financially supported by the Medical Research Fund of Tampere University 337 
Hospital, the Finnish Kidney Foundation and the European Commission Project “Diagnosis 338 
and control of rodent-borne viral zoonoses in Europe” (QLK2-CT-2002-01358), the 339 
Academy of Finland, Sigrid Jusélius Foundation, HUS/EVO grants TYH 7214 and 2008235, 340 
and the Helsinki Biomedical Graduate School.  341 
Conflict of interest: Nothing to declare 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
17 
 
References  352 
1. Vaheri, A., Mills, J.N., Spiropoulou, C.F. and Hjelle, B. Hantaviruses. In “Oxford Textbook of 353 
Zoonoses - Biology, Clinical Practice and Public Health Control” 2nd Edition, (Edited by S. R.  354 
Palmer, Lord Soulsby, P. R. Torgerson and David W. G. Brown). Oxford University Press. Oxford, 355 
U.K. (in press). 356 
 2. Makary P, Kanerva M, Ollgren J, Virtanen MJ, Vapalahti O, Lyytikainen O. Disease 357 
burden of Puumala virus infections, 1995-2008. Epidemiol Infect 2010:1-9.  358 
3. Vapalahti O, Mustonen J, Lundkvist A, Henttonen H, Plyusnin A, Vaheri A. Hantavirus 359 
infections in Europe. Lancet Infect Dis 2003;310:653-661.  360 
4. Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Pasternack A, et al. Genetic 361 
susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. 362 
Kidney Int 1996;491:217-221.  363 
5. Kanerva M, Paakkala A, Mustonen J, Paakkala T, Lahtela J, Pasternack A. Pulmonary 364 
involvement in nephropathia epidemica: radiological findings and their clinical correlations. 365 
Clin Nephrol 1996;466:369-378.  366 
6. Paakkala A, Makela S, Hurme M, Partanen J, Huhtala H, Mustonen J. Association of chest 367 
radiography findings with host-related genetic factors in patients with nephropathia 368 
epidemica. Scand J Infect Dis 2008;403:254-258.  369 
7. Paakkala A, Mustonen J. Radiological findings and their clinical correlations in 370 
nephropathia epidemica. Acta Radiol 2007;483:345-350.  371 
18 
 
8. Clement J, Colson P, McKenna P. Hantavirus pulmonary syndrome in New England and 372 
Europe. N Engl J Med 1994;3318:545-6; author reply 547-8.  373 
9. Makela S, Kokkonen L, Ala-Houhala I, Groundstroem K, Harmoinen A, Huhtala H, et al. 374 
More than half of the patients with acute Puumala hantavirus infection have abnormal cardiac 375 
findings. Scand J Infect Dis 2009;411:57-62.  376 
10. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foucar K, et al. Hantavirus 377 
pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 378 
1995;1463:552-579.  379 
11. Kanerva M, Mustonen J, Vaheri A. Pathogenesis of puumala and other hantavirus 380 
infections. Rev Med Virol 1998;82:67-86.  381 
12. Paakkala A, Mustonen J, Viander M, Huhtala H, Pasternack A. Complement activation in 382 
nephropathia epidemica caused by Puumala hantavirus. Clin Nephrol 2000;536:424-431.  383 
13. Walport MJ. Complement. First of two parts. N Engl J Med 2001;34414:1058-1066.  384 
14. Podack ER, Muller-Eberhard HJ. Isolation of human S-protein, an inhibitor of the 385 
membrane attack complex of complement. J Biol Chem 1979;25419:9808-9814.  386 
15. Vapalahti O, Lundkvist A, Kallio-Kokko H, Paukku K, Julkunen I, Lankinen H, et al. 387 
Antigenic properties and diagnostic potential of puumala virus nucleocapsid protein 388 
expressed in insect cells. J Clin Microbiol 1996;341:119-125.  389 
16. Temonen M, Vapalahti O, Holthofer H, Brummer-Korvenkontio M, Vaheri A, Lankinen 390 
H. Susceptibility of human cells to Puumala virus infection. J Gen Virol 1993;74 ( Pt 3)Pt 391 
3:515-518.  392 
19 
 
17. Terajima M, Hayasaka D, Maeda K, Ennis FA. Immunopathogenesis of hantavirus 393 
pulmonary syndrome and hemorrhagic fever with renal syndrome: Do CD8+ T cells trigger 394 
capillary leakage in viral hemorrhagic fevers? Immunol Lett 2007;1132:117-120.  395 
18. Linderholm M, Ahlm C, Settergren B, Waage A, Tarnvik A. Elevated plasma levels of 396 
tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in 397 
patients with hemorrhagic fever with renal syndrome. J Infect Dis 1996;1731:38-43.  398 
19. Tsukada H, Ying X, Fu C, Ishikawa S, McKeown-Longo P, Albelda S, et al. Ligation of 399 
endothelial alpha v beta 3 integrin increases capillary hydraulic conductivity of rat lung. Circ 400 
Res 1995;774:651-659.  401 
20. Ishikawa S, Tsukada H, Bhattacharya J. Soluble complex of complement increases 402 
hydraulic conductivity in single microvessels of rat lung. J Clin Invest 1993;911:103-109.  403 
21. Bossi F, Fischetti F, Pellis V, Bulla R, Ferrero E, Mollnes TE, et al. Platelet-activating 404 
factor and kinin-dependent vascular leakage as a novel functional activity of the soluble 405 
terminal complement complex. J Immunol 2004;17311:6921-6927.  406 
22. Langlois PF, Gawryl MS. Accentuated formation of the terminal C5b-9 complement 407 
complex in patient plasma precedes development of the adult respiratory distress syndrome. 408 
Am Rev Respir Dis 1988;1382:368-375.  409 
23. Colins JD, Burwell D, Furmanski S, Lorber P, Steckel RJ. Minimal detectable pleural 410 
effusions. A roentgen pathology model. Radiology 1972;1051:51-53.  411 
24. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS 412 
Immunol Med Microbiol 2008;533:287-299.  413 
20 
 
25. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, et 414 
al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural 415 
viral protein NS1 and complement. J Infect Dis 2006;1938:1078-1088.  416 
26. Nascimento EJ, Silva AM, Cordeiro MT, Brito CA, Gil LH, Braga-Neto U, et al. 417 
Alternative complement pathway deregulation is correlated with dengue severity. PLoS One 418 
2009;48:e6782.  419 
27. Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, et al. Severe 420 
pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 421 
2010.  422 
28. Makela S, Mustonen J, Ala-Houhala I, Hurme M, Koivisto AM, Vaheri A, et al. Urinary 423 
excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced 424 
nephritis. Am J Kidney Dis 2004;435:809-816.  425 
29. Katz Y, Revel M, Strunk RC. Interleukin 6 stimulates synthesis of complement proteins 426 
factor B and C3 in human skin fibroblasts. Eur J Immunol 1989;196:983-988.  427 
30. Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol 428 
1999;193:173-198.  429 
31. Weigelt JA, Chenoweth DE, Borman KR, Norcross JF. Complement and the severity of 430 
pulmonary failure. J Trauma 1988;287:1013-1019.  431 
32. Blanchong CA, Zhou B, Rupert KL, Chung EK, Jones KN, Sotos JF, et al. Deficiencies 432 
of human complement component C4A and C4B and heterozygosity in length variants of RP-433 
C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on 434 
major histocompatibility complex-associated disease. J Exp Med 2000;19112:2183-2196.  435 
21 
 
Tables  436 
Table 1. Clinical and laboratory findings in 61 patients with acute PUUV-HFRS  437 
                    Median (Range) 
Clinical finding:  
              SBPmin,mmHg    110 (82-162) 
              DBPmin, mm Hg 70 (46-100) 
              Diurmin,  ml       1620 (50-5800) 
              Diurmax, ml           3780 (1280-9740) 
              Change in weight, kg    2.7 (0-12) 
              Treatment time at hospital, days                       6 (2-15) 
Laboratory finding:  
               Leukocyte countmax, 10
9
/l   9.9 (3.9-31.2) 
               Hcrmin, %      0.36 (0.25-0.43) 
               Hcrmax, %      0.44 (0.34-0.57) 
               Platelet countmin 10
9
/l                     67.5 (9-238) 
               S-Creamax µmol/l                     175 (65-1285) 
               IL-6max, pg/ml                     11.6 (1.3-96) 
               S-Namin, mmol/l   131 (115-139) 
NOTE. SBPmin= lowest systolic blood pressure, DBPmin = lowest diastolic blood pressure, Diurmin= lowest daily 438 
urinary output, Diurmax= highest daily urinary output, Leukocyte countmax =highest blood leukocyte count 439 
(normal range 3.4-8.2 x 10
9
/l), Hcrmin= lowest blood hematocrit (normal range for women 35-46%, and for men 440 
39-50%), Hcrmax= highest blood hematocrit, Platelet countmin= lowest blood platelet count (normal range 150-441 
360 x 10
9
/l), S-Creamax= highest serum creatinine concentration (normal range for women 50-90 µmol/l, and for 442 
men 60-100 µmol/l), IL-6max=highest serum interleukin-6 level, S-Namin= lowest serum sodium level (normal 443 
range 137-145 mmol/l).  444 
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Table 2. Spearman rank correlations of minimum acute-stage level of C3 and C4 and 445 
maximum acute-stage level of SC5b-9 with clinical and laboratory findings in PUUV-HFRS 446 
patients 447 
             SC5b-9              C3                  C4 
Clinical finding: r P r P        r              P 
       SBPmin -0.28 0.1 0.232 0.07 -0.94      0.48 
       DBPmin, -0.33 0.013 0.37 0.004 0.076    0.57 
       Diurmin -0.3 0.82 0.38 0.003 0.182   0.17 
       Diurmax 0.41 0.002 0.15 0.26 -0.128   0.339 
Change in weight 0.42 <0.001 -0.32 0.012 -0.149   0.255 
 Treatment time at 
       hospital 
0.46 <0.001 -0.3 0.025 -0.137  0.296 
Laboratory finding:      
    Leukocyte countmax 0.43 <0.001 -0.3 0.020 -0.194   0.137 
        B-Hcrmin -0.24  0.07 0.52 <0.001 0.1        0.45 
        B-Hcrmax 0.3 0.024 0.046 0.73 0.01    0.942 
        Platelet countmin  -0.32 0.017 0.3 0.020 0.004   0.976 
        S-Creamax 0.27 0.03 -0.183 0.162 -0.134   0.307 
         IL-6max 0.14 0.34 -0.62 <0.001 -0.246    0.089 
         S-Namin -0.16 0.25 0.44 <0.001 0.059     0.67 
NOTE. r= correlation coefficient, SBPmin= lowest systolic blood pressure, DBPmin= lowest diastolic blood 448 
pressure, Diurmin= lowest daily urinary output, Diurmax= highest daily urinary output, Leukocyte countmax 449 
=highest blood leukocyte count, B-Hcrmin=lowest blood hematocrit, B-Hcrmax= highest blood hematocrit, 450 
Platelet countmin= lowest blood platelet count, S-Creamax= highest serum creatinine concentration, 451 
IL6max=highest plasma Interleukin-6 level, S-Namin= lowest serum sodium level. Significant correlations are 452 
highlighted in bold.   453 
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Figures 454 
Figure 1. (A) Paired plasma levels of  SC5b-9 of PUUV-HFRS patients during the acute 455 
stage upon admission to hospital and at full recovery. The median maximum SC5b-9 456 
concentration in the acute stage was 493 ng/ml (range 103- 1034 ng/ml) and the level at full 457 
recovery was 197 ng/ml, (range 100- 522 ng/ml).   458 
 459 
 460 
 461 
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(B) Paired plasma levels of  C3 of PUUV-HFRS patients during the acute stage and at full 462 
recovery. The median minimum C3 concentration in the acute stage was 1.26 g/l (range 0.65-463 
2.24 g/l) and the level at full recovery was 1.47 g/l (range 0.84-2.44 g/l).  464 
 465 
 466 
 467 
 468 
 469 
 470 
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(C) Paired plasma levels of  C4 of PUUV-HFRS patients during the acute stage and at full 471 
recovery. The median minimum C4 concentration in the acute stage was 0.26 g/l (range 0.08-472 
0.52 g/l) and the level at full recovery was 0.27 g/l (range 0.09-1.1 g/l). Wilcoxon's test was 473 
used to determine the statistical significance in (A), (B) and (C). 474 
 475 
 476 
 477 
 478 
 479 
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Figure 2. (A) Box plots of plasma SC5b-9 levels of patients with and without chest x-ray 480 
abnormalities in the acute stage of PUUV-HFRS and at full recovery. Box plot illustrate the 481 
median value (center horizontal line), interquartile range (the lower and upper quartiles), and 482 
the highest and lowest values (whiskers) that are not outliers. The outliers are presented as 483 
circles. The median maximum SC5b-9 levels in patients with and without chest x-ray 484 
abnormalities in the acute stage were 637 ng/ml (range 334-1034 ng/ml) and 464 ng/ml 485 
(range 103-977 ng/ml) and at full recovery 222 ng/ml (range 123-365) and 203 ng/ml (100-486 
522 ng/ml), respectively.  487 
 488 
 489 
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(B) Box plots of plasma C3 levels of patients with and without chest x-ray abnormalities in 490 
the acute stage of PUUV-HFRS patients and at full recovery. Box plot illustrates the median 491 
value (center horizontal line), interquartile range (the lower and upper quartiles) and the 492 
highest and lowest values (whiskers) that are not outliers. The outliers are presented as circles 493 
(minor outlier) or asterisks (major outlier). The median minimum C3 levels in patients with 494 
and without chest x-ray abnormalities in the acute stage were 1.1 g/l (range 0.65-1.64) and 495 
1.26 g/l (range 0.7-2.24) and at full recovery 1.46 g/l (range 1.2-1.94) and 1.41 (range 0.84-2-496 
44), respectively.  497 
 498 
 499 
28 
 
(C) Box plots of plasma C4 levels of patients with and without chest x-ray abnormalities in 500 
the acute stage of PUUV-HFRS and at full recovery. Box plot illustrate the median value 501 
(center horizontal line), interquartile range (the lower and upper quartiles), and the highest 502 
and lowest values (whiskers) that are not outliers. The outliers are presented as circles. The 503 
median minimum C4 levels in patients with and without chest x-ray abnormalities in the 504 
acute stage were 0.24 g/l (range 0.12-0.42 g/l) and 0.25 g/l (range 0.08-0.43 g/l) and at full 505 
recovery 0.23g/l (range 0.13-1.06 g/l) and 0.28 g/l (range 0.09-1.10), respectively. Mann 506 
Whitney test was used to determine statistical significance in (A), (B) and (C).  507 
 508 
 509 
 510 
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Introduction: Puumala virus (PUUV) infection is a viral hemorrhagic fever with renal syndrome (HFRS)
characterized by thrombocytopenia and acute impairment of renal function. We aimed to assess whether
genetic polymorphisms of platelet antigens together with those of von Willebrand factor (VWF) and
plasminogen activator inhibitor (PAI-1) correlate with disease severity.
Patients and methods
172 consecutive hospital-treated patients with serologically conﬁrmed acute PUUV infection were included.
Platelet glycoprotein (GP) IIIa T>C (rs5918), GP Ia T>C (rs1126643), GP Ib C>T (rs6065), GP VI T>C
(rs1613662), VWF A>G (rs1063856) and PAI-1 A>G (rs2227631) were genotyped. The associations of
the rarer alleles with variables reﬂecting the severity of the disease were analyzed.
Results: PAI-1 G-carriers had higher maximum creatinine level compared with the non-carriers (median
213 μmol/l, range 60–1499 μmol/l vs. median 122 μmol/l, range 51–1156 μmol/l, p=0.01). The GG-
genotypes had higher creatinine levels than GA- and AA-genotypes (medians 249 μmol/l, 204 μmol/l and
122 μmol/l, respectively, p=0.03). Polymorphisms of GP VI and VWF associated with lower creatinine levels
during PUUV infection. The minor C-allele of GP Ia associated with lower platelet counts (median 44×109/l,
range 20–90×109/l vs median 64×109/l, range 3–238×109/l; p=0.02).
Conclusions: Polymorphism of PAI-1, a major regulator of ﬁbrinolysis, has an adverse impact on the outcome
of kidney function in PUUV-HFRS. Platelet collagen receptor GP Ia polymorphism associates with lower plate-
let count.© 2011 Elsevier Ltd. All rights reserved.Introduction
Puumala hantavirus (PUUV) infection, also known as nephro-
pathia epidemica (NE), is the most common cause of hemorrhagic
fever with renal syndrome (HFRS) in Europe. [1] In Finland the aver-
age annual incidence is 31/100 000 population and the incidence
tends to increase. [2] The course of the disease may be divided intogic fever with renal syndrome;
inhibitor; GP, glycoprotein; NE,
; HPA, human platelet alloanti-
IL-6, interleukin-6; SNP, single
Tampere, Finland. Tel.: +358
rights reserved.febrile, hypotensive, oliguric, diuretic and convalescent phases, but
these phases may overlap, and the clinical severity varies. Renal in-
volvement results in the need for transient hemodialysis treatment
in 5% of hospital-treated NE patients. [1] Thrombocytopenia is a char-
acteristic ﬁnding but bleeding manifestations usually remain mild. [3]
The case fatality rate is 0.08%. [2]
The pathogenesis of NE is complex and multifactorial with host ge-
netic properties having an impact on disease severity. Human leukocyte
alloantigen (HLA) B8 and DRB1*0301 alleles are associated with severe
clinical disease, and genetic polymorphisms of the cytokines tumor
necrosis factor alpha, interleukin-1, and interleukin-1 receptor antago-
nist also inﬂuence the outcome of infection. [4,5] The surface density of
platelet β3 integrin, the cellular receptor of hantaviruses, is associated
with disease severity in patients with Hantaan virus. [6] However,
a human platelet alloantigen (HPA) -1 polymorphism which affects
Table 1
The clinical and basic laboratory ﬁndings in 172 patients with acute Puumala hantavi-
rus infection.
Clinical or laboratory variable Median Range
Days from onset of illness⁎ 4 1-14
Length of hospital stay (days) 6 2-15
Systolic BP min (mmHg) 113 74-170
Diastolic BP min (mmHg) 70 40-100
Daily urinary output min (ml) 1450 50-7000
Change in weight max (kg)⁎⁎ 2.1 0.0-12.0
Hematocrit min 0.36 0.25-0.46
Platelet count min (x109/l) 62 3-238
Leukocyte count max (x109/l) 10 3.9-31.2
CRP max (mg/ml) 75 11-269
Interleukin-6 max (pg/ml) 14.5 1.3-107
Creatinine max (μmol/l) 185 51-1499
Abbreviations: min=minimum, max=maximum. References: CRP b10 mg/l,
creatinine b105 μmol/l for males and b95 μmol/l for females, platelet count 150–360
and leukocyte count 3.4-8.2 x 109/l, hematocrit 0.35-0.50 for males and 0.35-0.46 for
females.
⁎ Days from onset of illness equals to the number of days of fever before the ﬁrst
blood test was taken.
⁎⁎ Change in weight during hospital stay reﬂects the amount of ﬂuid accumulating in
the body during the oliguric phase.
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with clinical disease severity. Instead, an association of HPA-3 with
the severe form of Hantaan virus infection was reported. [7]
In the acute phase of NE, hemorrhagic problems together with
thrombocytopenia and altered coagulation are known to occur, but
the data published on platelet function and coagulation activity re-
main limited. We recently reported decreased levels of natural anti-
coagulants, shortened thrombin time and enhanced ﬁbrinolysis in
patients with acute NE. [8] We also found that the levels of three
main platelet ligands for αIIβ3 (subunit β3integrin) were altered, i.e.
vonWillebrand factor (VWF) and ﬁbrinogen were increased and plas-
ma ﬁbronectin was decreased during acute NE. [9]
Here we studied the genetic polymorphisms of the main antigens
involved in platelet activation and aggregation, namely glycoprotein
(GP) IIIa (HPA-1), GP Ib (HPA-2), GP Ia (HPA-5) and GP VI, together
with VWF and plasminogen activator inhibitor (PAI) -1 in patients
with acute NE. Our aim was to establish a possible association be-
tween these polymorphisms and the clinical course of NE.
Methods
Patients
The study was carried out at Tampere University Hospital and
University of Tampere School of Medicine. All patients came from
the Pirkanmaa region and were hospitalized at Tampere University
Hospital due to serologically conﬁrmed acute PUUV infection during
the period from September 1997 to February 2009. [10] Written in-
formed consent was obtained from all patients, and The Ethics Com-
mittee of Tampere University Hospital approved the study protocol.
The study group was comprised of 172 prospectively collected,
consecutive patients (118 males), median age 40 years (ranging
from 15 to 74 years). Concomitant diseases included arterial hyper-
tension (n=12), dyslipidemia (n=7), coronary heart disease
(n=5), bronchial asthma (n=6), atrial ﬁbrillation (n=3) and rheu-
matoid arthritis (n=3). There were patients with celiac disease, in-
ﬂammatory bowel disease, valvular heart disease or neurological
disease (n=2 for each).
Clinical and basic laboratory data
The following variables were recorded: the number of days from the
onset of illness (i.e. fever) before the ﬁrst blood test was taken, the
length of hospital stay (days), clinical diagnosis of shock (yes/no),
need for transient hemodialysis treatment (yes/no), the lowest systolic
and diastolic blood pressure (mmHg), the lowest daily urinary output
(ml) and maximum change in weight (kg). The last variable reﬂects
ﬂuid retention during the hospital stay in the oliguric phase of the dis-
ease. Complete blood count (CBC), plasma C-reactive protein (CRP)
and plasma creatinine were measured according to the clinical indica-
tions, and were determined at the Laboratory Centre of the Pirkanmaa
Hospital District using standard methods. Plasma interleukin-6 (IL-6)
samples were collected up to ﬁve consecutive days after hospitalization
and determined from118 patients using a commercially available ELISA
kit following the manufacturer's instructions (PeliKine Compact ™
human IL-6 kit, Central Laboratory of The Netherlands, Red Cross
Blood Transfusion Service, Amsterdam, TheNetherlands). The detection
limit for the IL-6 assay was 0.4 pg/ml. The highest or the lowest individ-
ual value of the various variables measured during hospitalization was
designated as the maximum or the minimum value.
Genotyping
DNA was extracted from whole blood using a commercially avail-
able kit (QIAGEN Inc., Hilden, Germany). The gene polymorphisms of
GP IIIa (HPA-1) T>C (rs5918) and GP Ib (HPA-2) C>T (rs6065) weregenotyped with Assay-By-Design from Applied Biosystems under
standard conditions using the ABI Prism 7900HT Sequence Detection
System (Taqman, Applied Biosystems, Foster City, CA, USA). The GP Ia
(HPA-5) T>C (rs1126643) and the VWF A>G (rs1063856) were
genotyped as previously described. [11,12] Genotyping of the GP VI
T>C (rs1613662) was performed with minor modiﬁcations. [13]
For PAI-1 A>G (rs2227631) a commercial kit from Applied Biosys-
tems was used. The distributions of all single nucleotide polymor-
phisms (SNP) did not deviate from the Hardy–Weinberg equation.
Genotyping was successful in 162 of 172 patients (94%) for GP IIIa,
in all 172 patients for GP Ia, in 169 patients (98%) for GP Ib, in 171
patients (99%) for GP VI, in 162 patients (94%) for VWF and in 169
patients (98%) for PAI-1.Statistical analysis
Since all continuous variables were skewed, medians and ranges
were calculated to describe the data. Percentages were used for cate-
gorical variables. The allele frequencies were counted and the pa-
tients were divided in to the groups of carriers and non-carriers of
the rarer (minor) allele. Comparisons between the groups are based
on Mann–Whitney U or Kruskal-Wallis test for numerical and χ2 or
Fisher's exact test for categorical data. The limit of signiﬁcance was
set at 0.05 (2-tailed). If Bonferroni adjustments for multiple tests
were applied, the limit of signiﬁcance would be set at 0.01. SPSS ver-
sion 14.0 was used for computation.Results
Clinical and laboratory ﬁndings
All patients suffered from clinically typical PUUV infection. All pa-
tients were examined and hospitalized in the acute phase of the ill-
ness. The clinical ﬁndings and the basic laboratory values are shown
in Table 1. Of all patients, 97% had their platelet count minimum
below 150×10 /l, the lower limit of normal range. There was no cor-
relation between the minimum platelet count and the maximum
plasma creatinine level. Three out of 172 patients (2%) were in clinical
shock at the time of admission. Seven patients (4%) needed transient
hemodialysis treatment. All patients recovered.
613O. Laine et al. / Thrombosis Research 129 (2012) 611–615Polymorphisms and their associations with the clinical and laboratory
ﬁndings
Table 2 presents the genotype distributions and allele frequencies
of GP IIIa (HPA-1), GP Ib (HPA-2), GP Ia (HPA-5), GP VI, VWF and PAI-
1. GP Ib (HPA-2) genotypes did not correlate with any of the variables
measured (data not shown).Renal Function
Renal function impairment in the acute phase of the disease
associated with the rare G-allele of PAI-1 gene. The carriers of PAI-1
gene G-allele had 1.7 times higher maximum level of creatinine
than the non-carriers (median 213 μmol/l, range 60–1499 μmol/l vs.
median 122 μmol/l, range 51–1156; p=0.01; Fig. 1A). Also, the
level of creatinine exceeded 300 μmol/l 1.7 times more often in the
G-carriers compared with the non-carriers (38% vs. 22%, p=0.04).
As shown in Table 3, GG-homozygotes had the highest maximum
level of creatinine of all PAI-1 carrier genotypes, followed by AG-
heterozygotes and AA-homozygotes (median 249 μmol/l, median
204 μmol/l and median 122 μmol/l, respectively, p=0.03). Six out of
seven hemodialysis patients were G-allele carriers, and one of them
was a GG-homozygote.
The rare G-allele of VWF A>Gwas associated with a lower level of
maximum creatinine (median 131 μmol/l, range 52–1285 μmol/l vs.
median 241 μmol/l, range 51–1499 μmol/l; p=0.02). Accordingly,
the level of creatinine exceeded 300 μmol/l less often in the carriers
of the VWF G-allele than in the non-carriers (21% vs. 38%, p=0.03).
Analyses of genotype combinations revealed that the patients
(n=18, 11% of all patients) carrying the favorable VWF G-allele and
not carrying the unfavorable PAI-1 G-allele had lower levels of creat-
inine compared with the patients not carrying the VWF G-allele and
carrying the PAI-1 G-allele (n=73, 46% of all patients; 99 μmol/l vs.
250 μmol/l, respectively, p=0.002).
The carriers of the GP VI gene rare C-allele had maximum creati-
nine levels>300 μmol/l less often than non-carriers (17% vs. 36%,
p=0.03).Fig. 1. Box plots of the highest plasma creatinine (A) and the blood platelet count nadir
(B) in non-carriers (n=54) and carriers (n=115) of the plasminogen activator inhib-
itor (PAI-1) G-allele (rs 2227631) in 169 patients with PUUV infection. Box plot illus-
trates the median, the 25% and 75% percentiles, and the lowest and highest values
that are not outliers. Outliers are indicated by open circles and extreme values by
asterisks.Platelet count
The platelet count nadir was lower in carriers of the GP Ia (HPA-5)
gene rare C-allele compared to non-carriers (median 44×10 /l, range
20–90×109/l vs. median 64×10 /l, range 3–238×109/l; p=0.02).
The minor G-allele carriers of PAI-1 gene turned out to have a higher
platelet count nadir compared with non-carriers (median 65×10 /l,
range 9–238×109/l vs. median 54×10 /l, range 3–187×109/l;
p=0.04; Fig. 1B). Minimum platelet counts by genotypes of GP Ia
(HPA-5) and PAI-1 are presented in Table 4.Table 2
The genotype distributions and allele frequencies of platelet GP IIIa, GP Ib, GP Ia, GPVI,
VWF and PAI-1 in 172 patients with acute Puumala hantavirus infection.
Genotype % Allele %
Polymorphism homozygote
common
heterozygote homozygote
rare
common rare
GP IIIa (HPA-1) 66 (TT) 32 (TC) 2 (CC) 82 (T) 18 (C)
GP Ib (HPA-2) 78 (CC) 21 (CT) 1 (TT) 88 (C) 12 (T)
GP Ia (HPA-5) 93 (TT) 7 (TC) 0 (CC) 96 (T) 4 (C)
GP VI T>C
(rs1613662)
79 (TT) 19 (TC) 2 (CC) 89 (T) 11 (C)
VWF A>G
(rs1063856)
68 (AA) 25 (AG) 7 (GG) 81 (A) 19 (G)
PAI-1 A>G
(rs227631)
32 (AA) 53 (AG) 15 (GG) 59 (A) 41 (G)
Abbreviations: GP=glycoprotein, HPA=human platelet alloantigen, VWF=von
Willebrand factor, PAI-1=plasminogen activator inhibitor.Inﬂammation
The maximum level of plasma IL-6 was lower in carriers of the rare
GP IIIa (HPA-1) C-allele than in non-carriers (median 13.0 pg/ml, range
1.3-60 pg/ml vs. median 16.5 pg/ml, range 2.6-107 pg/ml; p=0.05).
There were no signiﬁcant associations with GP IIIa (HPA-1) genotype
and CRP or leukocyte count (data not shown).
We found no statistically signiﬁcant differences in the length of
hospital stay, lowest blood pressure, maximum weight change, needTable 3
Maximum creatinine levels in patients with acute Puumala hantavirus infection pre-
sented by genotypes of GP VI T>C (rs1613662), VWF A>G (rs1063856) and PAI-1
A>G (rs227631) polymorphisms.
Maximum creatinine μmol/l, median (range)
Polymorphism Homotsygote
common
Heterotsygote Homotsygote
rare
p-value
GPVI T>C
(rs1613662)
199 (52–1499) 191 (51–679) 137 (110–196) 0.381
VWF A>G
(rs1063856)
241 (51–1499) 125 (52–1285) 137 (60–384) 0.072
PAI A>G (rs227631) 122 (51–1156) 204 (60–1499) 249 (65–906) 0.033
Table 4
Minimum platelet counts in patients with acute Puumala hantavirus infection pre-
sented by genotypes of GP Ia T>C (HPA-5) and PAI-1 A>G (rs227631)
polymorphisms.
Minimum platelet count x 109/l, median (range)
Polymorphism Homotsygote
common
Heterotsygote Homotsygote
rare
p-value
GP Ia T>C (HPA-5) 64 (3–238) 44 (20–90) - 0.023
PAI-1 A>G (rs227631) 54 (3–187) 65 (9–181) 71 (14–238) 0.108
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ible with polymorphisms studied here (data not shown).
Discussion
In our study, carriers of the PAI-1 gene minor G-allele suffered
from more severe renal impairment than non-carriers. Both the max-
imum level of creatinine and the proportion of patients having their
creatinine value>300 μmol/l were higher in the carriers of G-allele
compared with non-carriers. GG-homozygotes had the highest
creatinine levels, and 6/7 patients who needed transient hemodialysis
treatment were G-allele carriers. The platelet count nadir of the
PAI-1 G-allele carriers was higher than that of non-carriers, and was
concordant with our observation that the severity of renal impairment
does not associate with the depth of thrombocytopenia in acute PUUV
infection.
PAI-1 is secreted by a variety of cells including platelets and endo-
thelial cells in response to inﬂammatory stimuli, and PAI-1 is the
primary physiological regulator of tissue- and urokinase-type plas-
minogen activators and ﬁbrinolysis. [14] PAI-1 polypeptide is
encoded by the SERPINE1 (SERine Proteinase INhibitor, clade E, mem-
ber 1) gene on chromosome 7q21.3-q2, and association of the 4 G/5 G
polymorphism (rs1799889) with increased PAI-1 levels of 4 G-allele
carriers has been suggested by several studies. Elevated levels of
PAI-1 have been related to poor outcome in several infections such
as pneumonia, sepsis, meningococcal disease, and dengue virus infec-
tion. [15-21] The 4 G-allele also seems to associate with atheroscle-
rotic diseases of coronary arteries and reduced kidney graft survival.
[14,22] We studied the SNP rs2227631 of the PAI-1 gene which is
very close to 4 G/5 G polymorphism (rs1799889) and has a relatively
high correlation with 4 G/5 G. [14,23] We found that the carriers of
the rare G-allele suffered from more severe renal failure during the
acute phase of NE compared with non-carriers. Unfortunately, we
could not measure the plasma levels of PAI-1, and to our knowledge,
there are no data on the plasma level and role of PAI-1 in hantavirus
infections. Thus the plausible increase of PAI-1 level in response to in-
fection and acute phase reaction and its modiﬁcation by polymor-
phisms of PAI-1 gene in hantavirus infection remain the subjects of
further studies.
The hemostatically active ligand VWF plays a critical role in plate-
let aggregation and adhesion to injured endothelium during primary
hemostasis and pathologic thrombus formation. The VWF gene is
highly polymorphic, and genetic factors are responsible for up to
66% of the variation in plasma VWF levels. [24] We recently observed
high plasma VWF concentrations during acute PUUV infection. [9]
Here we studied the A>G polymorphism of the WVF gene (rs
1063856) in exon 18 of chromosome 12. This polymorphism has
been associated with high VWF levels, and is close to SNP
rs10638857 which is known to associate with VWF levels in healthy
subjects. [24-26] We found the minor G-allele (rs 1063856) of the
VWF gene to have some protective role in kidney function, but we
were unable to conclude whether this favorable effect depends on
modulation of plasma VWF levels.
Binding of collagen to GP VI leads to platelet activation and pro-
coagulant activity contributing to the formation of the hemostaticplug. Low frequency allele homozygotes of GP VI, such as the CC
genotype of T>C rs 1613662, are associated with reduced activation
and platelet responses to collagen when compared with high
frequency allele homozygotes. [27] In this study, the rare C-allele of
GP VI offered some protection of renal function, but did not correlate
with the platelet count or other variables of disease severity. A lower
platelet count nadir was associated with the low frequency C-allele of
GP Ia (HPA-5), the other major platelet receptor for collagen. [28]
However, the associations between genetic polymorphisms and
platelet function could not be studied here.
GP IIbIIIa complex mediates platelet aggregation by binding the
adhesive proteins VWF, ﬁbrinogen, and thrombus stabilizing ﬁbro-
nectin. [29] GP IIbIIIa carries the HPA-1 polymorphism site and con-
tains subunit β3 integrin (IIIa), the receptor for hantaviruses.[30,31]
We found that carriers of the low frequency C-allele of GP IIIa
(HPA-1) had slightly lower levels of plasma IL-6, a variable known
to positively correlate with the severity of PUUV infection.[32] Our
ﬁndings are similar to the only previous study on hantavirus infection
and GP IIIa polymorphismwhich found that the HPA-1 polymorphism
does not associate with disease severity.[7]
Due to the design of the study, we were not able to obtain reliable
information about bleeding symptoms, plasma levels of PAI-1 and
VWF, or platelet functions. However, for the ﬁrst time, genetic poly-
morphisms related to platelet activation, blood coagulation and ﬁbri-
nolysis were shown to have an impact on kidney function and platelet
count in HFRS. Future studies could clarify the role of each of these
genetic polymorphisms, their synergistic effects, and their functional
relevances in PUUV-induced HFRS.
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